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FDA   Food and Drug Administration 
FF   Fenofibrate 
g   Gram    
GSH   Glutathione 
GST   Glutathione-S-transferase 
h    Hour 
HD   High dose 
ICH   International Conference of Harmonization of Technical Require- 
   ments for Registration of Pharmaceuticals for Human Use 
IPA®   Ingenuity Pathway Analysis 
kDa   Kilodaltons 
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l   Litre 
LD   Low dose 
                                                     
1 Gene symbols and the appropriate gene names are listed in the text or in the gene tables in the 
appendix and not in the list of appreviations. 
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ABSTRACT 
New human pharmaceuticals are required by law to be tested in pre-clinical studies 
in order to predict any potential drug side effects. However, during the last decade 
the number of new drug approvals has markedly decreased while the cost of drug 
development has increased. The reasons for this are twofold: firstly, due to adverse 
effects in humans which are not predicted by animal studies, leading to the 
compound’s failure in late phases of the development process, and secondly 
because some drug candidates never reach clinical trials due to intolerable toxic 
effects in animals. Thus, a need exists for new in vitro assays to be developed which 
enable the detection of a compound’s toxicity prior to animal studies. A better pre-
selection of drug candidates could increase the success rate during preclinical trials 
since very toxic compounds could be excluded from animal tests. Furthermore in 
vitro tests also provide mechanistic information which supports the interpretation of in 
vivo observations, as well as play a role in human safety assessment, since these 
tests could be performed in both animal and human cells.  
The present study describes one part of the research activities associated with the 
project Predict-IV financed by the European Commission. Predict-IV’s aim is the 
development of a non-animal based prediction system for the toxicity of new drugs 
related to the organs kidney and liver as well as the central nervous system. In the 
liver work package primary human and rat hepatocytes as well as the human 
hepatoma cell line HepaRG were treated for 14 days with toxic and non-toxic doses 
of eleven pharmaceutical reference substances of known in vivo toxicity. After one, 
three and 14 days, respectively, samples for proteomic, metabolomic, genomic and 
kinetic analyses were collected. 
The genomic endpoint was investigated by performing a whole-genome gene 
expression analysis with Illumina BeadChips. In the present study the global gene 
expression profiles of primary rat hepatocytes were interpreted biologically after 
treatment with seven of the eleven reference compounds to investigate the potential 
of drug-treated rat primary hepatocytes to reflect the in vivo effects noted in the 
literature. In this study the pharmaceutical mode of action was distinguished from off-
target mechanisms which were discussed in relation to hepatotoxic effects in vivo. In 
accordance with its pharmaceutical mode of action, the PPARα-agonist Fenofibrate 
increased the expression of genes involved in lipid metabolism. In addition, genes 
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were also induced which indicated the formation of oxidative stress and the depletion 
of glutathione which was considered to be a basic mechanism of Fenofibrate’s 
hepatotoxicity. Similar results were found for EMD335823, supporting the assumption 
that this withdrawn drug candidate is also a PPARα-agonist. However, the small 
number of genes deregulated by Valproic acid and Acetaminophen was insufficient to 
reflect any in vivo effects probably related to cellular treatment with too small doses.  
The PPARγ-agonists Troglitazone and Rosiglitazone induced genes which coded for 
drug-metabolizing enzymes known to oxidize these substances, especially 
Troglitazone, into reactive potentially cytotoxic metabolites. Additional genes involved 
in the metabolism of glutathione and the response to oxidative stress, a major toxic 
mechanism of Troglitazone and Rosiglitazone, were upregulated. Since both 
compounds pharmacologically act on muscle cells their mode of action could not be 
reconstructed. Metformin which acts on the liver without causing severe adverse 
effects was used as negative control. It deregulated a large number of genes but its 
gene expression profile clearly differed from that of the hepatotoxic compounds.  
In the last chapter of this study the genes commonly deregulated by Fenofibrate, 
EMD335823, Troglitazone, Rosiglitazone and Metformin were discussed. The major 
part of these genes was involved in lipid metabolism which seemed to be related to 
the mode of action of the tested compounds since PPARα- and PPARγ-agonists 
regulate lipid and glucose homeostasis.  
In conclusion the whole-genome gene expression profile of drug treated primary rat 
hepatocytes reflected cellular mechanisms which could explain hepatotoxic effects in 
vivo. During the next phases of Predict-IV the gene expression profiles of rat and 
human primary hepatocytes and HepaRG cells treated with all of the eleven 
reference compounds will be compared. The gene expression profiles of the four 
reference compounds not discussed in this study will be compared with their protein 
expression profiles. Additionally, the real cellular concentration of the test compounds 
and the kinetic of their metabolism will be calculated. Furthermore, species-specific 
effects as well as the responsiveness of the cell line compared to primary cells will be 
investigated in order to define the cell system best suited for an early predictive 
screening system. Finally, genomic and proteomic markers should be defined and 
validated which could enable the early prediction of new drugs’ hepatotoxic potential 
in future. 
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ZUSAMMENFASSUNG 
Die Prüfung neuer Arzneimittel in präklinischen Studien zur Voraussage potentieller 
Nebenwirkungen ist gesetzlich vorgeschrieben. In den letzten zehn Jahren sank die 
Anzahl an neu zugelassenen Wirkstoffen jedoch merklich, während die Kosten für 
deren Entwicklung anstiegen. Die Gründe hierfür sind zum einen Nebenwirkungen 
am Menschen, die durch Tierstudien nicht vorhergesagt werden konnten und zum 
Scheitern der Substanz in späten Entwicklungsphasen führten. Zum anderen 
gelangten einige Wirkstoffkandidaten aufgrund nicht tolerierbarer toxischer Effekte im 
Tier erst gar nicht in die klinischen Studien. Daher ist es notwending, in vitro-Tests zu 
entwickeln, die es ermöglichen, die Toxizität neuer Wirkstoffe vor dem Beginn der 
Tierstudien zu erkennen. Denn eine bessere Vorauswahl von Wirkstoffkandidaten für 
die präklinischen Studien könnte deren Erfolgsquote erhöhen, da sehr toxische 
Stoffe erst gar nicht am Tier getestet würden. Zudem liefern in vitro-Tests 
mechanistische Informationen, die die Interpretation von Beobachtungen in 
präklinischen und klinischen Studien unterstützen, da diese Tests mit tierischen und 
humanen Zellen durchgeführt werden können.  
Die vorliegende Dissertation beschreibt einen Teil der Forschungsarbeiten, die im 
Rahmen des von der Europäischen Union geförderten Projektes Predict-IV 
durchgeführt wurden. Das Ziel von Predict-IV ist die Entwicklung eines tierversuchs-
freien Prädiktionsmodells für die Toxizität neuer pharmazeutischer Wirkstoffe für die 
Organe Niere und Leber sowie das Zentrale Nervensystem. Im Bereich der Leber 
wurden primäre Human- und Rattenhepatozyten sowie die humane 
Hepatomazelllinie HepaRG über 14 Tage mit einer toxischen und einer nicht-
toxischen Dosis von elf pharamazeutischen Referenzsubstanzen mit bekannter in 
vivo Toxizität behandelt. Nach einem, drei bzw. 14 Tagen erfolgte die Probennahme 
für Proteom- und Metabolomanalysen bzw. genetische und kinetische 
Untersuchungen.   
Die genetischen Analysen wurden mit Hilfe einer globalen Genexpressionsanalyse 
mit Illumina BeadChips durchgeführt. In der vorliegenden Arbeit wurden die globalen 
Genexpressionsprofile von primären Rattenhepatozyten biologisch interpretiert, die 
mit sieben der elf Referenzsubstanzen behandelt worden waren. Das Ziel der Arbeit 
war, zu untersuchen, inwieweit wirkstoffbehandelte Rattenhepatozyten in der 
Literatur beschriebene in vivo-Effekte widerspiegeln. Dabei wurde der 
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pharmakologische Wirkprozess von solchen Effekten abgegrenzt, die im Bezug zu in 
vivo-Toxizitäten diskutiert wurden.  
Der PPARα-Agonist Fenofibrat erhöhte in Korrelation zu dessen pharmakologischen 
Wirkmechanismus die Expression von Genen, die für Enzyme des 
Lipidmetabolismus codieren. Zudem wurden Gene induziert, die im Zusammenhang 
mit oxidativem Stress und Glutathiondepletion stehen, den grundlegenden 
Mechanismen der Hepatotoxizität von Fenofibrat. Ähnliche Ergebnisse wurden für 
EMD335823 erzielt, was die Annahme stützt, dass auch dieser gestoppte 
Wirkstoffkandidat ein PPARα-Agonist ist. Valproinsäure und Acetaminophen 
deregulierten eine sehr geringe Anzahl von Genen, wodurch eine Rekonstruktion der 
in vivo-Effekte nicht möglich war. Dies schien in der Behandlung der Zellen mit einer 
zu geringen Dosis begründet gewesen zu sein.  
Die PPARγ-Agonisten Troglitazon und Rosiglitazon induzierten Gene, die für 
arzneimittel-metabolisierende Enzyme codieren, die speziell Troglitazon zu einem 
potentiell zytotoxischen Metaboliten oxidieren. Zusätzlich wurde die Expression von 
Genen erhöht, die in den Glutathionmetabolismus und die Antwort auf oxidativen 
Stress als Hauptmechanismus der Toxizität von Troglitazon und Rosiglitazon 
involviert sind. Da beide Substanzen pharmakologisch hauptsächlich in Muskelzellen 
agieren, konnte ihr Wirkmechanismus nicht rekonstruiert werden. Metformin, das 
pharmakologisch in der Leber wirkt ohne schwere Nebenwirkungen zu verursachen, 
wurde als Negativkontrolle benutzt. Es deregulierte eine große Anzahl von Genen. 
Das Genexpressionsprofil unterschied sich jedoch deutlich von dem der 
hepatotoxischen Substanzen. 
Im letzten Kapitel der vorliegenden Arbeit wurden die durch Fenofibrat, EMD335823, 
Troglitazon, Rosiglitazon und Metformin gemeinsam deregulierten Gene diskutiert. 
Der größte Teil dieser Gene war in den Lipidmetabolismus involviert, was mit dem 
Wirkmechanismus der untersuchten Substanzen zusammenzuhängen schien, da 
PPARα- und PPARγ-Agonisten den Lipid- und Glucosehaushalt regulieren.   
Abschließend kann gesagt werden, dass die globalen Genexpressionsprofile der 
wirkstoffbehandelten primären Rattenhepatozyten zelluläre Mechanismen 
widerspiegelten, mit Hilfe derer hepatotoxische in vivo-Effekte erklärt werden können. 
Innerhalb der nächsten Schritte von Predict-IV werden die Genexpressionsprofile von 
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primären Ratten- und Humanhepatozyten sowie HepaRG-Zellen verglichen, die mit 
allen elf Referenzsubstanzen behandelt wurden. Des Weiteren werden die 
Genexpressionsprofile der vier Substanzen, die in der vorliegenden Arbeit nicht 
diskutiert wurden, mit den Proteinexpressionsprofilen der behandelten Zellen 
verglichen werden. Zusätzlich werden die wahren Substanzkonzentrationen in der 
Zelle sowie die Kinetik des Substanzabbaus gemessen werden. Abschließend 
werden Speziesunterschiede sowie die Responsivität der HepaRG-Zellen im 
Vergleich zu den Primärzellen untersucht werden, um herauszufinden, welches 
Zellkultursystem am besten für den Aufbau eines frühen Screening-Tests geeignet 
ist. Zudem sollen Marker auf Gen- und Proteinebene gefunden und validiert werden, 
die in Zukunft die frühe Vorhersage der Hepatotoxizität neuer Wirkstoffkandidaten 
ermöglichen könnten.    
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1 Introduction 
 
1.1 Toxicology 
The term toxicology has its origin in the Greek words toxicon (toxin) and logos 
(science). Modern toxicology is a science which investigates adverse effects of 
(agro)chemicals, pharmaceuticals, environmental pollutants, additives in food and 
everyday objects as well as cosmetics on humans and the environment based on the 
principle that the effect is dependent on the concentration (dose) of the substance 
acting on. The physician Theophrastus Bombastus von Hohenheim called 
Paracelsus (1493-1541) was the first one who postulated dose-effect-correlations: 
“Was ist das nit gifft ist, alle ding sind gifft, und nichts ohn gifft. Allein die Dosis 
macht, dass ein ding gifft ist.” [Marquardt 2004] (What is not a poison, all things are 
poisons and nothing is without poison. Only the dose renders a thing to be a poison.)  
With the help of animal studies as well as biochemical and cellular assays 
experimental toxicologists define the test compound’s mode of action and the side 
effects in correlation to the exposed doses. Parameters like general condition, 
chemico-clinical markers, organ pathology and lethality are investigated. Then the 
task of regulatory toxicologists is to estimate the compound’s hazard towards 
chemical workers, consumers, patients and the environment by considering the 
exposed dose and the risk of exposure. Based on these data (agro)chemicals, food 
additives, cosmetics and drugs are approved and doses, working concentrations and 
limits for the daily uptake or emissions are determined [Marquardt 2004].   
However, a number of ethical and technical issues arise from the dependence of 
substance development on animal studies. Firstly, traditional toxicological methods 
need a large number of animals; therefore, the pharmaceutical industry has acted on 
the 3R’s principle in order to reduce, refine and replace animal studies where 
possible [Russel and Burch 1959]. In this context the total number of used animals is 
reduced, e.g., by an optimized combination of endpoints in one study. Refinement 
includes techniques diminishing pain and stress in the test animals, improved 
strategies for data analysis and interpretation as well as new biomarkers and test 
methods providing additional information. Finally, replacement means alternative test 
methods which completely replace animal experiments. Secondly, species-specificity 
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can decrease the predictive power of animal studies. Some compounds cause 
human adverse effects which could not be predicted by animal tests and lead to 
failures of drug candidates in late phases of the drug development process [Olson 
1998, Xu 2004, Uetrecht 2008]. Lastly, the European Commission prohibits trading of 
cosmetics containing compounds which were tested on animals after 11th March 
2013 and the new chemical regulation for “Registration, Evaluation and Authorisation 
of Chemicals” (REACH) dictated the re-testing of thousands of chemicals [ECHA 
2011]. In order to conform to these new regulations for an increased number of 
compounds, the chemical and pharmaceutical industry is forced to develop new non-
animal based test strategies for the prediction of human toxicities.   
 
1.2  Drug discovery and development 
Hundreds of new drug candidates are tested during the drug discovery phase with 
biochemical and cellular screening methods. Here the relevant pharmaceutical 
effects like target binding but also off-target effects like inhibition of necessary 
physiological functions or induction of drug metabolizing enzymes are investigated. 
Finally, one definite candidate reaches the first phase of drug development (phase 0; 
Figure 1.1) where preclinical tests in animals are conducted. Every pharmaceutical 
compound which is approved for human use has to pass animal and human 
regulatory tests which are well-defined and required by law. These tests should 
estimate the risk of the new drug, determine a safe dosage for human treatment and 
identify drug side effects as well as interactions with other drugs or food very clearly 
[Kola 2004, Preziosi 2004, Butcher 2005].  
During animal studies, the drug candidate’s potential to cause acute and chronic 
toxicity, dermal or ocular sensitization or irritation, adverse effects of the respiratory 
and cardiovascular system, as well as mutagenicity, teratogenicity and 
carcinogenicity, is tested. The pharmacokinetic profile is investigated which describes 
how the drug is taken up (bioavailability), distributed, metabolized and eliminated in 
an animal’s body. Finally the optimal dosage and formulation for the first-in-man 
studies is determined by extrapolation of the animal data with additional safety 
factors. Traditional endpoints in preclinical animal tests are histopathological 
evaluations to detect adverse modifications in different tissues and the measurement 
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of different parameters in blood and urine like elevated plasma level of liver enzymes 
[ICH-M3 2009].  
Drug candidates which successfully pass the preclinical studies are further tested in 
healthy human volunteers (phase 1 of clinical trials, Figure 1.1), with a few 
exceptions; for example in the case of anti-cancer therapies phase 1 trials are 
directly conducted in cancer patients. Here, the drug effects on the basic functions of 
the organism (safety) and the human pharmacokinetics are used to determine the 
maximum tolerable dose.   
New in vitro    
predictionmodels
Drug
Discovery 
Preclinical
Testing
(Phase 0)
Clinical 
Trials 
Phase 1‐3
Clinical 
Trials 
Phase 4
Approval
 
Figure 1.1: The process of drug discovery and development is divided into different phases.  
New non-animal based test strategies should support drug discovery to enhance pre-selection of drug 
candidates for the preclinical phase followed by three clinical trials, drug approval and clinical phase 4.  
During clinical phase 2 a small group of patients is treated with the drug candidate in 
order to validate the expected pharmacological efficacy. Phase 3 clinical studies are 
performed in comparison to the current standard therapy to show the superiority of 
the new drug candidate while treatment of a larger population of patients is 
necessary for statistical reasons [NIH 2011]. Based on the results of these tests, the 
new drug is approved if its risk-benefit ratio is deemed to be acceptable. Finally, after 
this long testing process which lasts on average 15 years and costs about US$ 880 
million per drug, the new drug is further observed during clinical phase 4 [DiMasi 
2003]. Rare clinical side effects are often not seen until this phase when a huge 
population is treated and can lead to the withdrawal of the drug. The major reasons 
for withdrawal of already approved drugs are cardiovascular and hepatic adverse 
effects [Watkins 2011].   
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Preclinical testing strategies are not always successful in extrapolating animal to 
human data and in predicting human toxicity which can result in attrition of drug 
candidates in the late phases of the drug development process [Olson 1998, Xu 
2004]. This is especially true for idiosyncratic effects - very rare side effects observed 
only in a small, susceptible portion of the human population - which are not detected 
until clinical phase 3 or 4 in most cases [Uetrecht 2008]. As a result, the amount of 
new drug approvals is decreasing while the costs of drug development are increasing 
[Mullard 2011]. Much of this attrition happens in the later phases of the drug 
development process, because earlier tests were not able to fully predict human 
toxicity. Therefore pharmaceutical companies have reinforced their research in the 
field of in vitro screening methods to enable a better pre-selection of drug candidates 
for preclinical studies and to detect a candidate’s toxic potential much earlier in the 
drug development process [Kola 2004, Preziosi 2004, Rawlins 2004, Watkins 2011].  
 
1.3 New testing strategies for non-clinical drug development 
Traditional toxicological methods describe changes of organ morphology and 
measures serum and urine parameter indicating organ damage [Marquardt 2004]. 
Some of these parameters possess limited organ specificity and sensitivity and are 
elevated only after a large part of the appropriate organ is already damaged [Muller 
2009]. For example, alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) are routinely measured serum markers for hepatocellular damage, while 
alkaline phosphatase (AP) and γ-glutamyl transpeptidase (GGT) are used to detect 
cholestasis. However, elevated plasma levels of these enzymes can also be caused 
by extra-hepatic injuries. Other common markers include total bilirubin (hepatobiliary 
injury) and serum bile acids (general liver damage) which are also influenced by 
hemolysis and diet, respectively [Ozer 2008].     
The US Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) recently approved seven urinary protein biomarkers for kidney injury in the rat 
which were submitted by the Predictive Safety Testing Consortium (PSTC) lead by 
the non-profit Critical Path Institute (C-Path). These biomarkers can improve renal 
safety assessment during non-clinical studies due to their higher sensitivity and 
specificity compared to traditional urine parameters. However, this non-invasive 
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method refines but does not replace or reduce animal studies. Their use is 
recommended by the FDA on a voluntary base and the validation for the use in 
human clinical studies is discussed [C-Path 2008]. Several research groups and 
consortia including the PSTC [Goodsaid 2007] also work on the establishment of 
novel biomarkers for hepatotoxicity which are more sensitive and liver specific than 
traditional ones. The major goal is the discovery of minimally-invasive biomarkers for 
preclinical and clinical use, which indicate liver injuries before they become 
irreversible [Halegoua-De Marzio 2008, Amacher 2010]. Therefore new ‘omics 
technologies are used to compare the changes in gene expression (genomics), 
protein expression (proteomics) and the products of cellular metabolism 
(metabolomics) to traditional toxicological endpoints [Dieterle 2008]. In the context of 
the EU-funded project PredTox, the kidneys, livers, blood and urine of drug treated 
rats were investigated according to this scheme [Suter 2011]. Nevertheless, not a 
single novel biomarker for hepatotoxicity has been approved by regulatory agencies, 
so far.  
Another current goal of biomarker discovery is the development of novel in vitro-
screening methods which enable the elucidation of a compound’s mode of action and 
the prediction of organ-specific toxicities prior to animal tests. These tests can 
enhance the selection of the best drug candidate for preclinical trials, increase the 
success rate of regulatory studies and reduce the time and costs of drug 
development [Butcher 2005, Ukelis 2008, Dash 2009, Schoonen 2009]. The methods 
performed in the phase of drug discovery (Figure 1.1) prior to animal studies are up 
to each company’s discretion and not required by law. Here, different in vitro animal 
and human cell-based methods are performed which investigate a compound’s 
potential to induce stress markers (NFκB signaling), DNA damage (p53 signaling),  
proliferation, GSH- or ATP-depletion, drug transporters, nuclear receptors or CYP-
enzymes as indicators of potential for drug-drug interactions [Mueller 2007]. The 
study in hand, as part of the EU-funded project Predict-IV, (chapter 1.7) supports this 
field of research in order to refine and reduce animal tests in terms of the 3 R’s 
principle.  
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1.4 Status quo of alternative methods 
Regulatory approved alternative methods for the replacement of animal tests are 
described in guidelines of the International Conference of Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) or the 
Organisation for Economic Co-operation and Development (OECD). ICH and OECD 
release guidelines for the international preclinical safety testing of pharmaceuticals 
and the toxicological testing of chemicals, respectively. These regulations are edited 
permanently related to the necessity of single studies and endpoints. Thus, lethality 
is no longer a desired endpoint and acute toxicity should not be tested in standalone 
studies if this information can be derived from other studies [ICH-M3 2009].  
ICH has approved different in vitro studies for the testing of genotoxicity; such as the 
mutation test in bacteria (Ames test) which is predictive for rodent mutagens, the 
chromosome aberration and micronucleus test (incorrect incorporation of 
chromosomes or fragments during cell cycle) in mammalian cells and the in vitro 
gene mutation assay in mouse lymphoma cells. These in vitro tests are approved if 
they are combined with an in vivo genotoxicity test which is recommended to be 
integrated into other studies, again to avoid standalone studies which increase the 
number of animals used. In vitro genotoxicity tests provide additional mechanistical 
data but they are not sufficient to completely replace in vivo tests since parameters 
like absorption, distribution, metabolism, and excretion by the animal or human body 
are missing [ICH-S2 2008]. 
The Hen’s Egg Test - Chorio-Allantoic Membrane (HET-CAM) test - is approved in 
the European Union for the detection of severe eye irritation. Here, the membrane of 
a fertilized chicken egg which is rich in blood vessels serves as a surrogate for an 
eye. Only substances with negative test results have to be re-tested in vivo (Draize 
test, rabbit eye) for a clear classification [ZEBET25]. OECD has also approved an in 
vitro test for severe eye irritation using isolated chicken eyes [OECD 438]. But again, 
substances with negative results also have to be re-tested in vivo.   
The OECD validated multi-layer human skin models (EpiDerm™, EPISKIN™) for the 
testing of skin corrosion [OECD 431] as an alternative to in vivo tests. Reconstructed 
human epidermis was also approved for the testing of skin irritation [OECD 439]. 
Furthermore, the 3T3 NRU assay was also accepted for the testing of phototoxicity 
as a possible drug side effect. During this test, the increased toxic potential of 
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compounds in UV-light is estimated via the vitality of a treated mouse fibroblast cell 
line with and without UV-light exposure [OECD 432]. Drugs not administrated orally 
have to be tested for endotoxins which can cause infections. The appropriate in vivo 
test was replaced by an in vitro test using an aqueous extract of horseshoe crab 
blood cells which forms a gel after incubation with endotoxins [ZEBET133]. Other 
fields of toxicology where the establishment of alternative methods is being fostered 
include embryotoxicity and teratogenicity. A few non-animal based methods have 
been validated and regulatory acceptance is pending. One approach monitors the 
suppression of the differentiation of mouse embryonic stem cells by embryotoxic 
compounds [ZEBET169].    
 
1.5 Hepatotoxicity 
The liver is one of the main target organs of drug-induced toxicities. The 
physiological principles as well as the major mechanisms of hepatotoxicity are 
explained in the following.   
 
1.5.1 Morphology and physiology of the liver 
The liver is the main organ of the metabolism of endogenous and xenobiotic 
substances, as well as the largest gland found in vertebrates. The liver contains a 
complex system of enzymes to produce and secrete proteins like albumin, 
coagulation factors, apolipoproteins, transferrin, acute phase proteins, and hormones 
(1) to maintain the xenobiotic metabolism (phase-I, -II, and - III enzymes), (2) to 
manage large parts of lipid catabolism and (3) to synthesize cholesterol. Furthermore 
the liver breaks down amino acids and synthesizes urea to detoxify amino acid-
derived ammonia. Another essential function of the liver is the production of bile 
which helps absorb lipids via the intestine and eliminate bilirubin, a product of 
hemoglobin catabolism which cannot be reused. The liver also stores iron, copper, 
and vitamins, especially Vitamin A, and stabilizes the blood glucose level by the 
synthesis and catabolism of glucose and glycogen [Schmidt 2005].  
In vertebrates, the liver is divided into four lobes which can be further divided into 
lobules. Nutrient-laden blood from the intestine reaches the liver via the portal vein. 
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Endogenous metabolic substances, proteins and, lipoproteins for breakdown enter 
the liver via the hepatic artery which also provides oxygenated blood. The liver is 
flushed with 1.5 l blood per minute while ¾ derives from the portal vein which fuses 
with the hepatic artery after entering the liver (Figure 1.2). The blood flows through 
the liver capillaries called sinusoids along the hepatocytes, the liver parenchymal 
cells, which are arranged into cords so that each hepatocyte comes in contact with 
two sinusoids [Marquardt 2004]. Besides the hepatocytes which build up 78% of the 
liver’s mass and the endothelial (2.8%) cells the organ contains three types of 
sinusoidal cells: The Kupffer cells (2.1%) are resident macrophages which secrete 
inflammatory factors and phagocytize bacteria and other substances. Pit cells have 
an anti-tumor activity and Ito cells (also called stellate cells, 1.4%) store Vitamin A 
and lipids and play a major role in the development of liver cirrhoses and fibrosis by 
producing collagen [Blouin 1977, Friedmann 1997]. The blood from all the sinusoids 
is collected in the liver vein which joins the vena cava (Figure 1.2). The bile produced 
by the hepatocytes is secreted into intercellular channels called bile canaliculi which 
fuse to bile ducts that lead the bile into the gall bladder [Marquardt 2004].  
hepatocytes
portal vein
hepatic artery
bile duct
central vein
 
Figure 1.2: Structure of the liver. 
In the liver the hepatocytes are arranged into cords. The blood coming from the portal vein flows along 
the beams into central vein while several substrates are exchanged with the cells. The bile is secreted 
into bile canaliculi located between the hepatocytes which join in bile ducts [© wissenmedia in the 
inmedia ONE] GmbH, Gütersloh/Germany, modified]. 
 
1.5.2 Hepatocytes and xenobiotic metabolism 
The major task of hepatocytes is the maintenance of the liver’s metabolic activity. 
Compared to other cell types in vertebrates hepatocytes contain the same cell 
organelles like the endoplasmic reticulum (ER) and the Golgi apparatus for protein 
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biosynthesis including a well-marked rough ER as residence of the Cytochrome- 
P450-dependent-monooxygenases (CYP), the peroxisomes for the breakdown of 
long chain fatty acids and mitochondria for the energy production and the breakdown 
of shorter fatty acids. Hepatocytes are differentiated and therefore highly specialized 
cells which proliferate very rarely. Around 20% of them contain two nuclei and a 
fourfold set of chromosomes. Hepatocytes abut on the bile canaliculi 
(apical/canalicular) with 15% and to the sinusoids (basolateral/sinusoidal) with 70% 
of their surface. The endothelium of the sinusoids lack a basement membrane and 
has many pores which allow molecules < 250 kDa to directly diffuse from the blood to 
the space of Disse, the interstitial space between the endothelium and the 
hepatocytes. Here an extensive exchange of metabolic products is enabled by 
passive diffusion via the cell membrane and water pores, pinocytosis, and receptor-
mediated endocytosis as well as carrier-mediated diffusion and active transport 
[Marquardt 2004].  
The metabolic activity of the liver enables the elimination of endogenous metabolic 
products as well as xenobiotica which cannot be used as educts or for energy 
production to prevent their accumulation in the body. Therefore these substances 
have to be transformed into a biologically non-reactive and hydrophilic form to 
facilitate their excretion via bile or urine without damaging endogenous material. The 
liver holds a broad spectrum of different enzymes covering a wide range of substrate 
specificities to be able to metabolize new and unknown compounds. The xenobiotic 
metabolism is divided into three phases: functionalisation (phase-I), conjugation 
(phase-II) and excretion (phase-III).  
Table 1.1: Overview of the major classes of xenobiotic metabolizing enzymes.  
Phase-I enzymes activate their substrates for the conjugation reaction in phase-II where water soluble 
endogenous compounds are covalently bound to the phase-I-metabolite [Marquardt 2004].  
Phase-I enzymes Phase-II enzymes 
Cytochrome-P450-dependent monooxygenases (CYP) Glutathiontransferases (GST) 
Flavin-dependent monooxygenases UDP-glucuronosyltransferases (UGT) 
Monoaminoxidases  Sulfotransferases (SULT) 
Cyclooxygenases  Acetyltransferases  
Alcohol- and Aldehyde dehydrogenases (ADH, ALDH) Aminoacyltransferases 
Esterases Methyltransferases 
Epoxidhydrolases    
Hydrolases   
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Phase-I enzymes (Table 1.1) transform apolar, lipophilic substances into more polar 
and hydrophilic ones. By oxidation, reduction or hydrolysis the appropriate enzyme 
introduces new chemically functional groups into the molecule which act as targets 
during phase-II reactions. The major group of phase-I enzymes are the CYPs which 
are related to their amino acid sequence organized into different families (ongoing 
numbered starting with one) and subfamilies (named with capitals from A-Z) while the 
different isoenzymes of one subfamiliy are again ongoing numbered starting with 
one. The major human CYPs involved in xenobiotic metabolism are CYP1A2, 
CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 
[FDA 2004]. CYPs of different species are evolutionarily related and their sequences 
are very similar. Therefore most human CYPs have orthologs in other species like, 
e.g., rodents and inducers, inhibitors as well as substrates are often but not always 
comparable (Table 1.2). 
Table 1.2: Inducers and substrates of the major CYPs in human and rat.  
CYP-inducers and -substrates are often comparable between human and rat [Hewitt 2007].            
BNF = β-Naphthoflavone, Dex = Dexamethasone, 3MC = 3-Methylcholantrene, OM = Omeprazole, 
Pac = Paclitaxal, PB = Phenobarbitone, Rif = Rifampicine, Testo = Testosterone, Tol = Tolbutamide 
 
CYP-family   Human  Rat 
1A CYP-isoform: 1A1/2 1A1/2 
 Inducer: OM, BNF, 3MC PB, BNF, 3MC 
  Substrate: Phenacetin Phenacetin 
2C CYP-isoform: 2C8/9/18/19 2C6/11 
 Inducer: Rif, PB Dex 
  Substrate: Pac, Tol, Diclo Diclo, Testo 
3A CYP-isoform: 3A4/5 3A1/2 
 Inducer: Rif  Dex, PB 
  Substrate: Testo, Midazolam Testo, Midazolam 
4A CYP-isoform: 4A9/11 4A1/2/3/8 
 Inducer: Clofibrate Clofibrate 
  Substrate: Lauric acid Lauric acid 
 
Phase-I biotransformation carries the risk of generating strong electrophilic 
metabolites which react with endogen nucleophiles like proteins or nucleic acids 
before they can be further metabolized in phase-II (Figure 1.3). So per se non toxic 
and chemically inert drugs could be transformed into very reactive hepatotoxic 
metabolites. Phase-I metabolites are conjugated by phase-II enzymes (Table 1.1) 
with endogenous water soluble components like glutathione (GSH), glucuronic acid 
or sulfonyl groups to increase their water solubility. The resulting phase-II metabolites 
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are then excreted into the bile canaliculi for the elimination via the bile or into the 
blood for the elimination via the kidney [Marquardt 2004]. 
RH 
CYP
ROH RO 
+ protein
R-protein
RO-SG 
hydrophilic
reactive
hydrophilic
reactive, electrophilic protein‐adduct
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Figure 1.3: Scheme of xenobiotic metabolism.  
More or less chemically inert, hydrophobic substances are oxidized by phase-I enzymes, conjugated 
with endogenous molecules by phase-II enzymes, and excreted into bile or blood. Very reactive 
metabolites may bind covalently to cellular components like proteins. R = residual. 
This excretion process is often called phase-III of the xenobiotic metabolism. The 
basolateral membrane of the hepatocytes is rich in transporters (Figure 1.4, Table 
1.3) for the uptake and the export of organic cations and anions, bile salts, different 
metabolic products, and xenobiotica. The apical surface of hepatocytes expresses 
transporters for the export of bile salts, endogenous products and xenobiotics and 
their metabolites into the bile canaliculi [Giacomini 2010, Klaassen 2010].  
Table 1.3: Hepatic transporters. 
Hepatocytes express in their basolateral membrane transporters for the exchange of products with the 
blood. On their apical side efflux transporters transfer bile salts and metabolic products into the bile. 
[Giacomini 2010] 
Uptake transporters  Efflux transporters 
Organic cation transporter (OCT) Multi drug resistance protein (MDR, MRP) 
Organic anion transporter (OAT) Breast cancer resistance protein (BCRP) 
Organic anion transporting protein (OATP) Bile salt export pump (BSEP) 
Na+/taurocholate cotransporting polypeptide (NTCP) Organic solute transporter (OST) 
Organic solute transporter (OST)   
 
NTCP is a sodium dependent cotransporter which takes up bile salts from the portal 
blood before they are again excreted into the bile by BSEP. So most of the bile acids 
are recycled rather than newly synthesized which becomes important during 
cholestasis where the expression of NTCP was found to be decreased in animals 
and humans [Hagenbuch 2003]. OATPs are symporters which exchange bile salts 
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and organic anions for intracellular bicarbonate and play a major role in the hepatic 
clearance of drugs while they were found to be downregulated in cholestatic animal 
models [Hagenbuch 2003]. MDR1, BCRP and MRP1 were found to be responsible 
for the resistance of tumors to chemotherapeutics and several studies showed that 
their overexpression in vitro make cells resistant to cytotoxic drugs. For the major 
human hepatic transporters rat orthologs with similar substrate specificity do exist 
[Giacomini 2010, Klaassen 2010].     
OCT OATPOAT NTCP
OST
MDR1
MRP
BSEP
bile
BCRP
MRP2
hepatocyte 1 hepatocyte 2  
Figure 1.4: Hepatic transporters.    
Hepatocytes express different transporters on their basolateral membrane for the exchange of 
metabolic educts and products as well as bile salts with the blood. The apical membrane contains 
transporters for the excretion of bile salts and metabolites into the bile [Giacomini 2010, modified]. 
The xenobiotic metabolism is regulated by four basic mechanisms: (1) Increase or (2) 
decrease of an enzyme’s (3) expression or its (4) activity. Especially CYPs are often 
induced by their substrate which allows a quick response to new xenobiotics. 
Thereby substrates often induce different enzymes of all three phases of the 
xenobiotic metabolism by a cascade starting from one of the following nuclear 
receptors: 
 
 Peroxisome proliferation-activated receptor (PPAR) 
 Farnesoid X receptor (FXR) 
 Pregnane X receptor (PXR) 
 Liver X receptor (LXR) 
 Constitutive androstane receptor (CAR) 
 
These receptors are located in the cytoplasm and are translocated into the nucleus 
after they were activated by a substrate. There they heterodimerise with the Retinoid 
X receptor (RXR) which is also activated by a cofactor. This heterodimer binds to a 
response element of the DNA and initiates the expression of transcription factors for 
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several enzymes of the xenobiotic metabolism. The helix-loop-helix receptor aryl-
hydrocarbon receptor (AhR) also binds its ligand in the cytoplasm, translocates to the 
nucleus and heterodimerizes with the AhR nuclear translocator (Arnt) in order to bind 
to a responsive element in the DNA and activate the transcription of several target 
genes [Waxman 1999, Patel 2007]. Nuclear receptors have an overlapping field of 
target genes (Figure 1.5) and crosstalk with each other [Xie 2004]. 
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 Figure 1.5: Regulation of the xenobiotic metabolism.  
The enzymes of the xenobiotic metabolism are regulated by nuclear receptors which act as 
transcription factors for a wide field of target genes after they were activated by a ligand. Overlapping 
fields of target genes and ligands make the system flexible for new xenobiotics [Xie 2004, modified]. 
The drug related induction and inhibition of various enzymes of the xenobiotic 
metabolism can result in drug-drug interactions which often cause drug side effects 
as explained in the next chapter [Guengerich 2008, Walsky 2008].  
 
1.5.3 Drug induced hepatotoxicity 
Hepatotoxicity is the most frequent reason for the failure of new pharmaceutical 
compounds during the process of drug development or for the withdrawal of drugs 
after they have been marketed [Lee 2003, Lee 2005, Halegoua-De Marzio 2008]. 
Several drugs cause idiosyncratic adverse effects [Lee 2003, Daly 2010] which are 
not dose-dependent, show variable latencies, occur very seldom (one in every 1000 
to one in every 100.000 patients) and are not predictable by regulatory studies in 
most cases. Idiosyncrasy seems to be related to the hypersensitivity of individuals 
which may be related inter alia to single nucleotide polymorphisms (SNPs) in 
enzymes of the xenobiotic metabolism. Thus, severe adverse effects which can lead 
to acute liver failure and the death of patients often occur not until a larger population 
is treated with these drugs after the approval [Li 2002, Kaplowitz 2004, Uetrecht 
2008, Hussaini 2007]. Some drugs show well predictable hepatotoxicity with dose-
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dependent effects which can be divided into cytotoxic effects (necrosis, apoptosis), 
cholestasis (dysfunction of bile secretion), steatosis (fatty liver), fibrosis (increased 
production of connective tissue), cirrhosis (increased production of connective tissue 
in consequence of steatosis or hepatitis), hepatitis (inflammation), and liver tumors 
[Lee 2003, Marquardt 2004]. Drug induced hepatotoxic effects can be caused by 
different mechanisms:  
a) Reactive metabolites: Phase-I enzymes biotransform drugs to metabolites with 
a higher solubility in water. Such biotransformations sometimes result in very 
reactive electrophiles which bind to proteins or other cellular components. This 
can lead to cellular dysfunctions like loss in ionic gradients and the 
intracellular calcium homeostasis followed by a decreased ATP-level, cell 
swelling and rupture or the activation of apoptosis. Furthermore protein 
adducts presented on the cell surface can cause immune reactions [Li 2002, 
Lee 2003, Kaplowitz 2004 and 2005, Uetrecht 2008, Guengerich 2008]. 
Reactive metabolites can also bind to the DNA which is a key event of 
genotoxicity [Boehme 2010, Hashizume 2010]. 
b) Apoptosis: Immune reactions as well as drugs and their metabolites can 
activate apoptosis pathways in the hepatocytes which lead to programmed cell 
death if protective survival pathways cannot rescue the cell [Kaplowitz 2000, 
Lee 2003]. 
c) Oxidative stress: Reactive oxygen species (ROS) like oxygen ions and 
hydrogen peroxide are produced during normal cell functions like fatty acid 
oxidation or the electron transport in the mitochondrial respiratory chain. 
Under normal conditions they are detoxified by enzymes like dismutases, 
catalases and glutathione (GSH) transferases. Reactive metabolites of drugs 
can trigger oxidative stress by for example disturbing the electron transport in 
the respiratory chain. ROS and reactive metabolites can be detoxified, e.g., by 
conjugation with GSH. However, intensive production of ROS leads to GSH 
depletion when the cellular antioxidant mechanisms are exhausted. Then 
several cellular components including the DNA can be damaged. Finally 
oxidative stress can result in cell death if too many cellular functions are 
diminished [Kaplowitz 2000, Jaeschke 2000, Lee 2003, Guengerich 2008, 
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Avery 2011]. Oxidative stress is furthermore discussed as a key mechanism of 
non-genotoxic carcinogens [Hernández 2009]. 
d) Immune reactions: Adducts of covalently bound metabolites to enzymes or 
other cellular components are transported in vesicles to the cell surface and 
presented to immune cells. Thus, the immunological cascade starts to 
eliminate the foreign compound and trigger inflammation, formation of 
antibodies or cytolytic reactions. Furthermore inflammation can be induced by 
drugs causing necrosis as a result of reactive metabolites or oxidative stress 
[Lee 2003, Ganey 2004, Kaplowitz 2004 and 2005].  
e) Transporter inhibition: Drugs like Cyclosporine A inhibit the bile salt export 
pump (BSEP). The disturbed secretion of bile salts from the hepatocyte into 
the bile canaliculi causes cholestasis. The block of transporters for bilirubin or 
organic ions causes a backlog of these substances in the hepatocytes and 
later in the blood which for example can lead to jaundice [Lee 2003, Tang 
2007, Giacomini 2010].  
f) Enzyme inhibition and induction: A reactive phase-I metabolites can covalently 
bind to its biotransforming CYP enzyme. This can result in irreversibly blocked 
enzymes and protein adducts which potentially activate the immune system. 
Other drugs block enzymes time-dependently and reversibly. If a compound 
inhibits a major CYP of its own catabolism the clearance of this drug may be 
decreased. Consequently, the drug’s plasma level and half life could be 
increased as well as its pharmacological and may be toxic effect. Against that 
the plasma level of the appropriate drug could be decreased if this CYP is 
induced and the drug metabolism is accelerated. This may lower the drug’s 
efficacy but also enhance the production of reactive metabolites with the 
consequences explained before. Enzyme inhibition and induction play a major 
role in drug-drug interactions which can trigger adverse effects while one drug 
inhibits or induces a CYP involved in the metabolism of a coadministered 
drug. A prominent example is Acetaminophen which is transformed by 
CYP2E1 into a reactive metabolite. The co-consumption of alcohol which 
induces CYP2E1 results in the rapid formation of a large amount of this 
metabolite and can cause oxidative stress, liver necrosis and acute liver failure 
[Lee 2003, Walsky 2008, Zhou 2008]. Since the inhibition and induction of 
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CYPs as well as the drug-drug interaction play a major role in drug induced 
hepatotoxicity the FDA demands the in vitro and in vivo testing of the major 
human CYPs [FDA 2004].    
g) Damage of mitochondria: The mitochondria can be affected directly or 
indirectly by drugs via many different ways. Since mitochondria are essential 
for energy production of the cell mitochondrial damage commonly leads to cell 
death by apoptosis or necrosis. Drugs like Acetaminophen can directly open 
the mitochondrial permeability transition (MPT) pore which results in loss of 
the mitochondrial transmembrane potential, rupture of the mitochondria due to 
water influx and the release of proapoptotic factors into the cytosol. These 
mechanisms can cause hepatitis and acute liver failure. Some drugs inhibit the 
mitochondrial DNA (mtDNA) transcription machinery and cause mtDNA 
depletion or block enzymes of the mitochondrial respiratory chain (e.g. 
Troglitazone) or the fatty acid catabolism (e.g. Valproic acid) which diminish 
the mitochondrial function and can result in the formation of ROS and 
oxidative stress. Modifications in the fatty acid metabolism can cause steatosis 
and hepatitis as a result of lipid accumulation. Cationic amphiphilic substances 
can dissipate the transmembrane potential via passing the inner membrane 
after they were protonated in the intermembrane space. These drugs act as 
uncoupling agents and inhibit the energy production. Furthermore glycolysis is 
induced in order to produce ATP in the cytosol when the mitochondrial ATP 
production is inhibited by mitochondrial damage. The incidental pyruvate 
which is usually further metabolized in the mitochondria is transformed into 
lactate and secreted into the blood. The protons produced during increased 
glycolysis and ATP hydrolysis as well as the increased plasma level of lactate 
lead to lactic acidoses (e.g. Metformin) [Lee 2003, Kaplowitz 2004, Lee 2005, 
Dykens 2007, Labbe 2008]. 
Although hepatocytes are the major target of hepatotoxicity other hepatic cell types 
can be affected as well. Kupffer cells, the immune cells of the liver, can activate 
cytokine signaling and inflammation reactions. The fat storing and collagen producing 
Ito cells are involved in the development of fibrosis and cirrhosis. Furthermore the 
canaliculi and the bile ducts can be damaged by drugs and metabolites excreted into 
the bile [Friedmann 1997, Marquardt 2004].  
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1.5.4 In vitro liver models for the prediction of human hepatotoxicity 
For the investigation of human toxic effects human material seems to be the best 
device but also animal models can provide substantial information about a drug’s 
metabolism, biological target and toxic effects. Generally more complex models 
better reflect the in vivo situation than less complex models but these are easier to 
standardize, manipulate and interpret [Tuschl 2008]. Commonly used in vitro systems 
for the investigation of hepatotoxicity are isolated perfused livers, liver slices, primary 
hepatocytes in an adherent cell culture or as suspension culture, liver cell lines and 
transgenic cells, as well as subcellular fractions like microsomes or S9 mix (Figure 
1.6).     
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Figure 1.6: In vivo and in vitro models for the study and prediction of human hepatotoxicity.  
More complex models reflect the human in vivo situation better but complicate handling, data 
interpretation and ethical acceptance [Tuschl 2008, modified]. 
Isolated perfused livers provide the complete set of liver cell types in their original 
three-dimensional architecture and function including the vascular and the biliary 
system, cell-cell and cell-matrix interactions, signaling, and regulation [Gordon 1972]. 
However, isolated livers are difficult to handle and maintain their function for only a 
few hours while the reproducibility of different experiments is quite low. Furthermore 
the availability of human organs is low and difficult to plan, the amount of animals is 
not reduced and only one compound can be tested per liver. 
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Liver slices are produced by cutting livers in thin slices which can be cultured for up 
to 72h in culture media. The optimal thickness of these slices is between 150µm and 
225µm to guarantee an optimal exchange of oxygen and nutrients and to keep the 
ratio of functional cells to cells damaged via the cutting process at an optimal 
balance. Liver slices possess all cell types in their original three-dimensional 
architecture as well as cell-cell and cell-matrix interactions, signaling, and regulation. 
Therefore they enable studies of drug metabolism and excretion into the bile in the 
same way like isolated livers. In addition a lot of slices can be produced out of one 
organ, so several different compounds can be tested which significantly decreases 
the amount of animals used. Another advantage of liver slices is the possibility to 
perform biochemical tests and histopathological examinations in parallel [Lupp 2001, 
Vickers 2004, Barth 2006]. Nevertheless, a big disadvantage is the short culture time 
of 72h.  
Liver cell cultures can be used in flexible formats and applications. Furthermore 
culture conditions are easy to standardize and experiments can be performed with a 
high reproducibility. Hepatic cell cultures are based on primary hepatocytes, 
transfected hepatocytes, hepatic cell lines or co-cultures of different cell types which 
are explained below in more detail. 
Co-cultures of hepatocytes and non-parenchymal liver cells enable intercellular 
signaling. Hence, effects on different liver cell types could be investigated in a minor 
complex system compared to isolated livers or liver slices. So sinusoidal endothelial 
cells co-cultured with hepatocytes stabilize each other and enable the detection of 
adverse effects in the liver’s vascular system [Hwa 2007, Dash 2009]. Kupffer cells 
as hepatic immune cells are involved in inflammatory processes and influence CYP 
activities in vivo and in vitro [Hoebe 2001, Sunman 2004]. 3D perfused liver 
bioreactors are built up by seeding different liver cell types onto scaffolds that mimic 
the vascular system and enables more complex studies for drug clearance, 
metabolite assessment and inflammatory adverse effects [Dash 2009]. These culture 
systems are currently used for special questions and are not suited for screening 
methods due to their complex handling. In another 3D-system better suited for high 
troughput approaches all cell types of the native liver are seeded onto an 
interconnecting porous scaffold in multiwell plates. This organotypic cell culture 
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system provides activity and inducibility of phase-II, -II, and -III enzymes for up to 70 
days near the in vivo level [Vidales 2011].       
Primary hepatocytes are the major in vitro system for early prediction of 
hepatotoxicity [Soars 2007, Hewitt 2007, Schoonen 2009, Gómez-Lechón 2010, Li 
2010]. Primary hepatocytes are freshly isolated out of animal or human livers by 
organ perfusion. During this process the liver is flushed via its vascular system with a 
buffer containing collagenases and/or proteinases which digest the vessels and the 
extracellular matrix to be able to isolate vital hepatocytes after organ homogenization 
and centrifugation. For the isolation of human primary hepatocytes several life 
science companies have cooperations with medical centers to receive organ parts 
removed during surgeries or livers of dead patients [Seglen 1976, Richert 2004]. 
Primary hepatocytes are highly differentiated cells which do not proliferate. Therefore 
they have to be isolated freshly for every experiment while the use of cryopreserved 
cells makes the investigator more flexible. Optimized protocols for cryopreservation 
and thawing guaranty the metabolic activity of thawed cells [Gómez-Lechón 2006, 
Hewitt 2007].  
Short time studies for drug transport and drug clearance are often performed with 
hepatocyte suspension cultures. In this culture system the cells are incubated on a 
shaker and remain vital for only a few hours due to the lack of cell-cell and cell-matrix 
contacts [Jouin 2006, Hewitt 2007]. In monolayer cultures the cells adhere onto cell 
culture plates coated with extracellular matrix proteins (Collagen I or Matrigel) and 
form close cell-cell and cell-matrix contacts assuming the polygonal hepatocyte-like 
shape with clear cytoplasm. Since they do not proliferate the cells are plated with a 
confluence of 100% and form a cell monolayer. After three to five days the cells look 
like fibroblasts and detach [Tuschl 2006, Sahu 2007]. Thus, monolayer cultured 
hepatocytes are used for short term studies like acute cytotoxicity and CYP-induction 
as a hint for drug-drug interactions [Hewitt 2007, Gómez-Lechón 2010].  
Cultured between two layers of gelled collagen or in monolayer culture overlaid by a 
film of Matrigel (extracellular matrix derived from Engelbreth-Holm-Swarm mouse 
sarcoma) primary hepatocytes additionally form bile canaliculi-like structures (Figure 
1.7) and maintain their characteristical shape at least for ten days. The functional 
activity of the canaliculi was proven by incubating the cells with a fluorescent dye 
which is known to be transported by MRP2 into the bile canaliculi where its 
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accumulation was detected. The so called sandwich cultured hepatocytes (Figure 
1.7), the cell culture system used for the present study, reorganize themselves during 
the first three days in culture and after that maintain a stable expression and 
inducibility of the major CYPs, phase II enzymes, transporters, nuclear receptors, 
transcription factors, as well as liver functions like albumin production near the in vivo 
level [Tuschl 2006, Tuschl 2009]. Thereby the culture conditions dramatically 
influence the vitality and functionality of hepatocytes. Cells cultured with fetal calf 
serum lose their characteristical shape and the expression of major enzymes of the 
xenobiotic metabolism much earlier than serum-free cultured cells [Tuschl 2006, 
Tuschl 2009].        
two layers of
collagengel
hepatocytes cell culture
medium
 
Figure 1.7: Scheme of the sandwich culture system. 
In the sandwich culture the cells are cultured between two layers of gelled collagen I. Cultured this 
way the hepatocytes maintain their function and morphology for at least ten days and build canaliculi- 
like structures (white arrow).   
 
Cell lines are immortal and grow constantly for an almost unlimited life-span [Donato 
2008]. Therefore their use enables long term studies of high reproducibility [Schmitz 
2007]. In contrast to primary cells cell lines are permanently available and make cell 
culture studies more flexible. However, nearly all hepatoma derived cell lines express 
enzymes of the xenobiotic metabolism to a lesser extent than primary cells [Donato 
2008, Fujimura 2010, Lin 2011]. HepG2 is a human liver hepatoma cell line with a 
very small basal expression and inducibility of nuclear receptors [Westerink 2007] 
and nearly all the major CYP enzymes as well as of some phase-II enzymes and 
transporters [Rodríguez-Antona 2002, Boehme 2010, Guo 2011]. Thus, they are 
often less sensitive towards hepatotoxic agents than primary hepatocytes and are 
only used for selected studies [Westerink 2007] or used with S9-mix to mimik the 
metabolic activity of the cells [Otto 2008, Boehme 2010]. HepaRG cells derive from a 
human hepatocarcinoma and differentiate during four weeks in culture into cells 
comparable to primary hepatocytes based on morphology, expression of major 
phase-I, -II, and -III enzymes and several liver functions which remain stable for at 
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least four weeks [Aninat 2006, Jossé 2008, Anthérieu 2010]. The application 
capabilities of this cell line for predicting liver toxicity of new drugs is tested in the EU-
project Predict-IV in comparison to human and rat primary hepatocytes. The non-
tumorigenic cell line Fa2N-4 originates from human primary hepatocytes 
immortalized by stable transfection. The inducibility of CYP1A2 and CYP3A4 is 
comparable to primary hepatocytes while CYP2B6 is less inducible and several 
hepatic transporters are expressed on lower level [Kenny 2008]. Lin et al. [Lin 2011] 
investigated the activities of major phase-I and phase-II enzymes in the five human 
hepatoma cell lines HepG2, Hep3B, HCC-T, HCC-M, and Huh-7. In conclusion the 
activities of all tested enzymes were lower than in human primary hepatocytes and 
varied over the ten assayed passages while Huh-7 showed the highest activities. The 
THLE-2 cell line is based on human adult liver epithelial cells immortalized by the 
introduction of a recombinant simian virus 40 large T antigen gene. These cells 
express different phase-II and antioxidant enzymes and activate different chemical 
carcinogens [Pfeifer 1993]. Their poor CYP activity was successfully stocked up by 
transfection [Bort 1999, Donato 2008]. H4IIE and FAO are rat hepatoma cell lines. 
Compared to rat primary hepatocytes they lack the expression of some genes coding 
for drug metabolizing enzymes or express them at a lower level while not all 
expressed CYPs are inducible [Clayton 1985, Fujimura 2010]. Therefore the results 
of studies performed in hepatic cell lines should be interpreted with respect to the 
differences in gene expression, enzyme activity, and inducibility of hepatic cell lines 
compared to primary hepatocytes.   
Subcellular fractions are commercially available and prepared by homogenization 
of the liver followed by specific centrifugation steps. Microsomes are one class of 
subcellular fractions which is often used in toxicology. These membrane surrounded 
vesicles containing fragments of the endoplasmatic reticulum and the thereon bound 
CYPs. A further commonly used class are S9-mixtures, supernatants which result 
from the centrifugation of liver homogenate at 9,000 x g and contain all enzymes of 
the xenobiotic metabolism. To increase the activity of these enzymes the donor 
animal is treated with CYP inducers before the liver is isolated to produce 
microsomes and S9-mixtures. These are used for short-time experiments with limited 
applications like CYP inhibition, CYP induction or drug metabolism studies [Callander 
1995]. S9-mixes are routinely used as an activation system for compounds tested 
with the Ames assay for their genotoxic potential [Ames 1973]. Furthermore they 
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provide a metabolic system for hepatic cell lines which often express enzymes of the 
xenobiotic metabolism very limited [Otto 2008, Boehme 2010 and 2011].  
 
1.6 Toxicogenomics can sustain drug discovery and 
development 
Genomics methods used in the field of toxicology are called toxicogenomics [Lord 
2006]. Compared to traditional studies toxicogenomics can detect drug induced 
toxicities before these effects become adverse and are observed histopathologically 
[Van Hummelen 2010]. Kier et al. could correlate gene expression changes in the 
liver tissue of rats 24 h after drug treatment with histopathological findings after 72 h 
[Kier 2004] while Hirode et al. describe early marker genes for phospholipidosis 
[Hirode 2008]. Zidek et al. identified 64 potential marker genes for hepatotoxicity in 
rat livers after single dose treatment and built a prediction model which classifies 
toxic and non-toxic compounds related to their gene expression changes before 
histopathological changes can be detected [Zidek 2007]. These changes can be 
investigated related to specific target genes (e.g. branched-DNA, qRT-PCR, Nothern 
Blotting) or genome wide (whole genome gene expression analysis) where tens of 
thousands of genes can be analyzed in parallel in one sample. Genomics tests can 
be performed in various matrices like tissue and body fluids or cultured cells and are 
therefore well suited for the discovery of novel early biomarkers [Van Hummelen 
2010]. Proteins which are in vivo secreted into urine, feces, or blood where they act 
as biomarkers for organ toxicity or a specific disease can be linked to altered genes 
in organs of drug treated animals. After the correlation between biomarker release, 
histopathology findings and changes in gene expression had been proven diagnostic 
kits and novel biomarkers are established for the support of preclinical and clinical 
studies. These in vivo findings can be also compared with genomic data of drug 
treated cells in order to define marker genes for the prediction of drug toxicity in vitro 
[Pennie 2000, Fielden 2006, Hewitt 2008, Mendrick 2008, Van Hummelen 2010]. 
Furthermore genomics enable the profiling of single nucleotide polymorphisms 
(SNPs) in individual patients. A large number of SNPs has been detected in the 
human genome while several SNPs are postulated to be disease relevant or involved 
in toxic side effects of drugs. Especially SNPs of CYPs are often involved in drug 
induced toxicity [Koo 2006]. Therefore the test kit AmpliChip™ was worldwide 
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approved to detect several SNPs of CYP2D6 which is involved in the metabolism of 
approximately 25% of the marketed drugs and triggers predispositions for adverse 
effects [Mendrick 2008].  
Toxicogenomics methods are well suited for the development of early prediction 
models for specific organ toxicities. In vitro screenings in different cell types 
performed prior to animal studies have the potential to prioritize less toxic drug 
candidates which are further developed while the toxic ones are stopped before they 
are tested in animals [Pennie 2000, Fielden 2006, Hewitt 2008, Menderick 2008, Van 
Hummelen 2010]. Thus, these early screening methods can help to reduce the 
amount of animals used for regulatory studies during drug development. These tests 
can furthermore give first information about target organs as well as species 
differences related to toxic effects and represent a giant stride towards the 3R’s 
principle [Russel 1959]. A prediction model is based on a database filled with gene 
expression data of as many as possible reference compounds with well known mode 
of action and in vivo toxicity where gene alterations are correlated with. Using the 
appropriate software a set of genes can be found which enables the classification of 
new drug candidates as toxic or non toxic [Lord 2006, Zidek 2007, Hrach 2011].  
During the last decade several public consortia and international initiatives have been 
founded in order to facilitate the application of toxicogenomics methods, investigate 
molecular mechanisms, establish genomic biomarkers, or to create reference 
databases for different fields of toxicology [Mattes 2008]:   
 International Life Science Institute Health and Environmental Science Institute 
Committee (ILSI HESI; international; academic, industrial and governmental 
partners) 
 Toxicogenomics Research Consortium (TRC; USA; academic) 
 Predictive Safety Testing Consortium (PTSC; USA; FDA, EMA, industrial 
partners) 
 InnoMed PredTox Consortium (EU, academic and industrial partners) 
 Toxicogenomics Project (Japan) [TGPJ 2011]  
 National Centre for Toxicogenomics (NCT) founded by the National Institute of 
Environmental Health Science (NIEHS; USA) [Tennant 2002].  
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Furthermore FDA and EMA perceived the potential of genomics methods to support 
clinical studies and encourage their establishment and application [Menderick 2008]. 
Therefore the FDA released the “Guidance for Industry Pharmacogenomics data 
submission” [FDA 2005] and enabled genomics data to be part of the approval 
package. Currently these data are assumed to be additional information and its 
submission is optional on a voluntary base. The EMA founded the Innovation Task 
Force to also integrate genomics into the drug development process and therefore 
published the “Reflection paper on co-development of pharmacogenomic biomarkers 
and assays in the context of drug development” [EMA 2010].  
The timeframe of toxicogenomic studies is very variable and strongly depends on the 
study design. In vitro screening models measuring a defined gene set followed by a 
standardized data analysis usually last a few days. The big advantage of in vitro 
models compared to animal studies is the possibility to test several different 
compounds and doses with the cells of one donor including the vehicle control. 
During preclinical trials one animal can only be treated with one dose of one specific 
compound while for the vehicle control a further animal is used [ICH-M3 2009]. 
However, the reagents, technical equipment and softwares required for genomics 
studies are relatively expensive [Farkas 2010]. Especially the establishment of 
screening models is cost-intensive and time-consuming since several biological 
replicates of cells treated with a large number of reference compounds have to be 
analyzed in order to obtain statistically significant results [Elashoff 2008]. Here the 
time points of sample collection have to be chosen carefully so as not to miss the 
critical time window of cellular changes. Furthermore during the first step of the 
development of a screening system whole-genome gene expression analyses are 
often perfomed. These methods usually include different working steps like cell or 
tissue lysis, RNA isolation and purification, cDNA or cRNA synthesis and purification, 
as well as the hybridization of the targets onto the gene chips, chip processing and 
scanning [Pennie 2000, Lord 2006]. Such multi-step operations take their time and 
always involve the danger of accumulating errors. Whole genome gene expression 
analyses detecting more than 20,000 different genes per sample produce large 
amounts of data whose biological interpretation is very complex [Hewitt 2008]. 
Therefore bioinformatic softwares like Genedata’s Expressionist™ have been 
developed providing tools for the normalization of raw data, the performance of 
statistical tests as well as the calculation of fold changes and the statistical 
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significance of gene expression changes [Genedata 2011]. Additionally a variety of 
software tools (IPA® [Ingenuity 2011], MetaTox™ [GeneGo 2011], ArrayTrack/FDA 
[Van Hummelen 2010]) supporting the biological data interpretation are commercially 
available. These tools access databases filled with information about the interaction 
of biological molecules like transcription factors, transporters, enzymes, and 
receptors with each other as well as with chemicals or drugs. After whole genome 
gene expression data were uploaded into these softwares a list of affected canonical 
pathways and physiological functions are shown. With the help of this information the 
molecular mechanisms of toxic effects, the mode of action of drugs, molecular 
targets, as well as changes in specific cell signaling or gene regulation pathways can 
be elucidated. However, drawing the right conclusions based on a long list of 
deregulated functions and pathways is anything but trivial and requires a keen 
scientific knowledge and experience [Hewitt 2008, Van Hummelen 2010]. 
Furthermore these informations are based on the current understanding and maybe 
not complete since several pathways and mechanisms have not been fully described 
yet. During analysis it is essential to verify if the gene probes of necessary target 
genes were contained on the processed array.   
Due to their complex performance and data analysis whole genome gene expression 
methods are less suited as routinely used screening models. Nevertheless, they 
enable the definition of predictive gene sets by correlation of the gene expression 
data with in vivo findings or by application of specific bioinformatic calculations. After 
that the resulting gene set need to be validated by another genomics method. Finally 
a standardized high throughput in vitro system can be established for the prediction 
of new drugs’ organ toxicities. Ideally this model is based on a cell culture system 
which is easy to handle and a fast genomics method measuring the gene expression 
changes of a defined gene set without the need of multiple working steps and 
complex data interpretation [Zidek  2007, Hrach 2011]. 
 
1.7 EU-project Predict-IV 
The study in hand is part of Predict-IV a collaborative project funded by the European 
Commission’s Seventh Framework Programme (FP7). FP7 is a financial tool to 
support the research and development of several scientific areas, while the full 
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project title is ‘Profiling the toxicity of new drugs: a non animal-based approach 
integrating toxico-dynamics and biokinetics’ (grant agreement no.: 202222). The 
project has started on May 1st 2008 for the duration of 60 months and includes 21 
partners from industry and academia. The overall goal is to develop in vitro testing 
strategies for a better prediction of drug safety during the phase of drug discovery or 
early stages of drug development. With the help of different ‘omics technologies 
(metabolomics, proteomics and genomics) as well as high content imaging (HCI) and 
kinetics novel and early in vitro biomarkers should be defined which may enable the 
prediction of human toxicities. Thus, a predictive in vitro screening battery could 
enable the identification of drug candidates which are potentially toxic in humans 
before they are tested in animals in future. This better pre-selection of drug 
candidates could reduce late stage failures resulting in decreased costs and duration 
of drug development and represents a major improvement towards the 3R’s principle 
[Predict-IV 2011].  
As part of Predict-IV the three organ systems liver and kidney as major target organs 
for drug-induced toxicities as well as the central nervous system (CNS) as a target of 
undesired side effects are tested. Different culture models of primary cells and cell 
lines from human, rat, mouse, and cow are treated with reference compounds of well 
known toxicity and kinetics in animals and human. These reference compounds were 
selected due to their organ specific toxicity in order to cover different molecular 
mechanisms and toxic phenotypes. After a dose finding study the cells were treated 
with two doses: A toxic dose around the TC10 (toxic concentration; concentration 
which kills 10% of the cells) and a non-toxic dose which was fixed at 1/10 of the toxic 
dose. The effect of the treatment was measured at different endpoints: Metabolomics 
(NMR, MS), proteomics (MS), genomics (global gene expression analysis), kinetics 
(HPLC), and HCI. Metabolomics methods detect changes in endogenous metabolites 
while with proteomics and genomics changes in the global protein and gene 
expression, respectively, are investigated. With the help of kinetics the in vitro 
catabolism rates of the reference compounds are determined. In addition the real 
intracellular concentrations of the substances are calculated as well as the amount of 
compound sticking to the cell culture plates since these data are essential for the 
correct extrapolation of the in vitro data to the in vivo situation and for the comparison 
with in vivo plasma concentrations.   
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Figure 1.8: Proposed Predict-IV approach for the use of in vitro data in drug safety assessment. 
NOEC = no observed effect concentration; PBPK = physiologically based pharmacokinetic; NOAEL = 
no observed adverse effect level; MOS = margin of safety [Predict-IV 2011]  
 
HCI enables the measurement of cellular changes via, e.g., fluorescent dyes. At time 
of writing the cell culture work was nearly completed while the measurement of the 
different endpoints was pending. The results of all these endpoints will be correlated 
with in vivo data from the literature in order to define novel biomarkers which predict 
human toxicities correctly. Thereby the concentration of a compound which does not 
change these biomarkers is called the no observed effect concentration (NOEC) 
(Figure 1.8). The NOEC calculated in vitro will be transformed into in vivo doses 
using physiologically based pharmacokinetic (PBPK) modeling, a mathematical tool 
which predicts the absorption, distribution, metabolism, and elimination of a 
compound in a living organism. Based on these calculated in vivo doses the so called 
no observed adverse effect level (NOAEL, dose which does not cause any adverse 
effects) for human and animals is estimated. In routine preclinical studies the 
calculation of human start doses is based on the animal NOAEL. The NOAEL 
estimated in our model is then compared with the NOAEL once measured in 
preclinical trials. Finally the difference between both NOAELs is used to calculate 
margins of safety (MOS) which enable the extrapolation from the in vitro data to safe 
human doses. 
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Table 1.4: Overview of the Predict-IV reference compounds for hepatotoxicity. 
[a: Miyamoto 2009, b: Robin 2008, c: Pollak 2004, d: Vassallo 2007, e: Boehmer 2011, f: Kassianides 
1990, g: Suzuki 2008, h: unpublished internal data, i: Rainsford 2009, j: Sandimmune 2011, k: James 
2003, l: RX-FF 2011, m: Willson 2000, p: Yokoi 2010, q: Smith 2003, r: Floyd 2009, s: press release 
11/10 BfArM, t: Lebovitz 2002, u: Chang 2006], ALT: Alanine transferase as serum marker for liver 
damage, ULNR: upper limit of normal range, KC: kinetic compound, BfArM: Bundesinstitut für 
Arzneimittel und Medizinprodukte  
 
 
Compound Therapeutic 
area 
Human 
hepatotoxicity 
Rodent 
hepatotoxicity 
Incidence of human 
hepatotoxicity 
Acetaminophen pain apoptosis, necrosis 
and inflammationk 
apoptoses, 
necrosis and 
inflammationk 
toxic at very high doses 
(overdosage, abuse)k 
Amiodarone 
(KC) 
arrhythmics phospholipidosisa, 
steatohepatitisb, 
hepatitiscd, 
cirrhosisd 
phospholipidosis a toxic at high doses and 
long-term usagec 
Chlorpromazine  
(KC) 
psychotic 
disorders 
cholestasisg cholestasisg -- 
Cyclosporine A  
(KC for liver, 
kidney, CNS) 
Immuno- 
suppressant 
cholestasisf ox. Stress, 
necrosise 
4-7%(all hepatotoxic 
effects)j 
EMD 335823 diabetic 
complications 
stopped prior to 
clinical trials 
bile duct and liver 
cell necrosish 
Unacceptable animal 
hepatotoxicity  
Fenofibrate dislipidemia, 
hypercholes- 
terolemia 
cholestatic hepatitisl non-genotoxic 
hepatocarcinogen, 
peroxisome 
proliferationm  
7.5% (abnormal liver 
function test)l 
Ibuprofen  
(KC) 
pain, arthritis -- -- 0.7%(liver and biliary 
effects)i 
Metformin non-insulin 
dependent 
diabetes 
mellitus 
-- -- -- 
Rosiglitazone non-insulin 
dependent 
diabetes 
mellitus 
-- -- ALT >3x ULNRt in 
0.17%, withdrawn due to 
cardiotoxicitys 
Troglitazone non-insulin 
dependent 
diabetes 
mellitus 
cholestasisp, acute 
liver failureq 
apoptosis, 
necrosis, 
steatosisq 
idiosyncratic, ALT >3x 
ULNR in 1.9%, 94 cases 
of acute liver failure, 65 
deathsrt, withdrawn due 
to hepatotoxicityr  
Valproic acid epilepsy steatosisu steatosisu elevated ALT in 30-50% 
of patients, idiosyncraticu 
 
In the liver workpackage the human hepatoma-derived cell line HepaRG will be 
compared with primary human and rat hepatocytes. Each cell system is treated 
under its optimized conditions with the same eleven reference compounds. These 
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compounds cover a range of toxic phenotypes and cause in vivo hepatotoxic effects 
of variable severity (Table 1.4). Samples for the same endpoint measurement at 
equal time points are prepared for all of the three cell culture systems. Furthermore a 
SNP analysis is performed for each donor since some SNPs are known to influence 
drugs’ toxicities [Koo 2006]. Thus, differences of the toxic effects of the various 
biological replicates could be possibly correlated with donor-specific variations in 
drug metabolizing enzymes. Furthermore the activity of the major drug-metabolizing 
CYPs is measured for every donor since the metabolic activity of the cells influences 
drug-induced toxicity and the kinetic of the drug’s catabolism.  
Primary rat hepatocytes have to be freshly isolated for every study. Therefore it is not 
planned to integrate these cells into the final model since the project’s goal is the 
development of a non-animal based prediction model. However, the data derived 
from human cells will be compared to the rat data in order to elucidate species-
specific effects which play a major role in terms of extrapolation of animal to human 
dosage and the prediction of human adverse effects.      
 
1.8 Aim of the study 
The work in hand describes the endpoint genomics for seven of the eleven reference 
compounds tested in rat primary hepatocytes. For statistical reasons cells of one 
biological replicate were planned to be treated with all the eleven compounds in one 
study. This study design was feasible for the dose finding studies but not for the final 
studies which included more endpoints and therefore had to be performed in a larger 
cell culture format and with more technical replictates. Hence, the eleven reference 
compounds were devided into the seven non-kinetic and the four kinetic compounds 
since the Predict-IV consortium agreed that the endpoint kinetics is only measured 
for Amiodarone, Chlorpromazine, Cyclosporine A and Ibuprofen.  
The first major task was the establishment of the sampling for the different endpoints. 
Therefore preliminary studies with variable preparations of the cell culture samples 
were performed in order to optimize the sampling for the metabolomic, proteomic, 
genomic and kinetic analysis conducted by other project members. Furthermore the 
protocol of the cell treatment for the CYP activity assay was established. After that 
the TC10s of the eleven reference compounds were determined and validated during 
46 Introduction 
 
a multi-step dose finding study. Finally three biological replicates of primary rat 
hepatocytes were treated for 14 days with the seven non-kinetic compounds 
including sample preparation for the different endpoints on day one, three and 14. In 
the course of the cell culture experiments it was declared that the metabolomics 
samples are not analyzed due to a capacity bottleneck of the appropriate project 
partner. Additionally the measurement of the proteomics samples was limited to the 
four kinetic compounds for the same reason.  
Hence, the present study describes the whole genome gene expression analysis of 
the non-kinetic compounds. Since the data of seven compounds is not sufficient for 
the establishment of a prediction model the gene expression profiles of the test 
compounds were mechanistically analyzed. Thereby it was focused on the 
reconstruction of the pharmaceutical mode of action of the different compounds as 
well as the detection of off-target effects and the mechanistical understanding of the 
drugs’ side effects. The biological interpretation of the genomics results was 
performed in comparison to in vivo literature data of the well known reference 
compounds in order to estimate the predictivity of sandwich cultured primary rat 
hepatocytes for rodent in vivo hepatotoxicity. The rodent gene expression results 
were also compared to human in vivo and in vitro literature data in order to estimate 
species-specific effects and the predictivity of primary rat hepatocytes for human in 
vivo hepatotoxicity. 
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2 Material 
2.1 Chemicals and reagents for hepatocyte isolation 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 
Merck KGaA, Darmstadt/Germany 
Bovine serum albumin (BSA) Merck KGaA, Darmstadt/Germany 
Calcium chloride dihydrate (CaCl2 × 2 H2O) Sigma-Aldrich, Steinheim/Germany 
D-glucose Merck KGaA, Darmstadt/Germany 
Ethylene glycol tetraacetic acid (EGTA) Merck KGaA, Darmstadt/Germany 
Liberase TM Roche Applied Science, 
Mannheim/Germany 
Magnesium sulfate hepatahydrate (MgSO4 × 7 H2O) Merck KGaA, Darmstadt/Germany 
Potassium chloride (KCl) Merck KGaA, Darmstadt/Germany 
Potassium dihydrogen phosphate (KH2PO4) Merck KGaA, Darmstadt/Germany 
Sodium chloride (NaCl) Merck KGaA, Darmstadt/Germany 
Sodium hydrogen carbonate (NaHCO3) Merck KGaA, Darmstadt/Germany 
Sodium hydroxide solution 1N (NaOH) Sigma-Aldrich, Steinheim/Germany 
 
2.2 Chemicals and reagents for cell culture work 
Acetaminophen Sigma-Aldrich, Steinheim/Germany 
Acetic acid Merck KGaA, Darmstadt/Germany 
Albumin solution 35% 
Ammonium bicarbonate 
α-Naphthoflavone 
Sigma-Aldrich, Steinheim/Germany 
Sigma-Aldrich, Steinheim/Germany 
Sigma-Aldrich, Steinheim/Germany 
CellTiter-GloLuminescent Cell Viability Assay Promega Corporation, Madison/USA 
Collagen I (rat tail tendon) 
 
Dexamethasone 
Roche Applied Science, 
Mannheim/Germany 
Sigma-Aldrich, Steinheim/Germany 
Dimethylsulfoxyd (DMSO) HYBRI-MAX Sigma-Aldrich, Steinheim/Germany 
D-MEM/F-12 (1:1) liquid - with GlutaMAX I Invitrogen, Karlsruhe/Germany 
D-MEM/F-12 (1:1) powder Invitrogen, Karlsruhe/Germany 
EMD335823 Merck KGaA, Darmstadt/Germany 
Fenofibrate Sigma-Aldrich, Steinheim/Germany 
Fetal bovine serum  HyClone, South Logan/USA 
Insulin solution 10 mg/ml Sigma-Aldrich, Steinheim/Germany 
Insulin Transferrin Selenium (ITS) 
Ketokonazol 
Invitrogen, Karlsruhe/Germany 
Sigma-Aldrich, Steinheim/Germany 
Metformin 
Methanol 
3-Methylcholanthrene 
Midazolam 
Calbiochem, Darmstadt/Germany 
Merck KGaA, Darmstadt/Germany 
Sigma-Aldrich, Steinheim/Germany 
Sigma-Aldrich, Steinheim/Germany 
PBS Dulbeccos w/o Ca, Mg Invitrogen, Karlsruhe/Germany 
Penicillin (10.000 U/ml) -Streptomycin (10 mg/ml) 
solution 
Phenacetin 
Phenobarbital 
Pregnane carbonitrile 
Quant-iT PicoGreen dsDNA Kit 
Sigma-Aldrich, Steinheim/Germany 
 
Sigma-Aldrich, Steinheim/Germany 
Sigma-Aldrich, Steinheim/Germany 
Sigma-Aldrich, Steinheim/Germany 
Invitrogen, Karlsruhe/Germany 
Rosiglitazone Cayman Chemical Company, 
Michigan/USA 
Sodium hydroxide solution 1N (NaOH) Sigma-Aldrich, Steinheim/Germany 
Sodium pyruvate 100 mM Invitrogen, Karlsruhe/Germany 
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Testosterone Sigma-Aldrich, Steinheim/Germany 
Troglitazone Cayman Chemical Company, 
Michigan/USA 
Trypan Blue 0.5% (w/v) in PBS  Biochrome AG, Berlin/Germany 
Valproic acid sodium salt Sigma-Aldrich, Steinheim/Germany 
 
2.3 Chemicals and reagents for molecularbiological methods 
Agencourt® RNAClean™ Agencourt/Beckham Coulter, Beverly/USA 
Block E1 buffer Illumina Inc., San Diego/USA 
β-mercaptoethanol Sigma-Aldrich, Taufkirchen/Germany 
Cy3™ labelled streptavidin (1mg/ml) Amersham Bioscience/GE Healthcare, 
Buckinghamshire/UK 
DEPC water  Ambion/ Applied Biosystems, Austin/USA 
E1BC buffer Illumina Inc., San Diego/USA 
Ethanol LiChrosolv™  Merck KGaA, Darmstadt/Germany 
GEX-HCB buffer Illumina Inc., San Diego/USA 
GEX-HYB buffer Illumina Inc., San Diego/USA 
High Temperature Wash buffer Illumina Inc., San Diego/USA 
HybE1 buffer Illumina Inc., San Diego/USA 
Illumina® TotalPrep™-96 RNA Amplification Kit  Ambion, Austin/USA  
Nuclease free water 
QuantiGene Plex 2.0 Assay 
Ambion, Austin/USA 
Affymetrix, Santa Clara/USA 
QIAshredder columns  Qiagen, Hilden/Germany 
RNA 6000 Nano Kit Agilent Technologies, Waldbronn/Germany
RNA 6000 Pico Kit Agilent Technologies, Waldbronn/Germany
RNAprotect cell reagent Qiagen, Hilden/Germany 
RNeasy Plus Mini Kit Qiagen, Hilden/Germany 
 
2.4 Technical equipment and auxiliary material 
Agilent 2100 Bioanalyzer Agilent Technologies, Waldbronn/Germany
Agilent 2100 Bioanalyzer Priming Station Agilent Technologies, Waldbronn/Germany
ART® BioRobotix™ Tips Molecular BioProducts, San Diego/USA 
Autoclave H&P Labortechnik, 
Oberschleißheim/Germany 
BeadChip® Hyb Cartrige (hybridisation chamber) Illumina Inc., San Diego/USA 
Bottle-top filter 0.2µm Nalge Nunc International, Rochester/USA 
Cell scraper IWAKI, Japan 
chemiluminometer lumistar Galaxy BMG Lab Technologies, 
Offenburg/Germany 
Combitips plus (1, 2.5, 5, 10 ml) Eppendorf, Hamburg/Germany 
Digital camera CC 12 Olympus, Hamburg/Germany 
Fuchs-Rosenthal-Chamber Paul Marienfeld GmbH & Co., Lauda-
Königshofen/Germany 
Glass ware Schott Glas, Mainz/Germany 
Heat block Thermo Stat Plus Eppendorf, Hamburg/Germany 
Hybridization Oven 650 Affymetrix, Santa Clara/USA 
Illumina BeadArray Reader Illumina Inc., San Diego/USA 
Illumina Sentrix® RatRef-12 v1 Expression BeadChip 
Arrays 
Illumina Inc., San Diego/USA 
Incubator Hera Cell Heraeus GmbH, Hanau/Germany 
Little Dipper™ Microarray Processor Model 650c SciGene Corporation, Sunnyvale/USA 
Megafuge 1.0 R Heraeus (Thermo Fisher Scientific), 
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Langenselbold/Germany 
Microcentrifuge 5415R Eppendorf, Hamburg/Germany 
Microscope Olympus IX70 Olympus, Hamburg/Germany 
Microtiter plate 96 well, white Nunc (Thermo Fisher Scientific), 
Langenselbold/Germany 
Microtiter plates (96/24/6 well) Nalge Nunc International, Rochester/USA 
Microtiter plates 96 well, sterile, white with clear bottom Becton Dickinson Labware, Franklin 
Lakes/USA 
Multifuge® 3S-R Heraeus (Thermo Fisher Scientific), 
Langenselbold/Germany 
NanoDrop ND-1000 NanoDrop Technologies, 
München/Germany 
Peristaltic pump 313S Watson-Marlow, Birmingham/UK 
pH meter 766 calimatic Knick GmbH & Co. KG, Berlin/Germany 
Pipet tips, sterile and Rnase free (10, 20, 100, 200, 
1000 µl) 
MolecularBioProducts, San Diego/USA 
Pipets (2-1000 µl) Eppendorf, Hamburg/Germany 
Pipets, serological (5, 10, 25, 50 ml) Nunc (Thermo Fisher Scientific), 
Langenselbold/Germany 
Pipettboy Hirschmann Laborgeräte, 
Eberstadt/Germany 
Plastic tubes (15/50 ml) Greiner Bio-One, Frickenhausen/Germany 
QIAcube Qiagen, Hilden/Germany 
Reaction cups nuclease free (1.5/ 2 ml) Eppendorf, Hamburg/Germany 
Rotor adapters Qiagen, Hilden/Germany 
Round bottom plates 96 well Bilatec AG, Viernheim/Germany 
Scale Navigator Ohaus, Giessen/Germany 
Scale Sartorius BP211D 
Sonoplus HD 3100 
Sartorius, Göttingen/Germany 
BANDELIN electronic GmbH & Co. KG, 
Berlin/Germany 
Sterile work bench Herasafe Heraeus GmbH, Hanau/Germany 
Surgical instruments Braun, Melsungen/Germany 
Syringes MT Braun, Melsungen/Germany 
Theonyx Liquid Performer AVISO, Jena/Germany 
Thermosprint® PCR plates 96 well Bilatec AG, Viernheim/Germany 
Ultra pure water processing system Pure Lab Plus ELGA, Celle/Germany 
U-RFL-T Power SupplyUnit  Olympus, Hamburg/Germany 
Vortex for Agilent Chips IKA™ Werke GmbH, Staufen/Germany 
Vortex Genie 2 Scientific Industries, Bohemia/USA 
Water bath Julabo SW22 Julabo GmbH, Seelbach/Germany 
 
2.5 Softwares 
2100 Expert Software Agilent Technologies, Waldbronn/Germany
BeadScan Illumina Inc., San Diego/USA 
Expressionist™ Analyst Pro 6.1 Genedata AG, Basel/Suisse 
GenomeStudio V2009.1 Illumina Inc., San Diego/USA 
IPA® Ingenuity Systems, Inc., Redwood 
City/USA 
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3 Methods 
3.1 Cell culture methods 
3.1.1 Isolation of fresh primary rat hepatocytes 
Primary hepatocytes were isolated using a modificated protocol of the two-step 
perfusion method described by Seglen [Seglen 1976]. During this in situ perfusion, 
the liver remaining in the anesthetized rat is flushed with two different buffers. The 
buffers are piped into the portal vein via a syringe which is connected to a peristaltic 
pump via flexible tubes. The connection of the pumping system with the organ is a 
very critical point since the original blood pressure of the organism should be 
sustained and pressure peaks must be prevented. Variations of the pressure in the 
organ disturb the physiology and especially high pressure can damage the 
hepatocytes since the organ is enclosed by a relatively stable capsule. In order to 
maintain the physiological pressure in the organ the syringe is connected with the 
pumping system at a very small flow rate and the inferior vena cava is opened shortly 
afterwards to let out the blood and the buffers. Then the flow rate is raised carefully.  
The first buffer removes the blood from the vascular system of the liver. It is Ca2+ free 
and the containing ethylene glycol tetraacetic acid (EGTA) complexes the Ca2+-ions 
remaining in the vascular system in order to loosen the intercellular adhesion since 
many cell-cell-adhesion molecules like Cadherins, Integrins and Selectins need Ca2+ 
as Co-factor. At the second step of perfusion the liver is flushed with a solution of 
Liberase TM (contains a medium concentration of Thermolysine). This enzyme is a 
blend of Collagenase I, Collagenase II and Thermolysine, a neutral protease, which 
digest the extracellular matrix of the liver tissue to release individual cells. Liberase 
blends are manufactured with different amounts of Thermolysine. A medium amount 
of this neutral protease (Liberase TM) resulted in a higher viability and functionality of 
the isolated cells than the usage of Liberase with a high concentration of 
Thermolysine (Liberase TH). Highly purified Liberase enzyme blends replaced the 
traditionally used collagenases since isoforms of highly specific activity combined 
with specific neutral proteases can be manufactured reproducibly without appreciable 
batch to batch variations.  
The components for the perfusion buffers 1 and 2 (PB1, BP2) and the washing buffer 
(WB) were weighed according to Table 3.1 in 1l-beakers and solved in 800ml of 
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distilled water. The pH = 7.4 was justified with 1M NaOH using a pH meter. The 
neutralized buffers were sterile filtered and stored up to four weeks at 4°C.  
Table 3.1: Components of perfusion buffer 1, perfusion buffer 2 and washing buffer. 
 
Stock solution for PB1, PB2 and WB  Supplements 
6.30 g NaCl  PB1 0.038 g EGTA 
0.32 g KCl  PB2 0.58 g CaCl2•2 
0.27 g MgSO4 • 7 H20  WB 0.58 g  CaCl2•2 
0.15 g KH2PO4    20.00 g BSA 
1.81 g NaHCO3     
3.58 g HEPES     
1.50 g D-Glucose     
 
Male Wistar-rats were kept according to animal welfare regulations (Deutsches 
Tierschutzgesetz) and the perfusion was done with authorization from the local 
authorities (Approval-Nr. v54-19c20/15, DA4/Anz271E). The rats had free access to 
food and water and were kept at a constant temperature of 20°C and a light dark 
circle of 12h each. Rats with a body weight between 200g to 300g were anesthetized 
by a mixture of Ketanest S (10%) and Rompun 2% at a concentration of 100mg/kg 
body weight and 15mg/kg bodyweight, respectively. The anesthesized rats were 
fastened supine, the abdominal wall was opened and a syringe was inserted into the 
portal vein and fixed with a clamp. After that the syringe was connected to a pumping 
system and the liver was flushed with perfusion buffer 1 (PB1) with a flow rate of 
50ml/min for two minutes and afterwards with a flow rate of 40ml/min for another 
three minutes to remove all the blood from the liver. The inferior vena cava was 
opened to enable the perfusion buffers to drain off. During this first step of liver 
perfusion the colour of the rat liver changes from reddish brown to gray.  
At the second step the liver was rinsed with perfusion buffer 2 (PB2) containing 
Liberase TM (10mg/ 300ml) at a flow rate of 50ml/min for two minutes following five 
minutes at 40ml/min. The time needed for digestion of the extracellular matrix highly 
depends on the individual rat and is therefore to be controlled carefully. The 
perfusion was stopped after a fine network on the surface of the liver appeared and 
dents remained on the organ’s surface when it was squeezed carefully with a finger. 
The liver was transferred into an ice cold washing buffer (WB), the liver capsule was 
opened and the separated cells were released. The washing buffer contained 2% 
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BSA which stops the enzyme activity of the Liberase blend to protect the isolated 
cells from digestion. The cell suspension was filtered through a coarse gaze to 
remove bigger cell clumps. To remove non-parenchymal and dead cells as well as 
the Liberase the cell suspension was centrifuged three times (43 x g, 4°C, 2min) 
while the hepatocyte pellet was resuspened very carefully in fresh ice-cold washing 
buffer to inhibit endogen proteases released from dead cells.  
 
3.1.2 Trypan Blue exclusion test  
Cell viability and cell number of isolated primary hepatocytes were assessed using 
the trypan blue exclusion test. Viable cells exclude trypan blue due to their intact cell 
membranes and appear uncolored, whereas dead cells are colored blue after the dye 
diffused into them.  
25µl cell suspension was incubated with 1ml trypan blue solution (100µl trypan blue 
0.5% + 900µl PBS) for three minutes at RT. After that viable and dead cells were 
counted in a Fuchs-Rosenthal-Chamber and the viability, the number of living cells 
per ml, as well as the total amount of viable cells were calculated. Cell suspensions 
with a viability greater than 85% were used for further studies. 
         5000/  DCellsmlCells Viable                 100% )( 
Dead
Viable
Viability Cells
Cells  
D = Dilution Factor = 41 
Figure 3.1: Formula for the calculation of vital cell concentration and cell viability. 
 
3.1.3 Preparation of culture dishes 
Primary rat hepatocytes are adherent cells which do not adhere optimally onto 
uncoated cell culture surfaces. They were cultured in two different culture systems: 
monolayer or sandwich culture. In the monolayer culture the cells are cultured onto a 
dried Collagen I layer. In this culture system the cellular functions remain stable for 
up to five days. After that the cells dedifferentiate, die and detach. In the sandwich 
culture the cells are cultured in between two layers of gelled collagen I which mimic 
the three dimensional structure of the liver tissue and the cell morphology and 
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function as well as the expression of main enzymes of the xenobiotic metabolism 
remain stable and near the in vivo level for up to four weeks.     
 
3.1.3.1 Monolayer culture 
The dishes for the monolayer cultures (ML) were coated by adding an acidic collagen 
I solution which was dried under sterile conditions over night (ON) or longer (Table 
3.2). 
 Table 3.2: Coating scheme of culture dishes for monolayer culture. 
Cell culture plate Volume Concentration Time to dry 
96 well plate 110 µl   20 µg/ml 2 d 
24 well plate 125 µl 100 µg/ml ON 
 6 well plate 600 µl 100 µg/ml ON 
  
 
3.1.3.2 Sandwich culture 
In sandwich cultures (SW) cells were seeded onto a layer of gelled collagen. 
Therefore an ice-cold acidic solution of collagen I (1 mg/ml) was mixed with 10x 
DMEM-F12 media resulting in a final collagen-concentration of 900µg/ml and was 
then neutralized to a pH of 7.2 to 7.4 with a 1M sodium hydroxide solution. Cell 
culture plates were immediately coated with this neutralized collagen I solution (Table 
3.3) and incubated in an incubator at 37°C for at least one hour to gelatinize the 
collagen. 
Table 3.3: Volume of collagen I solution used for bottom and top layer of sandwich cultures. 
Cell culture plate Volume for bottom layer Volume for top layer 
24 well plate   75 µl 100 µl 
  6 well plate 250 µl 400 µl 
  
 
3.1.4 Plating of cells 
Freshly isolated and counted primary hepatocytes were mixed with plating media 
(DMEM/F12 medium supplemented with 10% (v/v) FBS, sodium pyruvate (100X), 
antibiotics (100X) and 5µg/ml insulin) and seeded onto the collagen I coated cell 
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culture plates (Table 3.4). The amount of cells is linked to the used plate format and 
did not vary between sandwich and monolayer cultures. 
Table 3.4: Media volumes and amounts of cells used for cell seeding in monolayer and sandwich cultures. 
 
Cell culture plate Cells/ ml Volume Total number of cells 
96 well plates 500 *103 80 µl   40 *103 
24 well plates 500 *103 0.5 ml 250 *103 
  6 well plates     1 *106 1.5 ml   1.5 *106 
 
 
Cells were allowed to attach to the culture surfaces at 37°C and 5% CO2 in a 
humidified atmosphere for four hours. After that the cell culture media was changed. 
24 hours after cell seeding the cell culture medium of the monolayer cultures was 
replaced by FBS-free medium (DMEM/F12 medium supplemented with sodium 
pyruvate (100X), antibiotics (100X), ITS (100X) and 100nM dexamethasone), cells 
were cultured in an incubator (37°C, 5% CO2, humidified atmosphere) and 
experiments were started. 
24 hours after seeding sandwich cultures were washed with ice-cold PBS and 
overlaid with a second layer of collagen I (Table 3.3). The collagen was allowed to 
gelatinize for one and a half up to two hours in the incubator before FBS-free cell 
culture medium was given on top of the collagen. Cells were cultured in an incubator 
(37°C, 5% CO2, humidified atmosphere) and medium was changed every second day 
until experiments started at day three after cell seeding.  
 
3.2 CellTiter-Glo® Luminescent Cell Viability assay 
The CellTiter-Glo® Luminescent Cell Viability Assay was used to determine the 
viability of the cells after treatment with pharmaceutical substances. This test enables 
the quantitation of ATP in metabolically active cells based on a luciferase reaction 
(Figure 3.2) since the luminescence signal is proportional to the amount of cellular 
ATP. The amount of ATP is directly proportional to the amount of viable cells 
because they lose their ability to synthesize ATP soon after, e.g., loss of membrane 
integrity or other cytotoxic events. The protocol originally written for the use in the 96-
well plate format was adapted to 24- and 6-well plates. The cells were incubated at 
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RT for ten minutes on a shaker with a 1:1 mixture of CellTiter-Glo® Reagent and 
DMEM-F12 medium without supplements. Three times 50µl cell lysate was 
transferred into a white 96-well plate to eliminate stray light, and the bioluminescence 
was measured. The cell viability was calculated as percentage related to the vehicle 
treated control. 
HO
N
S
N
S
COOH
+ ATP + O2
Beetle Luciferin
Mg2+
Ultra‐Glo™ Recombinant
Luciferase ‐O
N
S
N
S
O‐
+ AMP + PPi + CO2 + Light
Oxyluciferin  
Figure 3.2: Chemical reaction of the CellTiter-Glo® Luminescent Cell Viability Assay.  
The reagent contains recombinant luciferase that uses the likewise contained luciferin as a substrate 
and reacts under the consumption of cellular ATP with the release of luminescence [CellTiter 2009]. 
 
3.3 Molecular biological methods 
3.3.1 RNA isolation 
The RNA was isolated using the RNeasy Plus Mini Kit and the QIAcube from Qiagen 
(Figure 3.3). This kit enables a selective removal of double-stranded DNA via gDNA 
Eliminator Mini Spin Columns without the need of DNase digestion. After that the 
total RNA binds to RNeasy Mini Spin Column and contaminants are washed away 
efficiently which results in very pure RNA samples. The RNA isolation was run fully 
automated on the QIAcube to reduce error-proneness. Primary hepatocytes were 
treated for one, three or 14 days, respectively, with pharmaceutical substances in 6-
well plate collagen I sandwich cultures. Then the cells were washed two times with 
ice-cold PBS and scraped in 3ml of RNAprotect Cell Reagent. The RNAprotect Cell 
Reagent stabilizes the RNA during cell harvesting and enables the separation of the 
RNA from the cells and the extracellular matrix by two additional centrifugation steps. 
The scraped cells were transferred to a 15ml centrifuge tube and centrifuged at RT 
for five minutes at 5,000 x g. The supernatant was aspirated, the pellet was 
resuspended in 5ml RNAprotect Cell Reagent by vortexing and centrifuged again for 
five minutes at 5,000 x g. The supernatant was aspirated and the pellet was 
loosened by flicking the tube. 350µl RLT Buffer Plus including 10µl β-
Mercaptoethanol (β-ME) per 1ml were added and the pellet was dissolved by 
vortexing. The cell lysate was pipetted into a QIAshredder spin column and 
centrifuged two minutes at 16,000 x g at RT to homogenize the sample. During this 
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step high-molecular-weight cellular components and genomic DNA was sheared to 
reduce the viscosity of the sample and enable an efficient binding of the RNA to the 
RNeasy Mini Spin Column membrane since a high viscosity of the sample could 
reduce the resulting RNA yield. The eluate was stored at -80°C. Frozen lysates were 
incubated at 37°C for five minutes and all the further steps (gDNA elimination, RNA 
binding and washing) were performed using the QIAcube. The rotor adapters were 
filled with gDNA Eliminator Mini Spin Columns, RNeasy Mini Spin Columns and 
empty collection tubes. The concentrate of Buffer RPE was filled up with 44ml of 
100% Ethanol.  
Mix cells with
RNAprotect
Cell Reagent
Dissolve pellet 
in Buffer RLT 
Plus
Remove 
genomic DNA
Genomic DNA
Total RNA
Add 
ethanol
Total RNA
Bind total 
RNA
Elute
Eluted RNA
Wash
 
Figure 3.3: Workflow of the RNeasy protect cell mini kit. [RNAprotect 2010] 
 
The QIAcube was loaded with the buffers RPE and RW1 as well as nuclease-free 
water, the samples, and the filled rotor adapters according to the manufacturer’s 
recommendations. The RNeasy Plus Mini Kit protocol was started, the RNA was 
eluted in 40µl of nuclease-free water and stored at -80°C [RNAprotect 2010].      
 
3.3.2 RNA quantification and quality check 
The quantification of the RNA and cRNA was performed with the UV-
spectrophotometer NanoDrop ND-1000. Therefore 1µl of the sample was given onto 
the measuring pedestal (Figure 3.4). After the instrument was closed two class fiber 
cables were connected by the sample and the absorption of a Xenon lamp’s light 
during the passage of the sample was measured. The ratio between the absorbance 
at 260nm and 280nm is a dimensionless parameter for RNA purity while pure RNA 
yields a ratio of 2. Contaminations with protein and phenol decrease this ratio. The 
concentration of the sample was calculated using the absorption at 260nm and the 
modified Lambert-Beer-Law together with the molar extinction-coefficient [NanoDrop 
2008]: 
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c = (A*e)/b 
c: concentration of nucleic acid in ng/µl 
A: absorbance in absorbance units (AU) 
e: wavelength-dependent extinction coefficient in ng-cm/µl (RNA: e = 40) 
 
Figure 3.4: RNA quantification with the NanoDrop ND-1000. 
The RNA is measured in 1µl sample which forms a drop of 
controlled thickness without the need of a cuvette [NanoDrop 
2008]. 
 
 
 
The quality of the RNA and the cRNA was checked using the Lab-on-a-Chip 
technology from Agilent Technologies. This technology is based on capillary 
electrophoresis of up to twelve different samples in capillaries arranged onto a plastic 
chip. The RNA or cRNA is fractioned according to their length and detected by a 
fluorescent dye which is applicated in combination with the gel matrix. The 2100 
Expert Software enables the visualization of the results as electropherograms or gel 
like pictures. A typical electropherogram of total RNA shows two peaks: the 18s and 
the 28s rRNA. The ratio of the 28s and the 18s is 2.0 or higher for RNA of high 
quality. The concentration of the samples is calculated based on the area under the 
curve of a RNA ladder. Furthermore the RNA Integrity Number (RIN) was 
automatically determined for each sample. The RIN is calculated based on the 
complete electropherogram and is therefore much better reproducible compared to 
the 28s/18s ratio. The RIN is ranged from one to ten while high quality RNA shows a 
RIN of ten and most degraded RNA a RIN of one, respectively (Figure 3.5) [Agilent 
2011].  
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Figure 3.5: Reference electropherogrames 
for the different RNA integrity categories.  
The RIN categories reach from ten (high 
quality) to one (completely degradated). A 
decrease in quality results in a shift towards 
shorter nucleotide fragment. X-axis = time, Y-
axis = fluorescence [Schroeder 2006].   
 
 
 
 
 
 
 
 
 
 
The quality check of the samples was performed using the Agilent RNA 6000 Nano 
Chip and the Agilent RNA 6000 Nano Kit which allows the parallel measurement of 
twelve samples. 550µl Agilent RNA 6000 Nano Gelmatrix were spun for ten minutes 
at 1,500 x g and RT in a centrifugation filter tube. 65µl of the filtered gel were mixed 
with 1µl RNA 6000 Nano dye concentrate, vortexed, and centrifuged for ten minutes 
at RT and 13,000 x g. 9µl of the gel-dye-mixture were added to the well named with 
“G” at the bottom of an Agilent 6000 RNA Nano Chip. The capillaries of the chip were 
filled with the gel-dye-mixture with the help of the Priming station for 30sec. After that 
both top wells named with “G” were filled with 9µl of the gel-dye-mixture and 5µl of 
RNA 6000 Nano Marker were given to every sample well as well as to the ladder 
well. The samples and the ladder were denatured for two minutes at 70°C and 1µl 
per sample or ladder, respectively, was added to the appropriate wells. The chip was 
vortexed for 60sec at 2,400rpm and measured with the Agilent Bioanalyzer [Agilent 
2006]. 
28s 
18s 
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Biotinylated cRNA shows a very different electropherogram (Figure 3.6) since the 
amplification process results in a mixture of fragments of various lengths over a wide 
region with a peak between 1,000 to 1,500nt.   
 
Figure 3.6: Electropherograms of cRNA and total RNA. 
The electropherograms differ from each other since during the amplification process a mixture of fragments is 
processed. 
 
3.3.3 The Illumina Technology 
The Illumina Sentrix® BeadChip technology was used to perform whole gene 
expression analyses. Therefore the isolated total RNA was transcribed by a first and 
a second strand synthesis step into cDNA followed by an in vitro transcription 
amplification that incorporates biotin-labeled nucleotides. The labeled cRNA was 
then hybridized to gene specific probes onto an Illumina Sentrix® RatRef-12 
Expression BeadChip (Figure 3.7). Twelve samples could be measured in parallel 
per chip and each chip contains 21,910 probes of the rat genome which was chosen 
with the help of the National Centre for Biotechnology Information (NCBI) Reference 
Sequence Database and UniGene based on parameters like inequality to other gene 
sequences and lack of repetitive genomic sequences. 
 
Figure 3.7: The different steps of gene expression analysis with Illumina Sentrix® BeadChips. 
cRNA RNA 
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The 50-mer gene specific probes are linked to a 29-mer address sequence which is 
covalently bound to a bead (Figure 3.8). Each bead type contains approximately 108 
copies of the gene-specific sequence and is present 30 times per array. The high 
amount of copies of the gene-specific sequences as well as the high abundance of 
the various bead types are internal technical replicates and guarantee a high 
reproducibility and good stability of the system. 
Address Probe 
Bead
Biotin‐
labeled
cRNA
 
Figure 3.8: The Direct Hybridization Assay from Illumina.  
Beads are immobilized onto glass chips and bound to an address sequence which is linked with a 50-base gene-
specific probe where the sample derived biotinylated cRNA is hybridized to [Illumina 2011].  
 
The beads are arranged randomly in small plasma etched wells onto silica slides and 
held there by Van der Waals forces and hydrostatic interactions with the well (Figure 
3.9). Because of that every array must be decoded by an individual algorithm which 
identifies the position of every bead or transcript, respectively, based on the specific 
address sequence [Gunderson 2004]. 
Photo resist
Plasma etching
Placement of
beads intowells
 
Figure 3.9: Manufacturing of Illumina Sentrix® BeadChips. 
The beads are placed into wells which were etched into the chip’s surface [Illumina 2011].  
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3.3.3.1 cRNA Synthesis from total RNA 
The isolated total RNA was transformed into biotinylated cRNA during different steps 
with the Illumina®TotalPrep™-96 RNA Amplification Kit from Ambion (Figure 3.10). 
The reactions were performed fully automated in 96-well plates with adapted 
volumes using the Theonyx Liquid Performer robot to standardize the process 
optimally including magnetic-bead based purification of both the cDNA and the cRNA 
which reduces the elution volumes and enables sample processing in 96-well plates. 
500ng total RNA per sample were reverse transcribed into first strand cDNA. 
Therefore the RNA was diluted with nuclease-free water to a concentration of 
45.45ng/µl and 11µl of the diluted RNA per well were given to a thermosprint 96 well 
plate and placed onto the cooled pipeting station of the robot. The master mixes for 
the first and second strand cDNA synthesis were set into the appropriate cooled 
positions. The robot added 9µl of the first strand master mix (Table 3.5) to each 
sample, mixed the solution and incubated the plate for two hours at 42°C in a 
thermocycler. After that 80µl of the cDNA second strand master mix (Table 3.5 ) was 
given to each sample and the plate was incubated another two hours in the 
thermocycler at 16°C. The double stranded cDNA was purified using magnetic beads 
which bind the cDNA. Therefore the samples are transferred to a round bottom 96-
well plate and 180µl of the magnetic bead solution were added. The magnetic beads 
sink to the bottom of the multiwell reaction plate attracted by a magnet and build a 
ring around the middle of the well so that the supernatant could be aspirated 
completely by pipetting into the centre of the well. The beads were washed three 
times with 200µl ethanol 70%. The cDNA was released from the beads by adding 
20µl of nuclease free water and shaking at 1,500 rpm and was transferred into a 
fresh thermosprint plate. The master mix for the in vitro transcription (IVT) (Table 3.5) 
was given to the appropriate cooled position, the robot added 7.5µl of this master mix 
to every sample and incubated the plate for 14h at 37°C in the thermocycler to 
synthesize biotinylated cRNA using biotinylated UTP nucleotides. The cRNA is 
purified the same way like the cDNA using magnetic beads but ethanol 80% and 
eluted with 40µl of nuclease-free water by shaking at 1,500 rpm. The quality of the 
cRNA was checked using the Agilent RNA 6000 Nano Kit. The cRNA was quantified 
with the NanoDrop 1000 and stored until the next working step at -80°C. 
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Figure 3.10: Workflow of the Illumina TotalPrep-96 RNA Amplification Kit from Ambion to 
synthesize biotinylated cRNA from total RNA [Illumina 2010]. 
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Table 3.5: Composition of the master mixes and purification solutions used for the cRNA synthesis 
.[Illumina 2010] 
 
Master mix Component Volume/sample (µl) 
1st strand T7 Oligo(dT) Primer  1.1 
 10x 1st Strand Buffer  2.2 
 dNTP mix  4.4 
 RNase Inhibitor  1.1 
  Reverse Transcriptase  1.1 
   
2nd strand 10x 2nd Strand Buffer 11.0 
 dNTP mix  4.4 
 DNA Polymerase  2.2 
 Rnase H  1.1 
  nuclease-free H2O 69.3 
   
IVT 10x Reaction Buffer 2.75 
 Biotin-NTP Mix 2.75 
  T7 Enzyme Mix 2.75 
 
 
Master mix Component Volume 
cDNA purification magnetic beads 7ml + 220µl/sample 
 nuclease-free H2O 3ml +   60µl/sample 
  70% Ethanol 3ml + 800µl/sample 
   
cRNA purification magnetic beads 7 ml + 120µl/sample 
 nuclease-free H2O 3 ml + 135µl/sample 
  80% Ethanol 3 ml + 800µl/sample 
 
 
3.3.3.2 Hybridization of cRNA to Illumina® BeadChips 
For the hybridization the biotinylated cRNA is diluted with nuclease-free water to a 
concentration of 750ng in 5µl and mixed with 10µl of hybridization buffer (GEX-HYB 
buffer) in a 96-well thermosprint plate and incubated at 65°C for five minutes to 
denaturate the cRNA. The reservoirs of the hybridization chambers were filled with 
200µl of humidifying buffer (GEX-HCB) and 15µl of each sample were pipeted into 
the sample port of the appropriate array. The chips were placed into the hybridization 
chambers and incubated for 20 hours at 58°C in the hybridization oven with rocker 
speed at five. After that the chips were transferred into a bath of E1BC Buffer, their 
plastic coverseals were removed carefully under the liquid’s surface and the chips 
were collected into a chip rack standing in the same buffer (Table 3.6).   
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Table 3.6: Preparation of the different buffers used for hybridization of cRNA onto Illumina® BeadChips. 
   
Working solution Compound 1 Compound 2 
High Temperature Wash Buffer   70ml 10X Stock 630ml RNAse-free water  
E1BC Buffer  2.4ml Stock 800ml RNAse-free water 
Streptavidin-Cy3 Stain 200µl Stock (1mg/ml) 200ml Block E1 Buffer 
 
The following washing and dying steps were performed with the Little Dipper® 
Processor for Illumina® BeadChips. The robot’s different bathes were filled according 
to the scheme in Table 3.7, the magnetic stirrers of all the bathes were set to a speed 
forming a vigorous vortex, bath one was heated to 55°C and the centrifuge was 
balanced with eight reference chips. Running the Bead2 protocol the robot dipped 
eight chips at a time standing in a chip rack for a fixed time at a specific frequency in 
turn into different washing solutions (High Temp Buffer, E1BC Buffer, Ethanol 100%), 
blocking buffer (Block E1), Streptavidin- Cy3 staining solution and a final washing 
step with E1BC Buffer. The robot dried the stained chips by centrifuging. After that 
the chips were stored in the dark at RT.          
Table 3.7: Overview of the buffers and parameters of the different steps of the Little Dipper’s™ Bead2 
Protocol for processing of Illumina® BeadChips after the sample hybridization. 
[Little Dipper 2008] 
 
Step Buffer Temperature Agitation (cycles/min) Time (sec) 
1 High Temp 55°C  250 600 
2 E1BC RT 250 300 
3 Ethanol RT 250 600 
4 E1BC RT 250 120 
5 Block E1 RT 50 600 
6 Strep-Cy3 RT 50 600 
7 E1BC RT 250 300 
8 Centrifuge RT - 300 
 
  
3.4 Gene expression analysis 
3.4.1 Quality control of microarray data 
After BeadArray chips are scanned first of all the quality of the data must be checked. 
Therefore Illumina included six different internal controls for each chip which can be 
analyzed using the software GenomeStudio from Illumina. These controls contain 
sample-independent features using oligonucleotides as part of the hybridization 
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buffer which indicate general problems during the process of hybridization, washing 
and staining as well sample-dependent features which indicate problems with the 
sample itself or the labeling process.  
For the control of the hybridization process each chip contains two different sets of 
probes. The first set bind special oligonucleotides in the hybridization buffer with high 
stringency (perfect match, PM) while the other set binds them with very low 
stringency (mismatch, MM) due to a slightly modified sequence and should therefore 
show a lower signal intensity than the PM. The staining process is checked via biotin-
controls in the hybridization buffer which show a high signal after a successful 
staining. Furthermore the control set includes negative controls which should not bind 
to any probes and are used to define the level of the background signal and the limit 
of detection. The sample-dependent controls are based on the signal of different 
species-specific housekeeping genes which are contained in every sample 
independent from the used tissue or cell type. The signal intensity of these 
housekeepers should always be higher than the signal of all the other genes.  
GenomeStudio provides different tools for a more detailed quality control. The 
visualization of the total number of detected genes or the signal-to-noise ratio of 
every single array enables the detection of outliers. Further possibilities for the 
search of outliers are box and scatter plots which visualize the data distribution. 
[Illumina-TN 2010] 
 
3.4.2 Normalization of microarray data 
For the comparison and the common analysis of a number of chips the data have to 
be normalized. In this way systematic errors, differences during the synthesis of the 
cRNA, the hybridization, the washing and staining of the chips which could be 
caused by processing of the chips at different time points could be compensated. 
The normalization and further statistical analysis of the gene expression data was 
performed with the software Expressionist providing several methods. The 
normalization method has to be adapted to the property of the data. Therefore the 
distribution of the data is visualized (Figure 3.11) using log-log-plots (scatter plots). 
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Figure 3.11: Visualization of the data distribution with scatter and box plots.  
Scatter plots (left) plot the signal intensity of every single gene of two different samples against each 
other and show the standard deviation of resulting data cloud. Box plots visualize the median and the 
quartiles for a single sample.   
If these plots show a shift of the data’s cloud parallel to the central line linear 
methods like the Central Tendency normalization could be used which shifts the 
median of each array to a common target value. Thereby the distances between the 
single gene’s signals are not altered so that this normalization makes the data of 
different chips comparable without influencing the individual data or the results. If the 
data’s cloud is curved non-linear methods like LOWESS (Locally Weighted 
Polynominal Regression) have to be used for normalization. LOWESS normalizes 
the data to a reference data set using a complex algorithm and should be performed 
with pre-normalized data (linear method) since the method is sensitive towards 
outliers [Expressionist 2011]. 
 
3.4.3 Fold change calculation and statistics   
The change of the gene expression level of treated cells relative to the vehicle control 
is expressed via the fold change. The fold change was calculated using the Relative 
Normalization while each sample was compared to its time-matched control which is 
set equal to one. The statistical significance of the gene expression changes was 
calculated using a paired Student’s t-test. This test calculates the p-value as the 
probability of the difference between the gene expression level of the sample and the 
control. Genes with p ≤ 0.05 were used for further analyses which means a 
probability of ≥ 95% that the gene expression of the sample differs from the control’s 
68 Methods 
 
expression level [Engesser 1991]. A second evaluation criterion for the statistical 
significance was the false discovery rate described by Benjamini and Hochberg (BH-
Q-value) which estimates the proportion of false discoveries in the given test set of 
discoveries [Benjamini 2001]. A BH-Q = 0.3 for example describes a probability of 
30% that the given discovery is false positive.      
 
3.4.4 Data visualization with Expressionist™ 
The software Expressionist™ provides several tools for the visualization of the 
results of gene expression analyses. The Principal Component Analysis (PCA) 
exhibits a multivariate statistical technique displaying each single experiment as one 
spot in a three-dimensional diagram (Figure 3.12). Therefore underlying algorithms 
reduce the dimensionality of the data set to three new variables (principal component 
1 to 3) regarding the most dominant differences of the single experiments. Each 
principal component is a linear combination of the original variables and the three 
principal components together account for as much of the variance in the original 
amount of variables as possible. The PCA visualizes samples of very similar 
expression profiles closer together than samples of more different expression 
profiles. So the PCA is well suited for a first overview of a data set, for the detection 
of outliers, and furthermore indicates experimental conditions, e.g. compound, dose, 
and time of treatment, which affected the gene expression profile of the appropriate 
samples [Expressionist 2011, Raychaudhuri 2000].  
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Figure 3.12: The Principal Component Analysis (PCA).  
The PCA clusters samples based on their differences in gene expression in a three-dimensional space 
while very similar samples clusters closer together than samples of different expression levels.      
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Gene expression changes can be further visualized using the Heat Map where the 
fold changes are encoded with the colors black, red and green. The color depth 
increases with the fold change while green codes for downregulation, red for 
upregulation and black for non-deregulated expression levels [Expressionist 2011]. 
 
3.4.5 Biological data interpretation 
The lists of significantly deregulated genes (p ≤ 0.05) were transferred from 
Expressionist into the software Ingenuity Pathway Analysis (IPA). The background of 
IPA is a database including information about genes, proteins, RNA and chemicals 
(including pharmaceuticals), their interaction with each other and alterations during 
diseases or treatment with pharmaceuticals or chemicals as well as several detailed 
physiological pathways like, e.g., lipid metabolism. This information is available for 
several species and is updated weekly to the state of the art in science. Therefore 
Ingenuity cooperates among others with the FDA, leading journals and databases 
like Entrez Gene, KEGG, Clinicaltrials.gov and many more. Based on this information 
the uploaded gene expression data (fold changes) is matched with biological (= 
physiological, e.g., carbohydrate metabolism) and toxic (= adverse effects, e.g., 
hepatocellular carcinoma) functions as well as canonical pathways (e.g. 
carbohydrate metabolism). Complete pathways can be visualized including the 
deregulated genes which are colored red or green when they are up- or 
downregulated, respectively. The functions and pathways are ranked related to the 
number of genes which can be matched with. 
IPA furthermore calculates a ratio for pathways by dividing the number of matched 
genes by the total number of genes making up the pathway. This enables a detection 
of the pathways most affected by the appropriate data set. Additionally IPA calculates 
a p-value for pathways and functions taking into consideration the total number of 
genes and associated functions or pathways in a reference set. The p-value 
describes the probability of a target’s association with a pathway or function while a 
small p-value implies a high probability [IPA 2011]. 
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4 Results and discussion 
4.1 Establishment of sample processing for metabolomics, 
proteomics, genomics and kinetics 
The final studies could not be performed until the sample preparation protocols for 
the different analytical methods had been established. With the exception of the 
whole genome gene expression protocol, well-described in the methods chapter, all 
the analyses were performed by other project partners. Since these analyses had not 
been finished at time of writing and the results are not part of the present study, only 
the challenges in establishing the sample preparation are discussed in this chapter.  
A common problem for all the analytical laboratories was the high content of 
collagen I in the samples. Heidebrecht et al. [Heidebrecht 2009] developed a method 
which enables the separation of collagen from sandwich cultured cells by 
centrifugation. However, this method could not be established during the present 
study. Despite varying the centrifugation time and g-force of the original protocol, the 
resulting cell pellet always was stuck to a cord of collagen. The pellet had to be cut 
from the collagen string manually, a procedure not suited to the parallel processing of 
the large number of samples expected in the final studies of the present work. A 
further idea, the enzymatic digestion of the collagen followed by the separation from 
the living cells, was also considered. However, this procedure was never tested due 
to various issues. Firstly, a similar method was performed during another in house 
project resulting in traces of the digesting enzyme and remaining collagen during gel 
electrophoresis. Secondly, the enzyme activity and time of digestion for this 
procedure is very critical since the cells could also be enzymatically attacked. Finally, 
the method was too labor intensive in the context of the present project.        
During proteomics analysis it was not feasible to distinguish if the Collagen I peptide 
identified was from the cellular protein or from the collagen I applied to the cell 
culture plate. This had a direct consequence on the validity of data interpretation 
since aliquots were taken for total protein content determination for the normalisation 
of the Omics data. In addition, especially for MS and HPLC analysis, sample spectra 
contained huge peaks representing components of the collagen gel, such as phenol 
red and acetate. In the end, most of the measurement procedures were optimized 
such that these peaks did not mask other essential peaks.  
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Figure 4.1: Schema of sample preparation for the different endpoint measurements. 
[Predict-IV 2011a] 
 
Preliminary sample preparation studies were conducted for all necessary endpoints. 
Before the final protocols for sample preparation (Figure 4.1) were fixed, draft 
protocols were developed in cooperation with the analytical laboratories and the 
following parameters were varied until satisfactory results could be measured: 
 Solutions used for cell washing 
 Solutions and liquid volumes used for cell scraping and lysis 
 Time and strength of sonication 
 Tubes used for sample preparation, transport and storage 
 Number of technical replicates for test compounds and controls 
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The Predict-IV consortium decided that the kinetics data would be normalized to the 
DNA content of the treated cells, since sandwich cultured cells could not be detached 
and counted. The DNA was quantified with the Quant-iT PicoGreen dsDNA Kit 
from Invitrogen which selectively stains double-stranded DNA with a fluorescent 
dye. The challenge during the establishment of this assay was the correct 
performance of the calibration curve. Since not all of the freshly isolated cells seeded 
onto a cell culture plate attached, the resulting adherent cell cultures contain a 
variable number of cells. Therefore, it was necessary to run the calibration curve 
using freshly isolated cells in suspension.  
Test experiments showed that the solution used for cell lysis heavily influenced the 
DNA quantification. Therefore, defined numbers of fresh hepatocytes were mixed 
with the appropriate amount of collagen used for one well of the sandwich culture 
and the appropriate volume of methanol as used for the kinetics protocol. Then the 
mixture was sonicated according to the protocol for kinetics sampling and the DNA 
content was quantified. The resulting calibration curve was used for the calculation of 
the DNA content of the adherent cells, and included an optimal dilution.  
 
4.2 Establishment of the CYP characterisation assays 
For every donor the basal expression, as well as the inducibility of several phase-I, II, 
and III enzymes, was estimated using a mRNA assay (QuantiGene Plex 2.0 Assay 
from Affymetrix, Figure 4.2). Additionally, the activity of two CYPs was measured by 
monitoring the metabolism of an appropriate, specific substrate. At the time of writing, 
these studies have not been finished. The samples from all donors have been 
collected and stored, but will only be measured in parallel after the last Predict-IV 
study is finished. Therefore, the establishment of these two methods is described 
herein in their entirety.  
The QuantiGene Plex 2.0 Assay was performed with a customized probe panel 
containing major CYPs, UGT, transporters and transcription factors involved in drug 
metabolism as well as three housekeeping genes. The housekeeping genes were 
selected out of a group of candidate genes tested in primary rat hepatocytes treated 
with the prototypical CYP inducers Dexamethasone (Dex; CYP3A), Pregnane 
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carbonitrile (PCN; CYP3A), Phenobarbital (PB; CYP3A/2C) and 3-
Methylcholanthrene (3MC; CYP1A2) [Hewitt 2007, Richert 2009]. 
bead
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Branched DNA 
tree with
fluorescence dye
 
Figure 4.2: QuantiGene Plex 2.0 Assay.  
The QuantiGene® Plex 2.0 Assay was used for the expression and induction analysis of genes coding 
for enzymes, transporters, and transcription factors involved in drug metabolism. The target RNA was 
captured by target-specific beads and the signal is amplified by a tree built up with short DNA 
sequences which carried a fluorescent dye [Panomics 2008, modified].   
 
The selection criteria were (1) stable expression over time, (2) no expression 
changes by cell treatment and (3) expression level similar to target genes of the 
customized panel. During the final studies, cells from every biological replicate in 96-
well plate monolayer culture were treated daily for three days with Dex, PCN, 3MC or 
PB. Subsequently, the cells were lysed by incubation with an appropriate cell lysis 
mixture and stored at -80°C. The QuantiGene Plex 2.0 assay started with an in situ 
hybridization of the target RNA in the cell lysate. The target RNA is captured by 
target-specific magnetic beads, followed by a signal amplification using the branched 
DNA technique. Finally, a fluorescent dye is bound and the signal intensity of the 
different targets is measured by a method similar to flow cytometry. A set of two 
lasers detect the target-specific beads as well as the signal intensity which is 
proportional to the number of bound target RNA molecules [Panomics 2008]. Using 
this assay, the donor-specific basal expression and inducibility of major drug-
metabolizing enzymes as well as transporters and transcription factors involved in 
drug metabolism was estimated.  
The enzyme activities of two major CYPs were measured for every donor. Cells in 6-
well plate monolayer culture were treated for 30, 60, and 90 minutes with different 
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concentrations of CYP specific substrates: midazolam (CYP3A; 2, 10, and 20µM), 
testosterone (CYP3A; 50, 100, and 250µM) and phenacetin (CYP1A; 2, 20, and 
80µM) [´t Hoen 2001, Kobayashi 2002, Hewitt 2007, Richert 2009]. The 
concentration of the the parent substrate and metabolites in the cell culture medium 
was measured by a cooperating group using specific HPLC methods. Based on the 
total protein content of the cells measured with the Bradford Assay, the amount of 
substrate metabolised per minute per milligram of protein was calculated. Although 
the measurement of the 6-hydroxylation of testosterone is commonly used to 
calculate the activity of rat CYP3A [Richert 2009], the appropriate metabolite was not 
detected in any donor. Midazolam and phenacetin were metabolized into 1-
hydroxymidazolam and acetaminophen, respectively. Based on this preliminary 
experiment an incubation time of 60 minutes and substrate concentrations for 
subsequent studies were fixed (Midazolam: 10µM; Phenacetin: 20µM). 
 
Figure 4.3: Preliminary study for the establishment of CYP activity measurement. 
Primary rat hepatocytes were treated with 10µM midazolam and 20µM phenacetin. The concentration 
of the products 1-hydroxymidazolam and acetaminophen were measured by HPLC at different time 
points. CYP3A and CYP1A were inhibited by 30 minutes pre-treatment with 10µM ketoconazole (KC) 
and 1µM α-Naphthoflavone (aNF) which markedly decreased the detected product concentration after 
incubation for one hour. Pre-treatment with the CYP inducers pregnane carbonitrile (PCN; 10µM) and 
3-Methylcholanthrene (3MC; 5µM) for three days heavily increased the product production after one 
hour incubation. n = 3. 
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The linearity of the CYP reaction over time was demonstrated throughout a range of 
cell treatments from 30 to 180 minutes. After 120 minutes the production of 
Acetaminophen increased less strongly while the synthesis of 1-Hydroxymidazolam 
reached a plateau (Figure 4.3). Thus, the most sensitive measurement was observed 
after a 60 minute incubation. Inhibition of CYP activity was shown after pre-treatment 
of the cells for 30 minutes with the CYP inhibitors ketoconazole (CYP3A; 1, 10, and 
50µM) [Brown 2007, Hewitt 2007] and α-naphthoflavone (CYP1A; 1, 10, and 50µM) 
[Liu 2009, Shi 2011] followed by addition of the substrate and incubation for one 
hour. The metabolism of midazolam was markedly decreased, while the synthesis of 
Acetaminophen was slightly diminished. This suggests a less effective inhibition of 
CYP1A or the involvement of other enzymes or isoforms in the metabolism of 
Phenacetin. Finally, the cells were pre-incubated for three days with known CYP-
inducers: PCN (CYP3A; 10µM), Dex (CYP3A; 50µM) and 3MC (CYP1A; 5µM), 
respectively. During this experiment the metabolism of both substrates was markedly 
increased. In conclusion, the CYP inhibition and induction studies indicated a specific 
metabolism of midazolam and phenacetin by CYP3A and CYP1A, respectively. 
Therefore, the established assays are well suited for the determination of the 
activities of these CYPs.   
   
4.3 Dose finding 
During the final studies, the cells were treated with two different doses of each 
reference compound. The high dose was defined to be the TC10 while the low dose 
was selected to be 1/10th of the high dose. In order to define the TC10 for the seven 
test compounds a dose finding study with three different steps was performed. 
Firstly, a pre-screening of a wide range of concentrations was conducted over a short 
time in 96-well plate monolayer culture. The large number of different compounds 
and doses could be only handled in the 96-well plate format which is incompatible 
with the sandwich culture. Based on the results of the pre-screening five to eight 
concentrations of each compound were selected for the subsequent long term study 
in a 24-well plate sandwich culture. This cell culture format enabled the use of the 
sandwich culture system as well as the measurement of several different doses and 
compounds in parallel. Finally, three doses around the TC10 were tested during the 
dose validation study in the 6-well plate sandwich format, the culture system which 
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was also used for the final studies (Figure 4.4). Finally, the high doses for the main 
studies were determined.  
Validation study
3 doses around TC10, 6-well plate sandwich, TP = 14d
Long term study
5 - 8 doses, 24-well plate sandwich, TP = 1, 3 and 14d
Pre-screening
Wide dose range, 96-well plate monolayer, TP = 24h
 
Figure 4.4: Schema of the different steps of the dose finding study. 
TP = time point of cell viability measurement 
 
4.3.1 Prescreening and dose selection for long-term dose finding study  
In order to get an overview of the cytotoxic potential of the different test compounds 
the seven compounds were screened in a 96-well plate monolayer culture with one 
biological replicate and three technical replicates over a wide dose range (Table 4.1). 
This cell culture system was used since monolayer cultures are well suited for short 
term cytotoxicity tests and the 96-well plate format needs a smaller number of cells, 
media, and test compound than bigger formats. For this first screening the doses 
were selected based on historical unpublished in-house data. Stock solutions were 
prepared at 200-fold concentrations in DMSO and DMEM-F12; 0.5% DMSO was 
used as vehicle control to enable treatment with very high doses, since the highest 
doses of fenofibrate, valproic acid and acetaminophen were near to the limit of 
solubility in medium. The cells were treated once for 24 hours one day after cell 
seeding and cell viability was calculated by ATP quantification.  
Based on the results of the 24h-pre-screening the doses for the long-term dose 
finding study were selected in order to cover the range of cell viability between 100% 
and 0% of vehicle control. For the generation of results which allow a robust 
definition of the TC10, it was necessary to choose enough doses spread uniformly 
over the entire cell vitality range. Furthermore, the increments between the individual 
concentrations had to be small enough to be able to recognize any rapid decrease in  
78 Results and discussion 
 
Table 4.1: Results of the 24h-pre-screening.   
Primary rat hepatocytes in 96-well plate monolayer cultures were treated with a wide dose range of the seven test compounds. After 24h the cell viability was 
calculated as percent of vehicle control by quantification of ATP. SD: standard deviation.  
Acetaminophen             
dose/µM 20000 10000 5000 2000 1000 500 200 100 50 25 10 1
cell viability/% 2.4 27.1 42.4 61.0 70.9 76.2 73.8 82.3 89.8 90.8 82.9 84.1
SD/% 1.5 4.0 2.5 2.0 5.1 2.3 1.2 5.6 3.7 1.8 4.7 9.2
EMD 335823             
dose/µM 5000 4000 3000 2000 1500 1000 750 500 250 100   
cell vitality/% 26.7 63.3 61.4 64.6 76.3 84.4 96.5 108.9 114.1 110.4   
SD/% 3.6 1.8 3.8 3.0 0.7 4.7 3.1 5.4 1.9 4.7     
Fenofibrate             
dose/µM 5000 3000 2000 1500 1000 750 500 250 100    
cell viability/% 87.4 84.4 88.0 91.4 82.0 79.0 90.6 90.1 91.2    
SD/% 3.9 2.0 6.1 3.3 3.7 3.8 1.8 3.3 3.3       
Metformin             
dose/µM 5000 3500 2000 1000 500 100       
cell viability/% 1.6 1.3 59.3 81.0 78.9 95.8       
SD/% 0.0 0.3 1.5 5.2 4.8 3.8             
Rosiglitazone             
dose/µM 750 500 400 300 100 75 50 25 10 1   
cell viability/% 0.1 0.5 100.9 66.2 85.9 99.5 107.5 110.1 101.7 104.2   
SD/% 0.2 0.2 10.9 22.5 7.1 4.2 2.8 5.3 7.9 4.3     
Troglitazone             
dose/µM 250 200 150 100 80 70 60 50 20 10 1  
cell viability/% 0.4 0.0 0.0 0.0 0.6 30.8 93.5 97.5 106.4 102.8 105.7  
SD/% 0.1 0.1 0.1 0.2 0.4 12.8 4.9 3.2 5.5 5.2 4.4   
Valproic acid             
dose/µM 1000 750 500 250 200 150 100 50 10 1   
cell viability/% 89.9 94.1 84.6 105.2 115.1 120.2 118.7 110.3 118.1 114.0   
SD/% 6.1 4.8 28.2 5.8 4.7 3.4 8.1 11.9 3.8 3.3   
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cell viability, an effect observed with troglitazone (Tro). In this case, the cell viability 
remained at around 100% up to a concentration of 60µM before rapidly decreasing to 
30.8 ± 12.8% at 70µM; 80µM Tro killed nearly all of the cells. 
Eight concentrations were chosen for the subsequent long-term dose finding study to 
enable the fine tuning of the TC10. For acetaminophen (APAP), fenofibrate (FF) and 
metformin (Met) 5000µM, 3000µM, and 2000µM, respectively, were chosen as the 
highest doses due to the low solubility of the compounds. These doses caused 
cytotoxicities of 42.4 ± 2.5%, 84.4 ± 2.0%, and 59.3 ± 1.5%, respectively, which was 
sufficient for the estimation of the TC10. APAP, Met, FF, EMD 335823 (EMD), and 
valproic acid (VA) showed cytotoxicity at relatively high doses compared to 
rosiglitazone (Rosi) and Tro. As a result, the gradations between the chosen doses 
for the latter two compounds were larger and the concentrations smaller. 
 
4.3.2 Long term dose finding study and dose selection for validation study 
The long term dose finding study was performed in the 24-well plate format. In 
contrast to 96-well plates, this format enables the application of the sandwich culture 
and therefore treatment for 14 days. Primary hepatocytes in monolayer cultures 
remain vital for only three to five days. The final studies had to be performed in 6-well 
plate sandwich cultures to enable the isolation of enough RNA for gene expression 
analysis. Since the historical data generated with primary hepatocytes cultured in 24- 
and 6-well plate sandwich cultures were comparable, the 24-well plate format was 
used for this dose finding study in order to decrease the demand for cells. The cells 
were treated daily for 14 days, starting on the third day after cell seeding, using 200-
fold stock solutions for each compound and 0.5% DMSO as vehicle control. During 
the dose finding study a higher DMSO concentration was chosen than in the final 
studies (0.2%) to enable treatment with high doses without reaching the upper limit of 
solubility. Since the cytotoxicity of FF and APAP was relatively low and FF showed a 
low solubility, a higher DMSO concentration was needed for these two compounds. 
The doses for the long-term dose finding study (Table 4.2) were based on the results 
24h-pre-screening test and selected to cover the viability range between 100% and 
0% of vehicle control.  
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After one, three and 14 days the cell viability was calculated as a percentage of the 
vehicle control by quantification of ATP. Furthermore, the cells were photographed 
and checked for morphological alterations. The long term dose finding study was 
performed with three biological and three technical replicates and the results were 
visualized graphically. Since the aim of the project is the detection of very early 
substance specific changes in gene expression, the TC10 was estimated for all 
seven compounds. During the final studies the TC10 was used as a high dose and 
1/10th of this as the low dose since cellular treatment with doses higher than the 
TC10 may trigger general unspecific effects related to apoptosis and necrosis. 
Table 4.2: Doses (in µM) used for long term dose finding studies in 24-well plates.  
 
  Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 Dose 8
Acetaminophen 10 100 500 1000 2500 5000  
EMD 335823 100 500 750 1000 2500 5000  
Fenofibrate 10 100 500 1000 3000  
Metformin 10 100 500 1000 2000  
Rosiglitazone 1 10 50 100 200 300  
Troglitazone 1 10 20 50 60 65 70 100
Valproic acid 10 100 250 500 750 1000    
 
The TC10 was estimated based on the results for the cell viability as well as the cell 
morphology. For Tro, VA, APAP, and EMD both parameters were in agreement. 
However, the morphology of the cells treated with Rosi, Met, and FF appeared 
unaffected while the ATP content was markedly decreased (Figure 4.6, appendix 
Table 7.1). This effect was comparable in all three biological replicates, thus 
hypersensitivity in one donor could be ruled out as a possible explanation. Sandwich 
cultures treated with one of these three compounds seemed to react more sensitively 
to ATP quantification than the monolayer cultures. Therefore, the dose selection was 
mainly based on the cell morphology since these data were comparable with 
historical in-house data collected for the three compounds. For each of the seven 
compounds, the doses for the validation study were selected using the results of the 
14 day timepoint, since cytotoxicity increased with both dose and time of treatment. 
Based on these results, three doses around the TC10 and the lowest concentration 
which seemed to affect the cell morphology were selected for a final validation study. 
For APAP and VA, three doses over the complete dose range of the 24-well plate 
study were chosen, since the measured cell viability after treatment with the lowest 
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dose on day 14 was less than 100%. Only slight changes in cell viability were 
observed using higher doses; throughout treatment the cell morphology seemed to 
be unaffected. Furthermore, VA seemed to be more cytototoxic at earlier time points, 
an observation which was not validated in a subsequent test. The highest dose of FF 
for the validation study was 1000µM, since higher concentrations were very difficult 
to dissolve in the vehicle and precipitated out after the stock solution was added to 
the cell culture medium. Furthermore, neither the effects on the cell viability nor on 
the cell morphology were increased by higher concentrations than 1000µM. For EMD 
and Met, doses up to the TC50 were selected such that the results of the ATP test 
could be compared with the changes in cell morphology. The day 14 ATP results 
were below 100% at the lowest doses of Met with a smooth decrease as a result of 
increasing dose, while the lowest doses of EMD showed viabilities higher than the 
vehicle with a strong decrease with higher dose.  
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Figure 4.5: Results of the long term dose finding study in 24-well plate sandwich culture.  
The cell viability was calculated as percentage of control and is plotted as the mean of the three 
biological replicates plus or minus the standard deviation as a function of the dose. 
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Figure 4.5 continued: Results of the long term dose finding study in 24-well plate sandwich culture.  
The cell viability was calculated as percentage of control and is plotted as the mean of the three 
biological replicates plus or minus the standard deviation as a function of the dose. 
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Rosi and Tro showed a marked decrease in cell viability at doses higher than 100µM 
and 65µM, respectively. Therefore, doses around these critical points were chosen 
for further validation. EMD also showed a marked time dependent increase in 
cytotoxicity at doses above 1000µM. This observation underlined the previous 
decision to select the final doses based on the results of 14 day repeated treatment 
since the assumption is that any effects which become apparent on day 14 may be 
be preceeded by gene expression changes, which can be developed as early 
biomarkers in further studies. 
 
4.3.3 Validation study and dose selection for final study 
During the long term dose finding study, three doses around the TC10 of every 
compound were selected for the subsequent validation study using the cell culture 
format of the final studies. Here, cells of one biological donor in 6-well plate sandwich 
cultures were treated in order to investigate whether the TC10 calculated in the 24-
well plate format could be transferred to the 6-well plate format. The cell viability was 
measured using the ATP test after 14 days of daily treatment. The results of the ATP 
quantification as well as the changes in cell morphology were comparable to the 
results of the study in 24-well plates. Based on these results the doses used during 
the final ‘omics and kinetics studies were selected (Table 4.3, Table 4.4).  
It was agreed within the consortium, together with members of the advisory board, to 
use 1000µM as the highest dose for the final studies if the TC10 of a compound was 
higher than 1000µM. This decision was in line with the ICH Guidance on genotoxicity 
testing and data interpretation for pharmaceuticals intended for human use [ICH-S2 
2008]. The cutoff was fixed in order to solve problems regarding the limit of solubility 
and to keep the discrepancy between doses used in cell culture and during in vivo 
studies as small as possible. So the high dose (HD) selected for APAP and FF was 
1000µM. The HD for Met was also selected to be 1000µM since this dose caused 
slight changes in the cell morphology. For EMD 750µM were selected as the HD 
although this dose did not affect the cell viability during the long term dose finding 
study; in this test the TC10 was 1000µM, but this concentration damaged the cells 
(Figure 4.6). VA seemed to be less cytotoxic at day 14 when compared to earlier time 
points during the long-term dose finding study; the cell viability was not decreased 
dose-dependently in contrast to days one and three. During the validation study, a 
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dose dependent decrease in cell viability was seen; concentrations of 500µM and 
1000µM affected the cell morphology and cells detached and died (Figure 4.6). 
Therefore, 100µM was selected as HD for VA. Tro showed cell viabilities around 80% 
at all of the three tested doses, but only 70µM changed the cell morphology to the 
effect that the cells began to round up. Therefore, 70µM was chosen as the HD. Rosi 
affected the cell morphology at 100µM, the critical dose during the long term dose 
finding study, but not at 10µM (Figure 4.6). Since the cell viability was markedly 
decreased by concentrations higher than 100µM the HD for Rosi was fixed at 80µM. 
With all treatments, this dose selection data correlated with that from another PhD 
project performed using the same cell culture system [Hrach 2008]. Accordingly, the 
low dose was fixed by the Predict-IV consortium and the advisory board to be 1/10th 
of the HD. This dose should represent a non-toxic dose (Figure 4.6), with no visible 
effect on cell morphology. 
Table 4.3: Doses (in µM) used for the validation study. 
 
  Dose 1 Dose 2 Dose 3
Acetaminophen 10 1000 5000
EMD 335823 500 1000 1500
Fenofibrate 10 500 1000
Metformin 100 1000 1500
Rosiglitazone 10 100 200
Troglitazone 1 50 70
Valproic Acid 10 500 1000
 
Table 4.4: Results of the validation study.  
The cell viability is shown as mean of three technical replicates in percentage of the vehicle control ± 
standard deviation. 
  Dose 1 Dose 2  Dose 3 
Acetaminophen 84.4% ± 4.1% 84.1% ± 2.5% 69.1% ± 2.6% 
EMD 335823 83.9% ± 1.4% 74.1% ± 1.2% 47.3% ± 4.5% 
Fenofibrate 49.6% ± 1.2% 43.9% ± 0.8% 37.6% ± 0.7% 
Metformin 65.6% ± 1.3% 45.3% ± 1.6% 12.9% ± 1.0% 
Rosiglitazone 62.1% ± 2.7% 49.5% ± 2.4% 22.9% ± 0.9% 
Troglitazone 81.9% ± 2.1% 77.8% ± 2.9% 82.9% ± 5.9% 
Valproic Acid 86.7% ± 2.6% 68.0% ± 4.3% 59.2% ± 2.1% 
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Figure 4.6: Pictures of treated primary hepatocytes.  
The cells were treated for 14 days with three doses of each of the seven test 
compounds (optical magnification: 2000X). 
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4.4 Final studies  
The final studies were performed with three biological replicates in 6-well plate 
sandwich cultures. The cells were treated daily for 14 days starting on day three after 
cell seeding with the doses selected and validated during the long term dose finding 
and the validation studies. Two technical replicates per time point were performed for 
each of the doses (Table 4.5). Two wells of vehicle control (DMSO) were treated per 
time point. After one, three and 14 days of treatment the cells were washed, lysed 
and frozen according to the protocol described in chapter 3.3.1.  
Table 4.5: Doses (in µM) used for cell treatment during final studies. 
 
  Low dose (µM) High dose (µM)
Acetaminophen 100 1000
EMD 335823 75 750
Fenofibrate 100 1000
Metformin 100 1000
Rosiglitazone 8 80
Troglitazone 7 70
Valproic acid 10 100
Dimethyl-Sulfoxide 0.2% 0.2%
 
One technical replicate of each biological replicate was processed. The second 
technical replicate was stored at -80°C as a backup. The RNA was isolated, 
quantified and tested for quantity and quality. All RNA samples had a high purity with 
RIN values of nine to ten. A minimal RNA concentration of 150µg/ml was required for 
cDNA synthesis, which was fulfilled by all samples except one for which the backup 
replicate had to be substituted. The cDNA was used to synthesize biotin labeled 
cRNA. This cRNA was also quantified and the quality was checked. A cRNA 
concentration of at least 45.45µg/ml was needed for microarray hybridization, 
requirements which were met by all the processed samples. The biotin labled cRNA 
was then hybridized to Illumina® Sentrix Bead Chips (chapter 3.3.3). All raw data 
generated was analysed using Expressionist™ and IPA® as described in the 
Materials and Methods.   
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4.4.1 Gene expression analysis 
The quality of the gene expression data was checked with the software 
GenomeStudio by assessing the response of the internal controls (chapter 3.4.1). No 
problems were observed for any of the measured samples. The visualization of the 
total number of detected genes did not show any outliers except in one array for 
which the scanning process failed. During the analysis with GenomeStudio no genes 
could be detected indicating a general problem during the hybridization process. 
Since the sample loaded onto this array was a fourth biological replicate, and for 
most of the substances only three replicates were measured, the hybridization and 
scanning for this single sample was not repeated and the array was excluded from all 
further analysis.  
The gene expression data was uploaded into Expressionist to check the distribution 
of the raw data using scatter plots in order to choose the appropriate normalization 
method. The scatter plots for all the scanned gene chips showed a linear data 
distribution with minimal parallel shifts around the centre (Figure 4.7).  
 
Figure 4.7: Data distribution before (left) and after (right) the Central Tendency Normalization. 
The left scatter plot shows a linear data distribution as assumption for the Central Tendency Normalization with a 
data cloud slightly shifted parallel to the central line. In the right plot the data cloud is placed onto the central line 
without modification of the clouds shape.   
 
Therefore, Central Tendency Normalization as a linear normalization method was 
performed. The non-normalized data were visualized in a box plot diagram (Figure 
4.8) where the medians of the single arrays were found to scatter around the signal 
intensity 100 which was used as a median target value during normalization. Figure 
4.7 shows the raw data in comparison to the normalized data. The data cloud which 
was slightly shifted from the central line before the normalization was then positioned 
on to the central line and the medians of the box plots were set to 100 (Figure 4.8). 
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Figure 4.8: Data distribution before (left) and after (right) the Central Tendency Normalization. 
The left box plot shows the medians of the different samples spread around a signal intensity of 100. 
The medians of all samples were shifted to a signal intensity of 100 by Central Tendency 
Normalization (right) without other modification of the data shown by unchanged shape of the boxes. 
The fold-change, the p-value and the BH-Q-value were calculated (chapter 3.4.3) 
and the deregulated genes (Table 4.6) were filtered using the cutoff criteria: p ≤ 0.05, 
BH Q ≤ 0.2, and fold-change ≤ -1.5 and ≥ 1.5. The biological interpretation of the 
gene expression data was performed using the IPA® (Ingenuity® Systems) software. 
Although the study reported here is focused on rat data, IPA®’s gene lists contained 
the gene symbols of the capitalized ortholog human genes. The precision of the 
orthology was spot-checked for several genes using the “BLAST” function provided 
by the National Center for Biotechnology Information [NCBI 2011]. For rat genes 
lacking a human ortholog the uncapitalized rodent gene symbols were used. 
Table 4.6: Overview of the number of deregulated genes.  
The data was filtered due to p ≤ 0.05, BH-Q ≤ 0.2, Fold change ≤-1.5 and ≥1.5, respectively. LD = low 
dose, HD = high dose, 1/3/14: treatment day 1, 3, and 14.  
  LD1 LD3 LD14 HD1 HD3 HD14
Acetaminophen - - - - 1 -
EMD 335823 - - - 37 864 1063
Fenofibrate 1 92 13 2 46 21
Metformin - - 1 3243 3401 -
Rosiglitazone - - - 3 466 857
Troglitazone - - - - 144 -
Valproic acid - - - - - -
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Figure 4.9: Gene expression results of EMD, FF, Rosi, Tro, and Met. 
Up- (red) and downregulated (green) genes were divided into functional groups and visualized by a 
heatmap. H = high dose, L = low dose, 1/3/14 = treatment day 1, 3, and 14.  
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4.4.1.1 Acetaminophen 
Acetaminophen (APAP), better known as Paracetamol, is 
a widely used analgesic drug. It has a weak anti-
inflammatory effect and reduces fever by inhibiting 
cyclooxygenase 1 and 2, which are involved in the synthesis of prostaglandins 
[Botting 2000]. At therapeutic doses APAP is relatively non-toxic, but if consumed in 
very high doses the liver is is a major target for significant toxicity. The kidney can be 
considered to be a secondary target organ for toxicity [Botting 2000]. APAP is an 
over-the-counter-medication and nearly 50% of all the cases of acute liver failure in 
the USA are related to APAP exposure. APAP overdose, whether intentional 
(suicide) or unintentional, causes the death of many patients each year [Lee 2004]. 
APAP is oxidized mainly by CYP2E1 but also by CYP2A1, CYP2A6 and CYP3A4 to 
N-acetyl-p-benzoquinone imine, which is detoxified by conjugation with GSH. Once 
GSH is depleted by high doses of APAP, oxidative stress, damage of the 
mitochondria, liver inflammation, necrosis, and apoptosis occurs in human and 
rodent liver [James 2003, Kaplovitz 2005]. Since ethanol induces CYP2E1, long-term 
ethanol exposure increases the hepatoxicity of APAP and should therefore not be 
taken together with the drug [Lee 2003]. The results of gene expression analyses 
performed with livers of APAP-treated rats and in vitro-treated primary human and rat 
hepatocytes correlate with the in vivo effects and have helped our understanding of 
the molecular mechanisms of APAP-induced hepatotoxicity. For example, the 
induction of CYPs (CYP3A) leads to an increased production of reactive metabolites 
and induces stress-related genes (Hmox, Gadd45, Txnrd1) and pro-apoptotic factors 
like c-Myc [de Longueville 2003, Kikkawa 2006, Morishita 2006, Suzuki 2008, Tuschl 
2008].    
During the present study APAP deregulated a very small number of genes. The sole 
gene to be upregulated significantly was the oxidative stress marker alpha/beta 
hydrolase 1 (ABHD1) [Stoelting 2009]. This may be a consequence of the doses 
used. The high dose was fixed at 1000µM by the Predict-IV advisory board facing 
problems with the limit of solubility and in vitro concentrations far away from in vivo 
doses. This decision was upheld by the ICH “Guidance on genotoxicity testing and 
data interpretation for pharmaceuticals intended for human use” which recommends 
1000µM as highest dose if the dosage is not limited by cytotoxicity or solubility [ICH-
S2 2008]. However, this concentration did not affect cell viability during our dose 
OH
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finding studies (chapter 4.1) and therefore was not expected to markedly change the 
gene expression level of treated cells. Research groups which published marked 
changes in cytotoxicity or gene expression treated their cells with concentrations 
starting at around 5000µM [Suzuki 2008, Jemnitz 2008]. 
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Figure 4.10: PCA of the Acetaminophen samples.  
The treated samples cluster together with the time-matched controls indicating that the treatment with 
APAP did not alter the gene expression of the cells compared to the control cells.  
The PCA, as a first overview of the data, underlined these expectations (Figure 4.10). 
All the samples of one time point - low and high dose and the time-matched control - 
clustered together, clearly showing that there are little differences in the gene 
expression of the treated cells related to the control. In addition to ABHD1, the high 
dose APAP-treatment after three and 14 days deregulated a small number of genes 
which met the defined cut-off criteria (Table 4.6, appendix Table 7.2). However, these 
genes possessed a BH Q-value  0.2 and have no relevant pharmacological or toxic 
associations.  
The recommended dosage for adult human patients is 650 - 1000mg of APAP every 
four to six hours or 1300mg every eight hours; and not exceeding 4000mg per day 
[RX-APAP 2011]. The maximum human plasma concentration (cmax) after taking 1g 
APAP averages 12.6µg/ml [Stangier 2000]. Rats orally dosed with 250mg/kg showed 
a cmax of 139µg/ml [Van Kolfschoten 1985] without developing histopathological 
changes [Kikkawa 2006, Morishita 2006] or elevated ALT and AST levels [Kikkawa 
2006]. The high dose used during the present study (1000µM = 151.16µg/ml) slightly 
exceeded rodent non-toxic plasma concentration. So while this in vitro study was 
performed with an in vivo relevant concentration, it was too low to investigate and 
predict hepatotoxic effects, since APAP causes in vivo and in vitro toxicities solely at 
very high doses.  
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4.4.1.2 Valproic acid 
Valproic acid (VA) is a first generation anti-epileptic drug which 
is also used for the therapy of bipolar disorders and migraine 
by increasing the synthesis and release of the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA). This relatively 
safe drug does however cause elevated serum 
aminotransferase levels in 30 – 50% of patients. These effects seem to be dose-
dependent and are in most cases transient without consequences for further 
treatment. However, VA can cause severe idiosyncratic effects in the liver and is a 
teratogen. It is heavily metabolized to more than ten different metabolites which are 
conjugated with GSH and glucuronide before they are eliminated via bile or urine 
[Löscher 1999, Tong 2005]. After CYP oxidation, the metabolite 4-ene-VA is β-
oxidized in the mitochondria and is then able to inhibit β-oxidation enzymes. The 
resulting disturbance of β-oxidation, as well as mitochondrial damage and a decrease 
in free Coenzyme A levels, can lead to hepatotoxic effects, including microvesicular 
steatosis, and has been reported in both rats and humans. Furthermore, this reactive 
metabolite can cause oxidative stress leading to GSH-depletion and necrosis [Chang 
2006, Tang 2007].    
During the present study VA deregulated a very small number of genes, but without 
statistical significance related to the BH Q-value (Table 4.6, appendix Table 7.3). 
Therefore, these gene changes were not considered biologically relevant. The small 
changes in the gene expression level of VA-treated cells could also be observed in 
the PCA (Figure 4.11), which showed results similar to APAP. The samples of the 
low and high dose clustered together with the appropriate time-matched control 
showing that the gene expression level of the compound treated cells did not 
markedly differ from the control. The very few alterations in gene expression may be 
a consequence of a too low concentration selected as the high dose (100µM). This 
dose decreased the cell viability during the dose finding study in the 24-well plate 
format to 54.1 ± 10.3%. During the subsequent validation study in 6-well plates the 
doses 10, 500, and 1000µM were tested. Here the cell viability was decreased to 
68.0 ± 4.3% by 500µM VA and the cells had started to round up and detach. The 
next lower concentration (10µM) decreased the cell viability to 86.7 ± 2.6% but did 
not affect the cell morphology. Therefore, the slightly higher dose of 100µM was 
chosen in order to avoid a non-toxic dose that was too low. To validate the optimal 
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concentration of VA for gene expression analysis the validation study in 6-well plates 
should have been repeated with additional doses in the range between 10µM to 
500µM. Furthermore, the cell viability should have been measured with a further 
cytotoxicity assay because of the discrepancy between the ATP data in monolayer 
and sandwich cultures. Since the ATP test quantifies ATP in living cells it may be 
more sensitive towards drug-induced effects in the mitochondria and therefore 
dependent on the test compound’s mode of action. This assumption is corroborated 
by the low ATP amounts also measured for Met and FF - while the cell morphology 
was not affected. A cytotoxicity test which measures the loss of cell membrane 
integrity (e.g. LDH assay) could provide additional information to aid in dose 
selection.   
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Figure 4.11: PCA of the Valproic acid samples. 
The treated samples cluster together with the time-matched controls indicating that the treatment with 
VA did not alter the gene expression of the cells compared to the control cells.  
For human use, an oral dose of 10 – 15mg/kg/day is recommended to reach the 
therapeutic plasma concentration of 50 – 100µg/ml [RX-VA 2011]. The acute 
hepatotoxicity of VA in human and animals is relatively low [Löscher 1999] and there 
is a lack of efficient animal and in vitro models for the investigation and prediction of 
idiosyncratic drug effects [Kaplovitz 2005, Uetrecht 2008]. However, VA induced liver 
necrosis and steatosis was shown in rats after intraperitoneal injection of 500mg/kg 
[Tong 2005] and also after coadministration of the CYP-inducer phenobarbital 
[Löscher 1993]. During a teratogenicity study, where doses which cause only 
minimum toxicities to the dams are recommended [ICH-S5 1993], pregnant rats were 
orally dosed with 200mg/kg/day. This resulted in a cmax of 340µg/ml [RX-VA 2011], 
which is equal to 3.4- to 6.8-times the human therapeutic dose. The high dose 
(100µM = 16.6µg/ml) used in the present study, reached neither human therapeutic 
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nor rodent minimum-toxic plasma concentrations. Kiang et al. investigated the 
cytotoxicity of VA as well as its potential to trigger oxidative stress production and 
GSH depletion in sandwich-cultured rat hepatocytes at doses of 1mM and higher 
[Kiang 2010, Kiang 2011]. A further study measuring gene and protein expression 
changes in in vitro cultured hepatocytes was performed with 1.2mM VA [Rogiers 
1995]. During the present study, a concentration of 1mM VA decreased the cell 
viability in the 6-well plate format to 59.2 ± 2.1% and markedly affected the cell 
morphology (Figure 4.6). Since the determination of gene expression changes 
caused by slight toxic doses (TC10) was the goal of this study a concentration of 
1mM VA would have been incompatible. However, the cytotoxicity caused by doses 
in the range of 10 to 500µM should have been further analysed in order to optimize 
the dose selection and for gene expression analysis. The performance of in vitro 
studies with in vivo relevant doses would not be possible in the present system due 
to marked cytotoxicity. Nevertheless, cellular treatment with higher doses of VA may 
deregulate genes which could be correlated to in vivo toxicities. This may enable the 
prediction of the dose-related mechanisms of VA’s hepatotoxicity while the prediction 
of idiosyncratic effects remains complex and probably not possible to elucidate with 
these cell models. 
 
4.4.1.3 Fenofibrate  
Fenofibrate (FF) belongs to the class of fibrates which 
are hypolipidemic drugs, are designed to lower the 
plasma triglyceride and cholesterol levels of patients with 
hypercholesterolemia or mixed dyslipidemia. As a 
prodrug fenofibrate is hydrolysed by esterases to its 
active form fenofibric acid which is an agonist of the 
peroxisome proliferator activated receptor alpha 
(PPARα). By PPARα signaling, FF activates lipoprotein 
lipase (LPL) a key enzyme in lipid metabolism which 
cleaves triglycerides into free fatty acids and glycerol. 
Furthermore, FF decreases the production of apolipoprotein B and C-III which are 
part of very low and low density lipoproteins (VLDL, LDL) and increases the 
expression of apolipoprotein A-I and A-II as part of high density lipoproteins (HDL). 
O
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The different lipoproteins enable the transport of the hydrophobic lipids in the blood 
while HDL has a higher affinity to cholesterol receptors in the liver and is therefore 
catabolized faster [DB-FF 2011]. PPARα is a type II nuclear receptor which is highly 
expressed in metabolically active tissues like liver, heart, kidney and muscle. It forms 
a heterodimer with the retinoid X receptor (RXR) after a ligand has bound. The 
activated PPARα/RXR heterodimer binds to peroxisome proliferator response 
elements (PRE) and acts as a transcription factor for several genes involved in lipid 
catabolism and glucose homeostasis. Its natural ligands include fatty acids, which 
activate their own metabolism, since PPARα activation increases fatty acid uptake 
and oxidation. This pharmacological effect was observed in preclinical studies with 
rodents as well as in human clinical trials [Corton 2000, Willson 2000]. However, 
PPARα activation also triggers several well described adverse effects. FF may cause 
dose-related elevation of ALT and AST levels, which are usually transient. After long-
term usage, cholestatic hepatitis, as a consequence of the increased excretion of 
cholesterol as bile salts, can lead to chronic active hepatitis followed by cirrhosis in 
extremely rare cases [RX-FF 2011]. In rodents, FF acts as a non-genotoxic 
hepatocarcinogen. The rodent and the human PPARα are very similar at the DNA as 
well as protein level but its expression in rodent livers is approximately 10 fold higher 
than in humans. In rodents, PPARα activates the proliferation of peroxisomes and 
regulates their function [Corton 2000, Willson 2000]. One hypothesis for the 
mechanism of action of non-genotoxic hepatocarcinogens like fenofibrate is their 
ability to elevate peroxisomal ß-oxidation. This can cause the excessive generation 
of hydrogen peroxide (H2O2) which is the product of lipid oxidation. Catalases 
transform H2O2 into water and oxygen and other anti-oxidant enzymes like 
superoxide dismutases, and also detoxify reactive oxygen species like H2O2. If the 
cellular rescue mechanisms are overextended, hydrogen peroxide can cause 
oxidative stress by lipid peroxidation and the generation of other reactive oxygen 
species (ROS). ROS may lead to oxidative DNA damage and eventually lead to the 
formation of liver tumors in rodents. Tumor promotion and the regulation of 
peroxisomal function seem to be restricted to rodents because of differences in the 
PRE which are not conserved across species [Corton 2000, Nishimura 2007]. 
Nevertheless, species-specific intracellular factors may also influence PPARα 
signaling, since PPARα overexpression in human primary hepatocytes and HepG2 
cells did not increase the expression of PPARα target genes after treatment with FF 
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[Lawrence 2001]. Furthermore, the transfection of human hepatocytes and HepG2 
cells with rat PPARα and rat PRE could not induce peroxisome proliferation and 
PPARα activation after cellular treatment with peroxisome proliferators 
[Ammerschläger 2004]. Fenofibric acid is directly conjugated with glucuronate and 
excreted via the urine. Only a small amount is reduced at the carbonyl moiety to 
benzhydrol metabolite and is subsequently excreted in urine as a glucuronide 
conjugate. Therefore, the formation of reactive metabolites seems not to be involved 
in FF’s hepatotoxicity [RX-FF 2011]. 
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Figure 4.12: PCA of the Fenofibrate samples.  
The treated samples (turquoise) cluster separated from the controls (gray to black) indicating a 
marked deregulation of genes in all samples by FF.     
 
Fenofibrate markedly altered the gene expression of treated hepatocytes 
The PCA (Figure 4.12) of FF showed a clear separation of the treated samples from 
the controls, while the high and the low dose of each time point clustered together. 
Thus, FF markedly altered the gene expression of the treated cells but the effects of 
the low dose were as prominent as those of the high dose treatment. This could 
indicate that the doses for treatment were too high to see dose-dependent effects. 
The major gene expression changes observed included deregulation of PPARα 
target genes. Since FF was reported to activate PPARα in a cell-based 
transactivation assay with an EC50 (concentration triggering 50% of an effect’s 
strength) of 18µM [Willson 2000] cell treatment with 100µM and 1000µM FF may 
suggest the reason for strong PPARα effects, even at the lower concentration used in 
our studies. These effects may be already saturated after cellular treatment with 
100µM so higher doses could not increase these effects any further.  
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During the short time screening in the monolayer culture FF showed nearly no 
cytotoxicity, up to a concentration of 5000µM. In contrast, concentrations of 500µM 
and higher decreased the cell viability after 14 days of treatment to values around 
60%. The cell morphology was not altered after treatment with 500µM while 1000µM 
slightly affected the cell morphology and was therefore chosen as the high dose - 
independently from the results of the cytotoxicity tests. Compounds like FF, which 
directly affect the mitochondria, may also alter ATP synthesis and make our standard 
cytotoxicity test more sensitive. Thus, the dose finding study for FF should be 
repeated with additional doses between 500µM and 1000µM using cytotoxicity tests 
with other endpoints, such as loss of cell membrane integrity in order to correctly 
define the TC10.  
Table 4.6 shows the number of significantly deregulated genes caused by FF 
exposure. Interestingly, treatment for three days altered the highest number of 
genes, independent of the dose. The genes selected for biological data interpretation 
are listed in the appendix (Table 7.4) and visualized in Figure 4.9. Genes with a BH 
Q-value > 0.2 were also discussed since they were involved in pathways known to be 
deregulated by FF or they are directly related to PPARα target genes containing a 
PRE within their promotor sequence.   
Fenofibrate induced genes triggering cellular lipid uptake and catabolism       
Cornwell et al. [Cornwell 2004] and Nishimura et al. [Nishimura 2007] showed that 
the pharmacological effects of FF, such as increasing lipid uptake and metabolism in 
the liver, can be reconstructed by gene expression profiling of rat livers after in vivo 
treatment of rats with FF and other fibrates. Their findings correlate well with the 
results of the gene expression profiling in primary rat hepatocytes described in this 
study. The gene encoding the very low density lipoprotein receptor (VLDLR), a cell 
surface protein that is responsible for the uptake of lipids from the blood, was 
upregulated in a dose- and time-related manner; up to 10.3-fold. Lipids are cleaved 
intracellularly by the PPARα target lipoprotein lipase (LPL) into glycerol and fatty 
acids (FA) [Mandard 2004]. LPL gene expression was induced by the low and the 
high dose of FF on day 14 (up to 60-fold) while the gene encoding apolipoprotein C-II 
(APOC2) which inhibits LPL was downregulated. Cornwell et al. described the 
downregulation of apolipoprotein C and A by FF in vivo which could also be shown in 
this in vitro study. However, the PPARα gene itself was not upregulated by FF during 
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the present study which also correlated well with previously reported gene 
expression studies with hepatocytes and livers of rats treated with PPARα agonists 
[Guo 2006, Tamura 2006].  
The expression of the Aquaporin 9 (AGP9) gene was downregulated at all time 
points and by both doses. This water channel is located in the basolateral membrane 
and manages glycerol uptake into the liver [Huebert 2002, Hibuse 2006]. In contrast, 
the gene expression of Aquaporin 7 (AQP7) was heavily induced and correlated well 
with the results reported by Tamura et al. after the treatment of rats as well as 
hepatocytes with PPARα-agonists [Tamura 2006]. AQP7 is highly expressed in 
adipose tissue, and to a minor extent in the liver, and acts as an efflux channel of 
glycerol into the blood. It is upregulated during fasting when triglycerides are cleaved 
in adipocytes in order to provide glycerol for hepatic gluconeogensis. The expression 
of hepatic AQP9 is also induced in order to increase the take up of higher amounts of 
glycerol for energy production [Hibuse 2006]. During the present study AQP7 
expression was upregulated, probably in order to release the increased levels of 
glycerol, produced by the enhanced lipid cleavage, back into the cell culture medium. 
In parallel, the uptake of further glycerol from the cell culture media was reduced by 
the downregulation of AQP9. Additionally, genes encoding proteins involved in the 
biosynthesis of cholesterol were repressed, especially after high dose treatment on 
days three and 14, which may be a consequence of a high break down rate of 
triacylglycerides and cholesterolesters (Figure 4.13). Sterol O-acyltransferase 1 
(SOAT1) gene expression was upregulated after 14 days of treatment, independent 
of dose. This enzyme esterifies cholesterol enabling its storage as lipid droplets in 
the cell. The gene encoding Perilipin (PLIN2), which is involved in lipid storage, was 
also upregulated at all time points and doses. 
Free FA’s are bound and transported intracellularly by fatty acid binding proteins 
(FABP), the gene expression of which were time- and dose-dependently upregulated 
up to 91-fold. FA’s are activated in the cytosol by acyl-CoA synthetase (ACSL) whose 
gene expression was upregulated relatively constantly by low and high dose at all 
time points. These results correlated well with other gene expression studies 
performed with primary rat and mouse hepatocytes treated with fenofibrate and other 
PPARα agonists [Guo 2006, Tamura 2006].  
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Fenofibrate enhanced expression of genes involved in mitochondrial and 
peroxisomal fatty acid degradation  
Activated FA’s are further oxidized in the mitochondria and transported into these by 
the PPARα target carnitin-palmitoyltransferase (CPT), the gene expression of which 
were upregulated up to 15-fold [Mandard 2004]. Carnitine O-acetyltransferase 
(CRAT) and carnitine O-octanoyltransferase (CROT) regulate the mitochondrial and 
peroxisomal concentration of FA-CoA and the expression of these genes were also 
induced. The expression of genes encoding enzymes involved in every step of 
mitochondrial β-oxidation of FA’s were increased by low and high dose FF at all time 
points up to 8.1-fold. These gene expression changes were consistant with results 
obtained after treatment of rats in vivo and hepatocytes in vitro with PPARα-agonists 
[Cornwell 2004, Guo 2006, Tamura 2006].  
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Figure 4.13: Alterations in lipid metabolism in FF treated cells. 
FF induced lipid uptake and metabolism and decreased energy production from glucose. 
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In most cell types the breakdown of FA’s is primarily performed in peroxisomes, small 
organelles surrounded by a single-layered membrane, while very long FA’s with more 
than 20 C-atoms are only rarely oxidized in peroxisomes [Lodish 2001]. Genes 
encoding transporters for the uptake of FA’s into peroxisomes were upregulated by 
both doses of FF. In addition, the gene expression of enzymes involved in the 
peroxisomal FA-oxidation (Acyl-CoA oxidase (ACOX1), acetyl-CoA acyltransferase 
(ACAA1), enoyl-CoA hydratase (ECH1) were increased independently from time and 
dose, up to 38.6-fold. Acyl-CoA oxidase (ACOX1) was identified as the first direct 
PPARα target and is used as a marker gene for PPARα-agonist action 
[Ammerschläger 2004, Mandard 2004].  
FF deregulated genes related to glucose metabolism 
The intensive breakdown of fatty acids seemed to saturate the cell’s energy 
consumption, which was exacerbated by the hepatic glucose uptake transporter gene 
GLUT2 being suppressed. Furthermore, genes encoding enzymes involved in 
glycolysis, including pyruvate kinase (PKLR) and lactate dehydrogenase (LDHB), 
and gluconeogenesis, such as glucose-6-phosphatase (G6PC) and glucose-6-
phosphate translocase (SLC37A4) were downregulated. Increased FA oxidation 
triggers the phosphorylation of the pyruvate dehydrogenase complex (PDC) which 
transforms the endproduct of glycolysis, pyruvate, into acetyl-CoA (AcCoA). The 
phosphorylation of PDC is catalysed by pyruvate dehydrogenase kinase (PDK) and 
inhibits PDC’s activity [Sugden 2001]. FF induced the gene expression of PDK4, 
indicating a metabolic switch triggered by enhanced lipid catabolism. In addition, FF 
upregulated the gene expression of enzymes involved in the Krebs cycle, like 
aconitase (ACO2), isocitrate dehydrogenase (IGH1) and succinate-CoA ligase 
(SUCLG1). The gene encoding glycerol-3-phosphate dehydrogenase (GPD), which 
transfers electrons into the electron transport chain and builds up the mitochondrial 
transmembrane potential as basis for ATP production, was also induced.  
In conclusion, the gene deregulations related to glucose metabolism and the 
induction of genes involved in the Krebs cycle seem to be a consequence of the 
increased lipid metabolism and do not indicate a response of the cells to toxic effects. 
The expression changes of genes involved in FA and glucose metabolism correlates 
well with Cornwell’s findings of in vivo treated rats [Cornwell 2004] as well as with 
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other gene expression studies performed with in vitro treated rodent hepatocytes 
[Guo 2006, Tamura 2006].     
Fenofibrate induced cellular markers of stress and DNA damage    
One hypothesis for the hepatocarcinogenic action of FF in rodents is oxidative DNA 
damage by ROS as a consequence of enhanced lipid metabolism. In particular, 
peroxisomal lipid catabolism generates hydrogen peroxide which can be detoxified 
by antioxidant enzymes, but only up to a specific limit [Corton 2000]. Supporting this 
hypothesis, the formation of oxidative stress was indicated by the data in the present 
study by the upregulation of several genes coding for antioxidant enzymes. Catalase 
(CAT) reduces hydrogen peroxide produced by lipid oxidation in the peroxisomes. 
Superoxide dismutase 2 (SOD2) and glutathione peroxidase (GPX1) detoxify ROS in 
the mitochondria [Marquardt 2004]. Heme oxygenase 1 (HMOX1) [Keyse 1990], 
ferritin (FTL) [Cairo 1995, Vogt 1995, Orino 2001] and thioredoxin interacting protein 
(TXNIP) [Watanabe 2010] are general markers for oxidative stress. In addition, FF 
induced the gene expression of phase-II enzymes like UDP-glucuronosyltransferase 
(UGT), sulfotransferase (SULT) and glutathione-S-transferase (GSTA) indicating an 
enhanced cellular detoxification activity. However, FF downregulated the gene 
expression of glutamate-cysteine ligase (GCLC) and GSH synthetase (GSS), which 
are involved in GSH synthesis. These genes are upregulated if additional GSH is 
required, e.g., for defense against oxidative stress and reactive metabolites [Yuan 
2009]. Therefore, FF seemed not to deplete cellular GSH during the present study. 
FF upregulated genes encoding enzymes involved in the repair of DNA damage, 
including growth arrest and DNA-damage-inducible alpha (GADD45A) [Smith 2000] 
and APEX nuclease (APEX1) which is induced by oxidative stress [Edwards 1998]. 
During a toxicogenomics study in rats treated with non-genotoxic hepatocarcinogens, 
APEX1 was also upregulated in the liver [Ellinger-Ziegelbauer 2005]. 
Fenofibrate did not induce genes involved in apoptosis and proliferation   
The second hypothesis of FF’s carcinogenesis in rodents is the induction of cell 
proliferation, without increasing apoptosis [Corton 2000]. The intrinsic apoptosis 
pathway is triggered by cytochrome c release from the mitochondria which activates 
caspases. This process can be inhibited by anti-apoptotic BCL2-family members 
[Matés 2008]. Pro-apoptotic factors like BAX, BAD and BAK can be activated by 
cellular stress [Hail 2006]. During the present study low and high dose treatment for 
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one and three days induced the expression of the pro-apoptotic member of the 
BCL2-family - BCL2-like 14 (BCL2L14). On day 14 genes encoding pro-apoptotic key 
factors like BCL2-antagonist/killer 1 (BAK1), BCL2-associated X protein (BAX) and 
BCL2-related ovarian killer (BOK) were downregulated and no caspases were 
deregulated. Furthermore, gene expression of the anti-apoptotic factor v-akt murine 
thymoma viral oncogene homolog 1 (AKT1) was downregulated. Hence, long term 
treatment with high and low doses of FF did not increase expression of genes 
encoding proteins which trigger apoptosis.  
Cyclin D, Cyclin E and cyclin-dependent kinase inhibitor 1B (p27, Kip1) play a major 
role in cell cycle progression from the G1 to S phase [Ogawa 2009]. The Cyclin D 
gene was downregulated on day 14 after high and low dose treatment while genes 
encoding Cyclin E and p27 were not deregulated in the present study. Genes 
encoding polymerase delta 4 (POLD4) [Liu 2006] and topoisomerase II beta (TOP2B) 
[Osheroff 1998] which are involved in DNA replication as well as tubulin alpha 1a 
(TUBA1A) which participates in spindle formation [Hernández 2009] were also 
repressed. This did not correlate with the already mentioned study from Ellinger-
Ziegelbauer et al. [2005] where tubulins and topoisomerase II alpha were 
upregulated by non-genotoxic hepatocarcinogens. Further indications that FF did not 
induce cell proliferation in the present study were the upregulation of genes 
G0/G1switch 2 (G0S2) and geminin (GMNN), which inhibit centrosome duplication 
[Lu 2009]. G0S2 is a PPARα target [Zandbergen 2005] which is upregulated during 
the re-entry from G0 into G1 phase of blood mononuclear cells [Russell 1991]. 
However, recent studies showed that G0S2 triggers apoptosis after DNA damage in 
human primary fibroblasts and acts as a tumor suppressor [Welch 2009]. In addition, 
FF repressed the annexin A5 gene (ANXA5), a calcium-dependent phospholipid 
binding protein whose induction is associated with many carcinomas in rats and 
humans [Glückmann 2007, Xue 2009]. Cimica et al. correlated the upregulation of 
serveral genes with liver regeneration in rats after partial hepatectomy [Cimica 2007]. 
Consistent with this study the angiotensinogen gene (AGT) and the serpin peptidase 
inhibitor clade E member 2 gene (SERPINE2) were induced while the genes 
encoding connective tissue growth factor (CTGF), syndecan 4 (SDC4) and alpha-2-
macroglobulin (A2M) were downregulated during the present study. Further growth 
factor genes, like epidermal growth factor (EGF), transforming growth factor 
alpha/beta (TGFA/B) and early growth response 1 (EGR1), were also repressed 
103 Results and discussion 
 
indicating that FF did not induce cell proliferation during the study presented here. 
One gene, the cell cycle promotor cell division cycle 25 homolog A gene (CDC25A) 
[Källström 2005], was induced which correlated with data published on livers from FF 
treated rats [Nishimura 2007].   
Fenofibrate affected genes related to different cellular functions  
Increased production of several enzymes involved in lipid and xenobiotic metabolism 
is hypothesised to trigger hepatomegaly in animal studies after exposure to FF 
[Cornwell 2004]. The peroxisomal biogenesis factors 11 alpha and 19 (PEX11A, 
PEX19) genes were time-dependently induced, indicating enhanced peroxisomal 
biogenesis and is a well known PPARα effect in rodents [Li 2002a]. This correlated 
with other in vitro and in vivo studies performed with FF and other PPARα agonists, 
respectively [Guo 2006, Tamura 2006]. The gene encoding uncoupling protein 2 
(UCP2) was heavily upregulated during the present study. UCP2 controls the ratio of 
adenosine triphosphate/adenosine diphosphate, plays a role in the generation of 
ROS and was induced in other studies performed with primary hepatocytes treated 
with PPARα agonists [Mandard 2004]. This proton channel is able to uncouple the 
oxidative phosphorylation process leading to an uncontrolled decrease in the 
mitochondrial transmembrane potential which can ultimately cause ATP depletion 
and cell death [Chavin 1999].  
FF downregulated the solute carrier family 10 member 1 gene (NTCP, SLC10A1). 
Decreased expression of NTCP was associated with human cholestasis in vivo but 
FF’s cholestatic hepatitis is thought to be caused by increased cholesterol excretion 
into the bile [RX-FF 2011]. In addition, the biliary efflux transporter ATP-binding 
cassette sub-family G member 1 (ABCG2, BCRP) was induced at the early time 
points, but ATP-binding cassette sub-family B member 1B (Abcb1b, MDR1) and the 
basolateral efflux transporter ATP-binding cassette sub-family C member 3 (ABCC3, 
MRP3) were heavily downregulated at day 14.  
Genes encoding different classes of proteins which are synthesized and excreted by 
hepatocytes were downregulated by FF, including the complement components C2, 
C6, and CFH, the chemokines CXCL11 and CXCL16, the acute phase proteins 
alpha-2-macroglobulin (A2M), alpha-2-HS-glycoprotein (AHSG), and fibrinogen 
(FGB) as well as the coagulation factors F5, F9, and F11. The expression of 
chemokines, complement factors and acute phase proteins is regulated by 
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intercellular signaling between hepatocytes and immune cells. Activated immune 
cells release mediators which bind to receptors on the hepatocyte membrane and 
trigger the synthesis and release of proteins related to the hepatic inflammatory 
response [Trautwein 1994, Dhainaut 2001, Tacke 2009]. Thus, the downregulation of 
genes related to inflammation and blood coagulation in the present study were 
probably associated with the toxic effects of FF since immune cells as essential 
initiators of inflammatory pathways were not present in the hepatocyte monoculture. 
Additional indications of drug-induced cytotoxic effects were the suppression of 
several genes involved in cellular adhesion and morphology, like laminin (LAMC2), 
E-cadherin (CDH1), fibulin (FBLN1), tubulin (TUBA1A), and vimentin (VIM) [Chen 
2006, Malcos 2011, Vuoriluoto 2011]. The cells started detaching and downregulated 
further genes encoding enzymes related to key hepatic functions, such as CYP7A1, 
which synthesizes bile acids. Furthermore, the gene encoding Na-K-ATPase 
(ATP1A1) was downregulated which plays a role in the maintenance of the cellular 
membrane potential. 
In conclusion, the whole genome gene expression data for the FF treated cells 
showed clear induction of lipid catabolism and corresponds to the compound’s 
pharmacological effect [Nishimura 2007, Cornwell 2004]. A similar study performed 
with mouse primary hepatocytes transfected with a PPARα response element in 
order to increase the pharmacological effect of FF resulted in similar findings after 
treatment of cells for 24 hours [Guo 2006]. The study presented here was performed 
with non-transfected cells and was therefore closer to the in vivo situation and also 
showed the deregulation of several in vivo-relevant genes being increased over the 
time of treatment. The gene expression data indicated the formation of oxidative 
stress and DNA damage which are known mechanism of FF’s hepatocarcinogenicty 
potential in rodents. However, the data did not support the hypothesis which 
assumes a disturbed balance of apoptosis and cell proliferation to be the reason for 
FF’s carcinogenicity [Corton 2000]. Tamura et al. directly compared the PPARα 
agonist mediated gene expression changes in primary hepatocytes and livers of in 
vivo treated rats. Genes involved in cell proliferation were markedly induced in vivo 
but hardly in vitro [Tamura 2006]. Parzefall et al. also showed that PPARα agonists 
failed to increase proliferation in in vitro cultured rat hepatocytes while DNA 
replication was increased when Kupffer cells were co-cultured or hepatocytes were 
treated with Kupffer cell derived TNFα [Parzefall 2001]. This discrepancy between in 
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vivo and in vitro derived results highlights one of the limitations of hepatocyte 
monocultures. Primary hepatocytes are well suited for the investigation of effects 
which are restricted to mechanisms and pathways taking place solely in the 
hepatocyte itself. However, effects triggered by intercellular signaling of different 
hepatic cell types were not detectable in the present system. FF downregulated 
genes encoding proteins which are synthesized in the hepatocytes and excreted into 
the blood after activated immune cells induced the appropriate pathways by the 
release of pro-inflammatory mediators [Dhainaut 2001]. Since these cells were not 
present in the hepatocyte monoculture the downregulation of chemokines, 
complement components and acute phase proteins could be related to drug-induced 
cytotoxicity, which secondarily decreases cellular protein production. This hypothesis 
is strengthened by the downregulation of genes encoding coagulation factors as 
another class of proteins which are synthesized and excreted by hepatocytes, but 
which have no relation to inflammatory processes. Further indications of cytotoxic 
effects mediated by FF include the downregulation of several genes involved in cell 
adhesion, morphology and maintenance of the cellular membrane potential. Based 
on the present gene expression data FF would have been classified as slightly 
hepatotoxic, since compared to EMD, as a potential PPARα-agonist, FF induced 
fewer genes related to oxidative stress. In addition, EMD enhanced the deregulation 
of these marker genes to a higher extent and also showed expression changes 
related to mitochondrial and metabolic impairment.                
FF’s toxicity is species-specific and the pharmacological mode of action also slightly 
differs between rodents and humans. Plasma triglyceride and cholesterol levels are 
decreased in both species by induction of PPARα, while proxisome proliferation and 
the enhanced expression of peroxisomal lipid metabolizing enzymes are restricted to 
rodents. Humans, as well as cultured human primary hepatocytes, lack the activation 
of rodent PPARα key targets like acyl coenzyme A oxidase, peroxisome proliferation 
and hepatocarcinogenesis [Roglans 2002, Klauning 2003, Ammerschläger 2004]. In 
primary human hepatocytes FF induced apoptosis but did not enhance proliferation 
[Klauning 2003, Kubota 2005]. In humans FF is regarded as a well tolerated and safe 
drug [Moutzouri 2010]. Increased ALT and AST serum levels, which preceeds 
transient FF induced hepatocellular reactions and chronic active hepatitis, have been 
reported [Tolman 2000]. The relative risk for cholelithiasis associated with fibrate 
treatment was 1.7-fold (80% of patients taking FF and 20% other fibrate derivatives). 
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A further study (FIELD trial) compared FF with a placebo in 9,795 patients while no 
case of biliary disease was reported and there was no increased incidence of cancer 
[Davidson 2007]. Thus, FF was chosen as a human low toxic reference substance for 
the Predict-IV project and only slight changes in the gene expression of FF treated 
human primary hepatocytes were expected. Therefore, the FF derived data reported 
here show in vivo relevant drug induced mechanisms and can be used as a basis for 
the investigation of species differences in primary hepatocytes. It also strengthens 
the need for in vitro studies prior to regulatory animal studies. If these tests are 
conducted in cells of rodents, as a standard species in toxicology and in cells of 
humans, species differences could be detected and regulatory studies could be 
performed in more human relevant species.  
During the present study the high dose used for cellular treatment with FF (1000µM) 
was approximately two times higher than the lowest in vivo dose causing liver 
damage in rodents. The rodent cmax after oral treatment with 100mg/kg was 381 ± 
120µM [Hanafy 2007]. Rats developed liver carcinomas during a 24-month study 
after daily oral dosing of 200mg/kg [FDA-FF 2004] and liver damage after two 
months of daily oral treatment with 60mg/kg [Pierno 2006]. The human steady state 
plasma concentration is achieved after five days of daily treatment. Then the cmax 
amounts to 63.7µM after 200mg of FF were taken [Keating 2002], approximately 2/3th 
of the LD used in the present study (100µM).   
 
4.4.1.4 Troglitazone and Rosiglitazone 
Troglitazone (Tro) and Rosiglitazone (Rosi) 
belong to the class of thiazolidinedione drugs 
(TZDs) which were developed for the treatment 
of non-insulin dependent diabetes mellitus 
(NIDDM). This disease is based on insulin 
resistance of muscle and adipose tissue and is 
associated with hyperglycemia. TZDs increase 
the insulin sensitivity of muscle, liver and 
adipose tissue by activation of the peroxisome 
proliferator activated receptor γ (PPARγ), a ligand activated transcription factor of the 
nuclear hormone receptor super family [Tugwood 2002, Yokoi 2010]. PPARγ 
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dimerises, like PPARα, with the retinoid X receptor (RXR) after a ligand has bound. 
The activated PPARγ/RXR heterodimer binds to peroxisome proliferator response 
elements (PRE) and acts as a transcription factor for several genes involved in lipid 
and glucose homeostasis, adipocyte differentiation and inflammation. PPARγ is 
mainly expressed in adipose tissue, heart, intestine, colon, kidney, spleen and 
muscle cells. One of its main target genes is the glucose transporter GLUT4 which 
increases the uptake of glucose into muscle and adipose tissue and thereby lowers 
the blood glucose level [Corton 2000, Willson 2000].  
Tro was the first TZD approved by the FDA in 1997. It was withdrawn from the 
market in March 2000 after 94 cases of severe drug-induced liver failure were 
associated with Tro treatment, including several liver transplantations and 65 deaths 
[Gale 2001, Tugwood 2002, Floyd 2009]. Preclinical tests with rodents showed no 
significant elevation of serum liver enzyme levels. Rats which received cardiotoxic 
doses of Tro developed liver necrosis and hepatocellular hypertrophy. Monkeys 
showed mild and tolerable hepatotoxic side effects, including bile duct hyperplasia 
[Smith 2003, Kaplowitz 2005]. During clinical studies 1.9% (48 persons) of the Tro 
treated patients (2510) had serum ALT levels greater than three times the upper limit 
of normal. Twenty patients were withdrawn from treatment and two patients 
developed reversible jaundice. The liver biopsies of two patients showed 
idiosyncratic hepatocellular damages while two others had also cholestatic effects. 
Tro’s adverse hepatic effects occurred after long term treatment (three to seven 
months) and could not be linked to the dose. Thus, it was classified as idiosyncratic 
and approved due to a positive benefit/risk ratio [Watkins 1998, Lebovitz 2002]. Since 
then it has been heavily discussed if the findings during the clinical studies were 
interpreted in the right way and if Tro should have been approved [Gale 2001, 
Kaplowitz 2005]. After its withdrawal scientists all over the world have begun to 
investigate Tro’s mechanisms of hepatotoxicity, which has not yet explained 
completely. In vitro Tro was found to be very cytotoxic, inducing depletion of GSH 
and damaging the mitochondria. Furthermore, Tro is a potent inducer of CYP1A, 2A, 
2B6, 2D6, 2E1 and 3A4, especially in humans. After oral uptake Tro is transformed 
by several CYPs (Figure 4.14) especially CYP3A4 is involved in the formation of a 
very active quinone which can undergo redox cycling to generate ROS. This 
metabolite may be further transformed by ring opening to a bifunctional reactive 
intermediate which can bind covalently to DNA and proteins or undergo further redox 
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cycling to produce more ROS [Tuschl 2008]. Rachek et al. showed that the main 
mechanism of Tro’s hepatotoxicity seemed to be the generation of oxidative stress, 
which damages mitochondrial DNA (mtDNA). This can lead to the depletion of ATP 
and the impairment of the electron transport chain, eventually triggering the 
production of further ROS. Finally, the mitochondria swell, their membrane 
depolarizes and cell necrosis or apoptosis is induced. This hypothesis is supported 
by a further experiment of this group where they showed that the co-treatment with 
an antioxidant diminishes the cytotoxicity of Tro [Rachek 2009].   
Tro is excreted into the bile after sulfation and glucuronidation and inhibits the bile 
salt export pump (BSEP) in vitro in rat hepatocytes as well as in human clinical 
studies and therefore has the potential to induce cholestatic liver injury [Marion 2007, 
Yokoi 2010].  
Compared to Tro, Rosi has a slightly modified molecular structure and shows a less 
cytotoxic potential at equimolar concentrations [Lloyd 2002, Guo 2006, Rachek 2009, 
Rogue 2011]. It was marketed in 1999 after clinical trials had been performed without 
any incidence of hepatotoxicity (but myocardial infarctions were observed). After its 
approval, Rosi was reported to be related to 11 cases of severe acute liver failure, 
including nine deaths [Floyd 2009]. This has been was challenged by other authors, 
who have stated Rosi’s unsuspicious hepatic safety profile [Beiderbeck 2009, Osei 
2009]. However, in September 2010 the EMA recommended the withdrawal of Rosi 
due to cardiovascular risks, whereupon Germany immediately stopped marketing the 
drug [press release 11/10 BfArM]. Rosi is extensively metabolized in the liver by 
CYP2C8 and CYP2C9. After N-demethylation and hydroxylation reactions the 
metabolites are conjugated with sulfate and glucuronic acid without the formation of 
reactive metabolites [DB-Rosi 2011, Kirchheiner 2005]. Rosi inhibits the 
mitochondrial respiration and induces apoptosis to a much lower extent than Tro, 
while ATP depletion and mtDNA damage have not been detected [Rachek 2009].  
Several case studies of severe adverse hepatic effects in human patients who were 
treated with Rosi or Tro reported abrupt elevation of serum liver enzyme levels and 
poor general condition of patients who had been taking the drug for months or years 
and underwent regulary liver function tests. Biopsy and autopsy findings of patients 
which developed liver failure showed hepatomegaly, liver necrosis, bile duct 
proliferation, inflammation and cholestatic hepatitis. These effects were interpreted 
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as idiosyncratic side effects since they occurred independently from dosage and time 
of treatment [Li 2000, Murphy 2000, Gouda 2001, Bonkovsky 2002, Su 2006, Floyd 
2009]. Since idiosyncratic reactions occur very rarely and are usually based on 
individual hypersensitivities or related to underlying diseases they are considered to 
be unpredictable with currently available in vitro and in vivo systems [Kaplowitz 2005, 
Uetrecht 2008].   
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Figure 4.14: Metabolism of Troglitazone. 
Tro is activated by different CYPs to active metabolites which can cause hepatotoxic effects when 
they are not detoxified by shown phase-II reactions [Tuschl 2008, modified].  
 
Rosi but not Tro markedly altered gene expression of treated hepatocytes 
During the study reported here Tro did not markedly alter the gene expression of the 
treated cells. This is visualized by the PCA (Figure 4.15) where the low and high 
dose of each time point clustered together with the time matched control. The dose 
finding for Tro was difficult since during the 24h screening assay the cell vitality 
seemed to be unaffected up to a dose of 60µM while 70µM decreased the vitality to 
30.8 ± 12.8% and 80µM killed all the cells (Table 4.1). The cytotoxicity was expected 
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to increase with the time of treatment so the critical dose 70µM was tested again in 
the long term dose finding study but the cell vitality after 14 days of treatment was 
nearly unaffected up to 70µM and the next higher dose (100µM) killed all cells 
(Appendix Table 7.1). These effects were reproduced during the validation study in 6-
well plates (Table 4.4). Thus, 70µM was chosen as the high dose since the 
morphology of the cells was slightly affected (Figure 4.6). In order to get better 
results in the gene expression study the dose range between 70µM and 100µM 
should have been investigated more precisely with small increments of the doses 
since these small changes in gene expression may be due to a high dose which was 
too low.  
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Figure 4.15: PCA of Troglitazone and Rosiglitazone samples.  
The Tro treated samples (left figure) cluster together with the time matched controls indicating that Tro 
did not change the gene expression of the treated cells. Rosi changed the gene expression of the high 
dose treated cells since the high dose samples cluster separately from the low dose samples (right 
figure). The low dose did not affect the cell’s expression level since the low dose clustered together 
with the time matched control.   
 
Rosi notably changed the gene expression of the low and high dose treated cells. In 
the PCA (Figure 4.15) the samples of the low and the high dose of day three and 14 
formed separate clusters while the samples of day one clustered together with the 
time matched control indicating that the gene expression after one day of treatment 
was similar to the gene expression level of the control cells. High dose treatment 
altered between three and 857 genes while the number of deregulated genes rose 
with the time of treatment (Table 4.6). Tro significantly deregulated 144 genes on day 
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three. However, some genes with a BH Q-value > 0.2 were also included into the 
biological data interpretation since they showed a trend correlating to the literature 
(Appendix Table 7.5, Table 7.6). The genes discussed in the following were also 
visualized using a heatmap (Figure 4.9).   
Tro and Rosi enhanced the expression of genes involved in lipid metabolism  
Tro and Rosi upregulated several genes involved in lipid metabolism, especially on 
day three (Appendix Table 7.5 and Table 7.6). In vivo the PPARγ agonists Tro and 
Rosi reduce the serum level of triglycerides and free FA’s [Kumar 1996, Lebovitz 
2001] by the activation of genes that lead to an increase in the differentiation of 
adipocytes and the fat storage in subcutaneous adipose depots. These tissues 
specifically highly express PPARγ, and especially the isoform PPARγ2 [Elbrecht 
1996, Yanase 1997, Montague 2000, Schadinger 2005]. Although the adipose tissue 
is the major target of the TZDS, Memon et al. showed, that genes involved in hepatic 
lipid uptake and metabolism were induced in livers of Tro treated mice. Obese mice 
showed stronger effects than lean ones, while also the PPARγ gene itself was 
upregulated in the livers of obese mice compared to the lean control group. 
Therefore, the authors concluded that Tro’s pharmacological effects are partly 
triggered by hepatic PPARγ [Memon 2000] and that especially PPARγ2 is 
upregulated in steatotic hepatocytes [Schadinger 2005]. Similar results were also 
obtained in Rosi treated mice [Watkins 2002]. Consistent with these data, in our in 
vitro study Tro and Rosi upregulated the genes encoding the low density lipoprotein 
receptor (LRP1) and the transporter CD36, which participates in hepatic lipid and FA 
uptake. Furthermore, the expression of genes involved in the breakdown of FA’s in 
the cytosol, the mitochondria and the peroxisomes, such as monoglyceride lipase 
(MGLL), acyl-CoA thioesterase (ACOT1), acetyl-Coenzyme A acetyltransferase 1 
(ACAT1) and peroxisomal acyl-CoA oxidase (ACOX1) were induced [Michael 1999]. 
Interestingly, the majority of these genes were deregulated to a higher extent by Rosi 
than by Tro (Appendix Table 7.5 and 7.6). In addition, genes encoding enzymes 
involved in fat storage, like perilipin 2 (PLIN2), were induced. Genes involved in the 
biosynthesis of cholesterol, for example sterol-C4-methyl oxidase-like (SC4MOL), 
were downregulated consistent with Wang et al. who showed the inhibition of 
cholesterol biosynthesis by Tro in HepG2 cells [Wang 1999].  
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Tro and Rosi altered the expression of genes involved in energy production 
Apart from genes involved in lipid metabolism, PPARγ regulates genes involved in 
carbohydrate homeostasis. By activation of PPARγ TZDs increase peripheral 
glucose uptake while insulin resistance is decreased. This is mainly triggered by 
induction of the glucose transporters GLUT1 and GLUT4, which are expressed in 
adipose and muscle tissues. Yonemitsu et al. showed that Tro improves glucose 
transport in a rat muscle cell line by enhancement of the translocation of GLUT4 to 
the plasma membrane [Yonemitsu 2001]. Similar results were obtained in rat adipose 
tissue [Furuta 2002] and rat adipocytes in vitro [Shintani 2001] while gene expression 
of GLUT4 was also increased. In in vitro cultured primary human muscle cells Tro 
induced the expression of the glucose transporter GLUT1 while GLUT4 expression 
was not affected [Park 1998]. Furthermore, the GLUT4 gene was upregulated in 
subcutaneous adipose tissue of human patients during treatment with Tro [Ciaraldi 
2002]. The hepatic glucose uptake and release is accomplished by GLUT2 while 
GLUT1 and GLUT4 are not expressed in hepatocytes [Uldry 2004]. GLUT2 was 
downregulated by Rosi during the present study on day three and 14 but not by Tro. 
Tro and Rosi also upregulated genes encoding enzymes which are involved in 
glycolysis, like phosphoglycerate kinase 1 (PGK1), phosphofructokinase (PFKL) and 
enolase (ENO1) [Michael 1999]. In addition, Rosi upregulated the gene expression of 
the glycolytic enzyme glucokinase (GCK), consistent with Kim et al. who detected a 
PPRE in the GCK gene [Kim 2004]. The decrease of hepatic gluconeogenesis by 
TZDs was shown in rodents in vivo [Fujiwara 1995, Aoki 1999] and in vitro [Davies 
1999, Davies 2001] while the gene expression and/or the activity of enzymes like 
glucose-6-phosphatase (G6P) and phosphoenolpyruvate carboxykinase (PCK1) 
were found to be repressed. In the present study Rosi induced the PCK1 gene on 
day one while it was downregulated on day three and not deregulated after 14 days 
of treatment. Rosi decreased the gene expression of the catalytic subunit of G6P 
(G6PC) on day three while Tro had no effect on either gene. In contrast, Tro and 
Rosi induced the expression of the pyruvate carboxylase gene (PC) after three days 
of treatment. PC is also involved in gluconeogenesis and is hypothesised by 
Fulgencio et al. to be inhibited by TZDs [Fulgencio 1996]. The pyruvate 
dehydrogenase kinase (PDK4) gene was induced by Tro and Rosi. PDK4 inhibits the 
formation of acetyl-CoA from pyruvate, as the end product of glycolysis, and its 
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upregulation may be triggered by enhanced lipid catabolism, required to provide 
enough energy for the cell [Sugden 2001].  
Uncoupling protein 2 (UCP2) gene expression was induced by Tro after three days 
and by Rosi after one and three days of treatment. UCPs are proton channels which 
are able to uncouple the oxidative phosphorylation in the mitochondria by proton 
influx, independent from the ATPase. This energy consumptive process is normally 
used to generate heat in the adipose tissue and can lead to ATP depletion and cell 
death by the uncontrolled decrease of the transmembrane potential [Chavin 1999, 
Voet 2002]. The upregulation of UCP2 gene expression was also detected in rodent 
livers after in vivo treatment with Tro [Memon 2000]. Impairment of mitochondrial 
respiration appears to be a major mechanism of Tro’s hepatotoxicity. Nadanaciva et 
al. reported Tro, but not Rosi, to act as an uncoupler and inhibitor of oxidative 
phosphorylation [Nadanaciva 2007]. A further study showed that Tro induced 
mitochondrial permeability transition while Rosi did not [Masubuchi 2006a]. During 
the present study Tro and Rosi induced UCP2 to a similar extent, which was 
considered to be an indicator of drug-induced mitochondrial effects. Therefore, based 
on these gene expression changes it could not be shown whether Tro is more toxic 
than Rosi.       
Tro and Rosi induced stress markers and genes involved in drug metabolism 
Tro is a potent inducer of its own metabolism, via CYP3A4 induction [Sahi 2000], 
which was upregulated up to 39-fold by day 14. Rosi also induced CYP3A4 in a time-
dependent manner up to 31-fold. Phase-II enzymes like UDP-
glucuronosyltransferase (UGT), sulfotransferase (SULT) and glutathione-S-
transferase (GSTA) were upregulated by both substances, indicating an active 
detoxification process. Tro heavily enhanced (12.4-fold) the gene expression of 
GSTA5 on day 14, which suggests the formation of reactive metabolites as they are 
usually detoxified via conjugation with GSH (Figure 4.14). These metabolites can 
then bind to cellular components and cause oxidative stress and DNA damage. Rosi 
lacks the chroman ring which is metabolized to form Tro’s toxic metabolite. This may 
be the reason for Rosi’s lower hepatototoxic potential [Smith 2003]. Interestingly, 
genes encoding antioxidant enzymes like glutathione peroxidase (GPX1; which 
detoxifies ROS in the mitochondria [Marquardt 2004]), ferritin (FTL) [Cairo 1995, Vogt 
1995, Orino 2001] and thioredoxin interacting protein (TXNIP) [Watanabe 2010], 
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which are general markers for oxidative stress, were induced by both Tro and Rosi to 
a similar extent. The strong induction of genes related to the metabolism and transfer 
of GSH, like GSTA5 and GPX1, indicate a depletion of GSH in the Tro treated cells, 
and is a well described mechanism of Tro’s hepatotoxicity [Smith 2003]. Masubuchi 
et al. showed that Tro is transformed into reactive metabolites faster than other TZDs 
and possesses a high GSH-conjugation rate in rats and humans [Masubuchi 2007]. 
Neither Tro nor Rosi induced the expression of genes related to DNA damage in the 
present study. However, oxidative stress can also be produced by extensive 
oxidation of FA’s, especially in the peroxisomes. Enzymes like ACOX1, whose gene 
expression was induced during the present study, are known to produce hydrogen 
peroxide [Corton 2000]. Consistent with this, the gene encoding catalase (CAT), 
which reduces hydrogen peroxide, was induced by Tro and Rosi, and can be 
considered to be a compensatory mechanism. 
Tro and Rosi suppressed proliferation-associated genes and induced pro-apoptotic 
factors 
PPARγ agonists were shown to inhibit proliferation and to induce apoptosis in several 
human cancer cell lines [Morosetti 2004, Freudlsperger 2006, Lin 2007]. Rosi also 
reduced tumor incidence in a mouse model for hepatocarcinogenicity [Galli 2010]. In 
mouse hepatocytes the suppression of cyclin D1, as a key mechanism for cell cycle 
arrest in the G1 phase, is mediated by PPARγ2 activation [Sharma 2004]. However, 
in several clinical studies Rosi and Tro failed to inhibit tumor growth of the breast 
[Burstein 2003, Yee 2007], prostate [Smith 2004], thyroid [Kebebew 2009] and colon 
[Kulke 2002]. During one study, Tro stabilized the disease state of prostate cancer 
patients for up to 90 weeks [Mueller 2000]. Hepatocytes are differentiated cells which 
proliferate very rarely [Marquardt 2004] and are therefore not well suited for the study 
of cell cycle arrest.  
However, after one day of high dose treatment Rosi upregulated the gene encoding 
cyclin D1 (CCND1), which is involved in the cell cycle progression from G0 to early 
G1 phase [Flatt 2000]. The cell cycle promotor cell division cycle 25 homolog A gene 
(CDC25A) was also induced on days one and three [Källström 2005]. Furthermore, 
the genes for the cell cycle inhibitors p21 (CDKN1A) and p27 (CDKN1B), which act 
during the G1 phase [Owa 2001], were downregulated on day 14. The G0/G1switch 
2 (G0S2) gene expression was induced after three and 14 days. G0S2 is reported to 
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be upregulated during the re-entry from G0 into G1 phase in blood mononuclear cells 
[Russell 1991], while recent studies showed that G0S2 acts as tumor suppressor 
triggering apoptosis after DNA damage in human primary fibroblasts [Welch 2009]. 
Further genes which were associated with liver regeneration after partial 
hepatectomy in vivo, such as angiotensinogen (AGT) and serpin peptidase inhibitor 
clade E member 2 (SERPINE2), were also induced after three and 14 days [Cimica 
2007]. In contrast, the genes encoding connective tissue growth factor (CTGF), 
syndecan 4 (SDC4) and alpha-2-macroglobulin (A2M) were downregulated in the 
present study while their induction has been correlated to liver regeneration and 
proliferation [Cimica 2007]. Genes encoding polymerase delta 4 (POLD4), which is 
involved in DNA replication [Liu 2006], and tubulin alpha 1a (TUBA1A), which 
participates in spindle formation [Hernández 2009], were also repressed. The 
annexin A5 gene (ANXA5), the induction of which has been associated with many 
carcinomas in rats and humans [Glückmann 2007, Xue 2009], was downregulated on 
day 14 as well as transforming growth factor alpha/beta (TGFA/B). The expression of 
the pro-apoptotic member of the BCL2-family BCL2-like 14 (BCL2L14) [Matés 2008] 
was induced on days 3 and 14, as was the cell death inducing DFFA-like effector A 
gene (CIDEA) [Valousková 2008], indicating the induction of apoptosis. However, 
genes encoding pro-apoptotic key factors, like BCL2-antagonist/killer 1 (BAK1) and 
BCL2-related ovarian killer (BOK) [Hail 2006], were downregulated on day 14 and no 
caspases were deregulated.  
In conclusion, these results indicate that Rosi did not enhance proliferation but 
induced apoptosis in the treated cells. Since the present study was performed in 
primary hepatocytes, which are differentiated cells remaining in the G0 phase, any 
cell cycle arrest effects caused by Rosi could not be shown directly with this in vitro 
system. Although several publications have described Rosi’s anti-proliferative action, 
the upregulation of the cyclin D1 gene on day one and the suppression of the cell 
cycle inhibitors p21 and p27 on day 14, together with the induction of genes 
associated with liver regeneration on days 3 and 14 indicate a re-entry of the 
hepatocytes into the cell cycle during the earlier time points. In contrast, the 
downregulation of genes encoding proteins and enzymes involved in later phases of 
the cell cycle, like POLD4, TUBA1A and ANXA5, indicate that after 3 and 14 days of 
treatment with Rosi cell cycle progression was inhibited. This hypothesis is supported 
by the gene expression profile of the cell cycle promotor CDC25A which was 
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upregulated at early time points but not on day 14. In addition, Rosi induced the gene 
expression of pro-apoptotic factors on day 14 while anti-apoptotic factors were not 
upregulated. 
The gene expression profile of the Tro treated cells resembled the one of the Rosi 
treated hepatocytes, although Tro affected a smaller number of genes. Genes 
encoding cyclins or cell cycle inhibitors were not deregulated. Gene expression of 
SERPINE2 and AGT, which are associated with liver regeneration, was induced by 
high dose treatment on day three while genes encoding the growth factors CTGF and 
EGR1 were downregulated. On day three the G0G2 gene, which might be involved in 
cell cycle re-entry from the G0 phase or the induction of apoptosis, was induced as 
well as the gene encoding the cell cycle promotor CDC25A while on day 14 the 
polymerase TOP2B gene was repressed. In addition, gene expression of the pro-
apoptotic factors, BCL2L14 and CIDEA, was upregulated indicating that Tro like Rosi 
did not activate cellular proliferation but apoptosis in the present study.  
Tro and Rosi deregulated genes associated with different cell functions 
Tro was shown to inhibit the bile salt export pump (BSEP) in rat hepatocytes as well 
as in human clinical trials while a decrease of bile salt excretion can lead to Tro-
induced intrahepatic cholestatic liver injury [Marion 2007, Yokoi 2010]. Tro inhibits 
rodent BSEP protein with a Ki value of 1.3µM [Funk 2001]. During the present study 
the gene expression of BSEP was not affected by Tro and Rosi, agreeing with Rogue 
et al. [Rogue 2011] while Rosi downregulated the gene encoding the transporter 
MDR1 which is also involved in biliary excretion. On day 14 both compounds induced 
the gene expression of the basal uptake transporter OATP8 while Rosi also 
upregulated the gene encoding OAT2 - a transporter involved in the efflux of 
substances from the blood [Giacomini 2010].     
Tro and Rosi induced the gene expression of PEX11A and PEX19 which are markers 
for peroxisomal biogenesis [Koch 2010]. The expression of the PPARγ gene was not 
significantly induced by Rosi or by Tro during this study. However, Davies et al. 
showed that Tro induces PPARγ on mRNA and protein levels in in vitro cultured rat 
hepatocytes, as well as in livers of in vivo treated rats [Davies 1999a, Davies 2002]. 
Rogue et al. detected a significant PPARγ induction in rat hepatocytes treated with 
40µM Tro but not in Rosi treated cells [Rogue 2011]. The rodent EC50 for PPARγ 
was calculated to be 0.076µM for Rosi and 0.78µM for Tro [Willson 2000]. Thus, the 
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compound concentrations used during the present study were high enough to have 
activated PPARγ, which was confirmed by gene expression changes correlating with 
relevant PPARγ associated effects described in the literature.  
Tro and Rosi downregulated genes involved in cell adhesion and morphology, for 
example E-cadherin (CDH1), fibronectin (FN1) and tubulin (TUBA1A) indicating that 
the cells started to detach due to cytotoxicity [Chen 2006, Malcos 2011]. 
Furthermore, genes encoding proteins which are synthesized and secreted by 
hepatocytes, such as the coagulation factors F5, F9, and F11, the complement 
components C6, CFH, and CFI, the chemokines CXCL9, CXCL11, and CXCL16 as 
well as the acute phase proteins alpha-2-macroglobulin (A2M) and fibrinogen (FGB), 
were all downregulated. Except for the coagulation factors these proteins are 
involved in hepatic inflammatory processes and are regulated by the intercellular 
signaling between hepatocytes and immune cells [Trautwein 1994, Dhainaut 2001]. 
Since this cell type was missing in the present system and the gene expression of 
other hepatic proteins like coagulation factors were also suppressed, these 
deregulations appear to be associated with drug-mediated toxic effects impairing 
cellular protein production. 
 
In conclusion the pharmacological effects of Tro and Rosi could be only partly 
reconstructed by the whole-genome gene expression analysis in primary hepatocytes 
reported here. This was expected since the targets of TZDs are adipose and muscle 
tissue which highly express PPARγ [Grossman 1997]. Nevertheless, the upregulation 
of lipid metabolism associated genes and the downregulation of genes involved in 
hepatic gluconeogenesis could be shown, confirming what is known from the 
literature. The gene expression data presented here were consistent with a similar 
study performed by Rogue et al. [Rogue 2011] as well as with results of an in vivo 
study in mice [Memon 2000, Watkins 2002]. TZDs were shown also to have anti-
proliferative effects [Freudlsperger 2006, Galli 2010]. Although hepatocytes, as 
differentiated cells, are not well suited for the study of cell cycle arrest our data 
indicated that genes related to cell cycle promotion were suppressed by Tro and Rosi 
while apoptotic factors were induced. However, the focus of the present study was 
the investigation of genes involved in any toxic effects. Both compounds are known 
to induce CYP3A4 which can transform Tro into reactive metabolites [Sahi 2000]. 
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The CYP induction, as well as the upregulation of genes related to oxidative stress 
and uncoupling of the oxidative phosphorylation, could be clearly shown. 
Interestingly, Rosi deregulated a higher number of genes and triggered higher fold 
changes for genes involved in lipid and energy metabolism than Tro although the 
used concentration for cellular treatment was only slightly higher. In vivo Rosi 
possess a higher efficacy than Tro since the recommended daily doses for humans 
are 4 - 8mg for Rosi and 200 - 600mg for Tro [RX-Rosi 2011, RX-Tro 2011]. 
However, Tro was shown to be more cytotoxic than Rosi at equimolar doses in vitro 
[Lloyd 2002, Guo 2006, Rachek 2009, Rogue 2011] which was confirmed during the 
dose finding part of the present study. Furthermore, Tro induced the CYP3A4 gene 
and several genes encoding enzymes of the xenobiotic metabolism to a higher extent 
than Rosi but not marker genes of oxidative stress. This was not expected, since 
Rosi was assumed to be less hepatotoxic than Tro, based on the different molecular 
structures that can prevent the formation of reactive metabolites [Smith 2003, 
Kirchheiner 2005]. Nevertheless, Masubuchi et al. showed that Rosi can be 
conjugated to GSH. They concluded that Rosi is also transformed into reactive 
metabolites but to a lesser extent and at a much slower rate than Tro [Masubuchi 
2007]. Tro and Rosi were also part of a set of reference compounds used for the 
development of an in vitro prediction model for hepatotoxicity based on gene 
expression changes in sandwich cultured primary rat hepatocytes [Hrach 2011]. In 
their study one of three biological replicates of Tro was misclassified as non-
hepatotoxic while Rosi was rightly predicted to be non-hepatotoxic. The doses used 
for cellular treatment with Tro and Rosi were similar to these used in the present 
study. Based on the present gene expression data Rosi would have been classified 
as a weak hepatotoxic compound, since it upregulated marker genes for oxidative 
stress while there were no indications for mitochondrial impairment and DNA 
damage. Tro would have been classified as non- or weakly hepatotoxic due to minor 
expression changes of genes associated with oxidative stress and energy 
production.  
The doses used for cellular treatment during the present study were in vivo relevant 
for Tro (LD = 7µM, HD = 70µM) but not for Rosi (LD = 8µM, HD = 80µM). Tro caused 
hepatomegaly during a 104 - week study where male rats were orally dosed with 
400mg/kg/day or 800mg/kg/day, while the highest dose also caused liver necrosis. 
Interestingly, female rats seemed to absorb Tro more effective than males since they 
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possessed higher plasma levels and therefore showed greater adverse hepatic 
effects already after oral dosage of 200mg/kg. The cmax of male rats after the 
administrations of 400mg/kg amounted to 36.4 ± 24.9µM and was comparable to the 
cmax of rats which received 800mg/kg of Tro. The cmax of female rats after the 
administrations of 200mg/kg amounted to 166.8 ± 42.6µM [FDA-Tro 1997]. Female 
rats which received 400mg/kg/day of Rosi had a cmax of 350.3 ± 8.2µM and 
developed hepatomegaly during a four-week study [FDA-Rosi 1999]. Concentrations 
in the range of the rodent cmax of Rosi could not be used for the treatment of 
hepatocytes in the present in vitro system since a dose more than four times the 
present high dose was very cytotoxic. The human cmax, after taking recommended 
doses was 1.6 ± 0.9µM for Rosi [Cox 2000] and 2 - 4µM for Tro [Funk 2001]. Short 
term studies in primary human hepatocytes detected no or only slight cytotoxicity for 
Rosi with concentrations up to 200µM [Lloyd 2002, Rogue 2011a]. Thus, human 
hepatocytes can be treated with doses more than 100 times the safe human plasma 
concentration of Rosi, which is a good basis for the investigation of dose-dependent 
human cytotoxicity. Tro was found to be more cytotoxic in human than in rat 
hepatocytes [Lauer 2009, Rogue 2011 and 2011a]. Cellular treatment can be 
performed with doses which are several times the human safe plasma concentration, 
therefore enabling human in vitro investigations similar to Rosi. However, these tests 
can detect dose-related predictable toxicities while the idiosyncratic part of Tro’s and 
Rosi’s hepatotoxicity will remain unpredictable with our present system. Studies with 
primary human hepatocytes of different donors are suited better for the investigation 
of idiosyncratic effects since donors may express varying isoforms of drug-
metabolizing enzymes possessing different activities. Furthermore, individual 
hypersensitivities and immunological parameters may be studied if co-cultures with 
Kupffer cells are implemented.     
 
4.4.1.5 EMD 335823 
EMD 335823 (EMD) was a drug candidate developed by 
Merck KGaA for the treatment of diabetic complications. 
During phases of high intracellular glucose levels, for 
example due to diabetes mellitus, glucose is transformed via 
two steps into fructose (polyol pathway) in addition to normal 
glycolysis. The first and rate limiting reaction is the formation of sorbitol catalyzed by 
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aldose reductase (AR) [Lorenzi 2007], the target molecule of EMD 335823 [internal 
data]. Sorbitol is a very hydrophilic alcohol which cannot diffuse through cell 
membranes and therefore accumulates in the cell. The resulting osmotic changes are 
discussed to trigger common diabetic complications like retino-, nephro- and 
neuropathy. Another hypothesis assumes that these effects are caused by oxidative 
stress. Firstly, AR consumes NADPH which is also a co-factor for GSH-reductases. 
Reduced GSH is essential for the cellular defense against reactive metabolites. 
Secondly, the enzyme transforming sorbitol into fructose produces NADH. An altered 
NAD+/NADH ratio affects several cell functions and increased levels of NADH may 
activate NADH oxidases which can cause oxidative stress [Lorenzi 2007, Cunha 
2008, Matsumoto 2008].  
During a preclinical two-week oral study EMD caused strong elevations of serum 
levels of liver enzymes in rats, indicating marked liver damage. Histopathological 
findings included bile duct necrosis and inflammation as well as liver cell necrosis 
after low (25mg/kg) and high dose (500mg/kg) treatment. Furthermore, EMD induced 
several PPARα target molecules, like members of fatty acid β-oxidation, and was 
therefore assumed to be a potential PPARα activator. It also induced enzymes 
involved in the detoxification of reactive metabolites, oxidative stress and damaged 
proteins, such as glutathione-S-transferase (GSTA2), UDP-glucuronosyltransferase 
(UGT1A6) and FK506 binding protein (FKBP11). EMD inhibited its pharmacological 
target AR. AR is furthermore involved in the transformation of toxic lipid metabolites 
like 4-hydroxy-trans-2-nonenal (HNE) into 1,4-dihydroxynonene (DHN). GSH-
conjugates of HNE and DHN were found in liver, blood and urine of treated rats 
[internal data] indicating that EMD reduced the formation of DHN by inhibition of AR, 
which was shown also by Srivastava et al. for other AR inhibitors [Srivastava 2001]. 
The development of EMD was stopped prior to any clinical studies, since the 
preclinical findings showed a high risk of the formation of drug induced liver injuries in 
humans. In the context of the PredTox project, funded by the European Commission 
as part of the Sixth Framework Programme (FP6), EMD was re-tested in rats which 
developed similar adverse hepatic effects at high dose (350mg/kg) but not at low 
dose (15mg/kg) treatment [Adler 2010].       
 
 
121 Results and discussion 
 
EMD markedly altered gene expression of treated cells 
EMD markedly changed the gene expression level in the high dose treated cells 
during this study. This was shown in the PCA (Figure 4.16) where the high dose 
samples of all time points clustered separately, as well as by the large number of 
statistically significant deregulated genes (Table 4.6) which increased with the time of 
treatment. The low dose samples clustered very close to the time-matched controls 
illustrating that their gene expression levels were not markedly altered compared to 
the control samples. The PCA also showed the time-related difference between the 
gene expression level of the low and the high dose treated cells since the low and 
high dose of the first time point cluster closer together than the low and high dose 
samples of day three and 14. High dose treatment with EMD dose-dependently 
deregulated between 37 and 1063 genes (Table 4.6). The genes discussed in the 
following biological interpretation are listed in the appendix (Appendix Table 7.7) and 
are visualized by a heatmap (Figure 4.9). 
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Figure 4.16: PCA of EMD samples. 
The low dose treated samples of all three time points cluster very close to the time matched controls 
indicating a slight difference of the gene expression level of these sample groups. The high dose 
treated samples cluster completely separately as a consequence of a markedly altered gene 
expression profile compared to the control.   
 
EMD induced genes involved in lipid metabolism   
In agreement to the preclinical findings, EMD induced many genes involved in lipid 
metabolism, including direct PPARα target genes [Mandard 2004]. The genes 
encoding the very low density lipoprotein receptor (VLDLR) and the transporter 
CD36, which are involved in the uptake of lipids from the blood, as well as the 
PPARα target gene encoding lipoprotein lipase (LPL) which cleaves lipids into 
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glycerol and FA, were upregulated. In addition, the expression of genes involved in 
FA metabolism, including acyl-CoA thioesterase (Acot1), were enhanced up to 90-
fold. Expressions of the PPARα target genes CYP4A11 and FA binding protein 
(FABP1) were induced, and are involved in catabolism and intracellular transport of 
FA. Genes involved in the import of FA into the mitochondria, like carnitine O-
octanoyltransferase (CROT), carnitine O-acetyltransferase (CRAT) and carnitine 
palmitoyltransferase (CPT1B), were also induced as well as several genes involved 
in mitochondrial and peroxisomal FA catabolism. Interestingly, the strongest 
upregulations were observed on day three (Appendix Table 7.7), which correlates 
well with the gene expression study performed in livers of rats treated with EMD 
[Ellinger-Ziegelbauer 2011]. Cholesterol synthesis seemed to be downregulated 
since genes encoding lecithin-cholesterol acyltransferase (LCAT) and ATP citrate 
lyase (ACLY) were repressed while genes involved in fat storage, such as fat 
storage-inducing transmembrane protein (FITM2) and perilipin (PLIN2), were 
induced. Genes associated with peroxisome proliferation, a typical effect of PPARα 
agonists in rodents [Li 2002a], were upregulated up to 5.1-fold. These included 
genes involved in peroxisomal FA catabolism, for example acyl-CoA thioesterase 
(ACOT8) and the PPARα target gene acyl-CoA oxidase (ACOX1), as well as genes 
related to peroxisomal biogenesis and division (e.g., peroxisomal biogenesis factors 
11 alpha and 19 (PEX11A, PEX19)). The expression changes of genes involved in 
lipid metabolism caused by EMD is consistent with gene expression results of 
hepatocytes and livers of rats treated with known PPARα agonists [Guo 2006, 
Tamura 2006] as well as with the gene expression profile of the FF treated cells 
reported in this study. Thus, these findings support the hypothesis of EMD being a 
potential PPARα agonist. However, the PPARα gene itself was not upregulated by 
EMD during the present study, but this is in agreement with previously published 
reports for FF and other PPARα agonists [Guo 2006, Tamura 2006, Ellinger-
Ziegelbauer 2011, Sposny 2011].   
EMD increased the expression of drug-metabolizing enzymes and stress markers 
EMD upregulated genes encoding several phase-I enzymes, including alcohol 
dehydrogenase (ADH1C), aldehyde oxidase (AOX1) and epoxide hydrolase (EPHX) 
while CYP3A4 induction increased time-dependently up to 26.3-fold. EMD also 
upregulated the expression of genes encoding the phase-II enzymes glutathione-S-
transferases (GSTA) and UDP-glucuronosyltransferases (UGT) at all time points, 
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indicating an enhanced activation of detoxification processes within these cells. Here 
the strongest inductions were observed for GSTA5, which conjugates reactive 
metabolites with GSH and was upregulated time-dependently up to 20.9-fold. EMD 
induced further genes encoding enzymes which are involved in GSH metabolism: 
GSH reductase (GSR) regenerates oxidized GSH, GSH peroxidase (GPX2) reduces 
and detoxifies peroxides while GSH is oxidized and glutamate-cysteine ligase 
(GCLC) catalyzes the first step of GSH synthesis. The enhanced gene expression of 
enzymes involved in the synthesis, regeneration and conjugation of GSH suggests 
the formation of reactive metabolites and ROS in the EMD treated cells followed by a 
possible GSH depletion [Yuan 2009]. This hypothesis is strengthened by the 
upregulation of genes encoding stress markers, like oxidative stress induced growth 
inhibitor (OSGIN1) and FK506 binding protein (FKBP8) as well as antioxidant 
enzymes like superoxide dismutase (SOD2), heme oxygenase (HMOX1), catalase 
(CAT), thioredoxin interacting protein (TXNIP) and NAD(P)H quinone dehydrogenase 
(NQO1). These changes clearly show that EMD induced oxidative stress and 
activated the NRF2 related stress defense [Kaspar 2009]. The results also support 
the effects found in preclinical studies and are consistent with a gene expression 
study in livers of rats treated with EMD [Ellinger-Ziegelbauer 2011, Sposny 2011].  
EMD deregulated genes involved in energy production  
EMD downregulated different genes involved in glycolysis, such as glucokinase 
(GCK), pyruvate kinase (PKLR) and lactate dehydrogenase B (LDHB), as well as 
gluconeogenesis like glucose-6-phosphate isomerase (GPI), glucose-6-phosphatase 
(G6PC) and glucose-6-phosphat translocase (SLC37A4). Furthermore, the glycogen 
synthase gene (GYS2) and the gene encoding the glucagon receptor (GCGR) were 
downregulated. GYS2 is involved in the storage of glucose by synthesizing glycogen 
while GCGR triggers the cellular signaling for the utilization of stored glycogen [Voet 
2002]. In addition, the gene expression of pyruvate dehydrogenase (PDHB) and 
malate dehydrogenase 2 (MDH2), which are involved in the Krebs cycle, were 
repressed and the gene encoding pyruvate dehydrogenase kinase (PDK4), an 
inhibitor of PDHB, was induced. The downregulation of genes related to glycolysis, 
gluconeogensis, the Krebs cycle as well as the catabolism and the synthesis of 
glycogen indicated toxic effects leading to an impairment of cellular energy 
production, as well as effects on mitochondrial function. This is strengthened by the 
upregulation of the gene encoding malic enzyme (ME1) which transforms malate, an 
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intermediate of the Krebs cycle, into pyruvate [Heart 2009], as well as the increased 
gene expression of lactate dehydrogenase A (LDHA) which is involved in anaerobic 
glycolysis. In addition, gene expression of uncoupling protein (UCP2) was increased. 
UCP2 plays a role in the generation of ROS, sustains the ratio of adenosine 
triphosphate/adenosine diphosphate and is able to uncouple oxidative 
phosphorylation leading to an uncontrolled decrease of the mitochondrial 
transmembrane potential. This can cause ATP depletion and eventually cell death 
[Chavin 1999]. UCP2 was also induced in studies performed with primary 
hepatocytes treated with other PPARα agonists [Mandard 2004] but also in 
hepatocytes treated with the PPARγ agonist Tro which is known to cause 
mitochondrial damage [Memon 2000]. The upregulation of the glycerol-3-phosphate 
dehydrogenase gene (GPD1) on day 14 seemed to be an attempt by the cells to 
maintain mitochondrial function, since GPD1 mediates the entrance of electrons into 
the electron transport chain, thus building up the mitochondrial transmembrane 
potential.  
 
Genes related to protein production and cellular adhesion were downregulated  
EMD time-dependently downregulated genes involved in cellular adhesion, like 
laminin (LAMC2), cadherin (CDH1), vitronectin (VTN), as well as cell morphology 
such as vimentin (VIM), tubulin (TUBA1A) and filamin (FLNA) [Chen 2006, Malcos 
2011, Vuoriluoto 2011]. The suppression of these genes indicates that the cells may 
have started to detach. Detaching of hepatocytes was associated with 
dedifferentiation and the loss of hepatic function, since primary hepatocytes in 
suspension retain their functional activity only for a few hours [Jouin 2006, Hewitt 
2007]. Consistent with this, genes encoding proteins which are synthesized and 
released by hepatocytes like the coagulation factors F5, F11, and F12, the 
complement components C2, C5, C6, CFB and CFH, as well as the acute phase 
proteins alpha-2-macroglobulin (A2M) and alpha-2-HS-glycoprotein (AHSG) were 
downregulated. The excretion of complement factors and acute phase proteins, as 
part of the inflammatory response, is triggered by activated immune cells by the 
release of mediators which bind to receptors on the hepatocyte membrane [Tacke 
2009]. Since these cell types are not present in a hepatocyte monoculture the 
deregulation of the appropriate genes can be assumed to be a toxic effect due to a 
diminished cellular protein production within the hepatocytes. In addition, the gene 
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expression of CYP7A1, which is involved in the synthesis of bile acids, as one of the 
hepatic key functions was downregulated as well as Na-K-ATPase (ATP1A1) which 
plays a central role in maintaining the cellular transmembrane potential. 
 
EMD-treatment affected the gene expression of different transporters 
The gene encoding the basolateral transporter SLCO2B1 (OATP-B) which imports 
substrates from the blood into the hepatocyte was time-dependently downregulated. 
Furthermore, the biliary efflux transporter encoded by the gene ABCG2 (BCRP) was 
induced on day three while the Abcb1b gene (MDR1) was time-dependently 
downregulated. The gene expression of basal transporters was also affected 
contrarily since MRP3 was upregulated on days one and three while MRP6 was 
downregulated on day 14. In summary, genes encoding efflux and influx transporters 
were deregulated without any obvious trend. While the apical cholesterol transporter 
encoded by the gene ABCG5 was upregulated up to 6.2-fold. An increased excretion 
of cholesterol into the bile has been reported to be associated with FF-mediated 
hepatitis [RX-FF 2011] and may also account for biliary adverse effects of EMD. 
However, whether EMD increases the biliary cholesterol efflux from treated 
hepatocytes has to be validated using other functional tests.  
MRP3 inter alia transports conjugated bilirubin, the product of hemoglobin 
breakdown, back into the blood when the biliary excretion via MRP2 is disturbed. 
Thus, an increased expression of MRP3 can cause hyperbilirubinemia [Kamisako 
2000]. Although MRP2 gene expression was not affected, the deregulation of the 
MRP3 gene may be a hint that there was an adverse effect of the bile ducts during 
preclinical studies. It has been shown that sandwich cultured primary hepatocytes 
form functional bile canaliculi-like structures [Tuschl 2006, Tuschl 2009]. However, 
these structures lack endothelial cells which coat the bile ducts in vivo and are 
involved in biliary adverse effects [Marquardt 2004]. During preclinical studies rats 
treated with EMD developed bile duct necrosis and inflammation. Effects like these 
can not be studied using monocultures of primary hepatocytes since this system 
lacks the affected endothelial cells. Furthermore, inflammation is usually triggered by 
the release of inflammatory mediators like cytokines by the Kupffer cells which can 
activate apoptosis in hepatocytes and recruit peripheral immune cells into the liver 
[Tacke 2009]. Thus, the deregulation of transporters in compound-treated 
hepatocytes can give only hints for biliary effects.      
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EMD induced the gene expression of its pharmacological target molecule 
EMD upregulated the gene expression of its target molecule AR (AKR7A3) at all 
three time points, with the greatest induction seen on day 3 (13.5-fold). These results 
correlate well with the in vivo EMD rat data, where this molecule was induced on the 
gene and protein levels [Sposny 2011]. The induction of the gene could be a direct 
consequence of the inhibition of the AR enzyme as EMD’s pharmacological effect. 
The blockade of the polyol pathway, as the alternative for glycolysis, should 
consequently lead to an increased rate of this catabolic pathway. However, genes 
involved in glycolysis were downregulated while the polyol pathway is only activated 
at high glucose levels and therefore difficult to study at physiological glucose 
concentrations [Lorenzi 2007]. 
EMD downregulated genes involved in apoptosis and proliferation 
On day 14 EMD downregulated genes encoding pro-apoptotic key factors like BCL2-
antagonist/killer 1 (BAK1) and BCL2-related ovarian killer (BOK), which can be 
activated by cellular stress [Hail 2006]. On day three gene expression of the pro-
apoptotic member of the BCL2-family, BCL2-like 14 (BCL2L14) [Matés 2008] and the 
cell death-inducing DFFA-like effector gene (CIDEA) [Valousková 2008], were 
induced. 
Gene expression of cyclin D1 (CCND1), which promotes cell cycle progression in 
early G1 phase, and cyclin-dependent kinase inhibitor 1B (p27, Kip1) which plays a 
role in cell cycle progression from G1 to S phase [Ogawa 2009], were downregulated 
on day 14, consistent with the findings in vivo [Ellinger-Ziegelbauer 2011]. Further 
indications that EMD did not induce cell proliferation were the upregulation of genes 
geminin (GMNN), which inhibits centrosome dublication [Lu 2009], and growth arrest 
and DNA-damage-inducible alpha (GADD45A), which triggers cell cycle arrest due to 
DNA damage. Genes encoding growth factors involved in cellular proliferation and 
growth, like transforming growth factor alpha (TGFA), connective tissue growth factor 
(CTGF) and early growth response 1 (EGR1), were repressed on day 14 while the 
cell cycle promotor cell division cycle 25 homolog A gene (CDC25A) was induced on 
day one and three [Källström 2005, Cimica 2007]. The downregulation of genes 
involved in proliferation and cell cycle progression indicate that EMD did not enhance 
cellular proliferation during this study. Pro-apoptotic genes were downregulated on 
day 14 but upregulated on day three in correlation with the induction of the 
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GADD45A gene which is involved in cell cycle arrest after DNA damage. However, 
no other genes associated with DNA damage were upregulated.   
 
In conclusion, the gene expression profile of EMD treated hepatocytes was similar to 
the profile of FF as well as literature data of hepatocytes treated with other known 
PPARα agonists [Cornwell 2004, Guo 2006, Tamura 2006]. The induction of genes 
involved in lipid metabolism and peroxisomal biogenesis, as well as the upregulation 
of known PPARα targets, could be shown. However, PPARα agonists usually act as 
non-genotoxic hepatocarcinogens in rodents while the formation of oxidative stress 
and the disturbance of the balance between proliferation and apoptosis are 
discussed as molecular mechanisms [Corton 2000]. EMD induced the gene 
expression of different antioxidant proteins and enzymes involved in the 
detoxification of reactive metabolites indicating the formation of these as well as of 
oxidative stress. Except for the induction of the GADD45A gene there was no 
indication for DNA damage. EMD did not induce genes involved in proliferation and 
did not markedly suppress apoptosis during the present study. As already discussed 
in chapter 4.4.1.3 the induction of proliferation associated genes could be shown in 
livers of rats treated in vivo with PPARα agonist while these genes were unaffected in 
PPARα agonist treated hepatocytes in vitro [Tamura 2006]. Parzefall et al. showed 
that DNA replication in PPARα agonist treated hepatocytes was increased when 
Kupffer cells were co-cultured or by co-treatment of hepatocyte monocultures with 
Kupffer cell derived TNFα [Parzefall 2001]. Therefore, these effects triggered by 
intercellular signaling of different hepatic cell types are not detectable using 
hepatocyte monocultures. Primary hepatocytes are well suited for the investigation of 
effects which are restricted to mechanisms and pathways taking place solely in the 
hepatocyte itself.  
The gene expression results also showed the activation of the pharmacological target 
while further pharmacological effects are difficult to explain with the present system 
since activation of the polyol pathway and the resulting changes in glycolysis only 
appear at high intracellular glucose levels [Lorenzi 2007]. Due to the dergulation of 
genes encoding basolateral and apical transporters the hepatic elimination of 
substrates seemed to be slightly shifted towards basolateral excretion which could be 
a hint for a disturbed biliary transport, as was also seen in vivo. EMD induced several 
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genes encoding phase-I and -II enzymes which indicates an active drug metabolism 
but not per se a toxic effect. However, in agreement to the preclinical findings EMD 
caused oxidative stress and possibly depleted GSH since genes related to these 
pathways were heavily upregulated. Furthermore, energy production and 
mitochondrial function appeared to be disturbed since anabolic and catabolic 
pathways of glucose and glycogen were downregulated. Other indications for EMD-
mediated toxic effects were the suppression of genes involved in cellular adhesion 
and morphology as well as the production of different classes of hepatic proteins. 
Therefore, EMD would have been classified as potentially hepatotoxic based on the 
present data.  
During the present study cells were treated with 750µM EMD as the high dose while 
rats which orally received a hepatotoxic dose of EMD (350mg/kg) had a cmax of 1,389 
± 287µM [internal data]. Thus, in vivo relevant doses could not be used with the 
present system since they would cause a very high cytotoxicity. The EMD derived 
results of the study presented here will be compared to gene expression data of EMD 
treated human hepatocytes in the context of Predict-IV. It was shown that humans in 
vivo as well as in in vitro cultured human primary hepatocytes lack the activation of 
rodent PPARα key targets like acyl coenzyme A oxidase, peroxisome proliferation, 
and hepatocarcinogenesis [Roglans 2002, Klauning 2003, Ammerschläger 2004]. 
Therefore, if EMD is a PPARα agonist, the gene expression profile of the human cells 
is expected to markedly differ from that of the rat hepatocytes regarding the induction 
of genes involved in lipid metabolism and peroxisomal biogenesis as well as PPARα 
target genes.    
 
4.4.1.6 Metformin  
Metformin (Met) belongs to the class of biguanides and was 
approved in the 1950s for the treatment of type 2 diabetes 
[Strack 2008]. It activates the hepatic AMP-activated protein 
kinase (AMPK) which diminishes gluconeogenesis and 
enhances hepatic glucose uptake and catabolism. Additionally, the insulin sensitivity 
is improved by decreasing intestinal glucose uptake and increasing insulin binding to 
insulin receptors [DB-Met 2011]. However, in contrast to TZDs, Met does not 
increase peripheral glucose disposal but acts predominantly in the liver [Natali 2006]. 
CH3 N
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Met is predominantly excreted renally without transformation by drug-metabolizing 
enzymes and is a very safe drug with very few side effects being reported [Strack 
2008]. Nevertheless, Met’s guanidium group gets positively charged under 
physiological conditions and binds to negatively charged cell surfaces. Thus, Met 
accumulates in mitochondria and can disturb cellular energy production. Met directly 
inhibits complex I of the mitochondrial respiratory chain and reduces ATP production. 
The resulting increase in glycolysis depicts the cell’s attempt to compensate for the 
diminished stocks of ATP. Heavily increased rates of glycolysis enhance the 
production of lactate by anaerobic glycolysis and cause lactic acidosis, Met’s rare but 
major adverse effect which could become life-threatening in rats and human [Dykens 
2008, Strack 2008, Brando 2010].  
During the present study Met was used as a negative control because of its rare side 
effects and low cytotoxicity in vitro [Lauer 2009]. The PCA (Figure 4.17) of the Met 
treated cells showed that the high dose samples clustered separately indicating a 
marked change in gene expression related to the control. The low dose samples 
clustered together with the time matched vehicle controls and showed only slight 
changes on days three and 14. These findings correlated with the number of 
statistically significant deregulated genes. Low dose treatment with Met altered only 
one gene on day 14 while high dose Met changed the gene expression level of more 
than 3000 genes on days one and three (Table 4.6). The genes discussed in the 
following are listed in the appendix (Table 7.8) and also visualized in a heatmap 
(Figure 4.9).   
Comp. 1
Comp. 2
Comp. 3
d1
d3
d14
Low dose 
High dose
control
 
Figure 4.17: PCA of the Metformin samples. 
The low dose treated samples cluster together with the time matched controls indicating a comparable 
gene expression level while high dose treatment markedly changed the gene expression level since 
the appropriate samples cluster separately.    
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Metformin downregulated genes related to lipid metabolism and energy production 
The most affected pathway by Met was lipid metabolism. Here several genes 
involved in lipid transport, such as apolipoprotein A-V (APOA5) and low density 
lipoprotein receptor (LDLR), lipid catabolism like lipase (LIPC) and monoglyceride 
lipase (MGLL), fatty acid transport and catabolism including fatty acid binding protein 
(FABP1), members of the CYP4A family and acyl-CoA thioesterase (ACOT1), fat 
storage like fat storage-inducing transmembrane protein (FITM2) and cholesterol 
synthesis like lecithin-cholesterol acyltransferase (LCAT) and sterol-C4-methyl 
oxidase-like (SC4MOL) were downregualted. Genes encoding enzymes involved in 
peroxisomal fatty acid breakdown, such as acetyl-CoA acyltransferase (ACAA1) and 
peroxisomal enoyl CoA hydratase (ECH1) as well as mitochondrial -oxidation like 
carnitine O-acetyltransferase (CRAT), long chain acyl-CoA dehydrogenase (ACADL) 
and acetyl-CoA acetyltransferase (ACAT1) were suppressed. The downregulation of 
these genes was stronger on day three than on day one of treatment. Several genes 
related to glycolysis and/or gluconeogenesis were also downregulated, except for the 
genes encoding phosphoglycerate kinase (PGK1) and phosphoenolpyruvate 
carboxykinase (PCK2) which were slightly induced on day three. In addition, the 
gene encoding glycerol-3-phosphate-dehydrogenase (GPD1), which is involved in 
the transport of electrons from cytosolic NADH to the mitochondrial respiratory chain, 
was downregulated [Michael 1999, Voet 2002]. Two genes encoding glycogen 
catabolizing enzymes were induced which could be related to the repression of 
genes involved in lipid and carbohydrate metabolism. The hepatocytes seemed to be 
no longer able to produce energy from fatty acids or glycolysis and therefore broke 
down glycogen for ATP production. This disturbance could be a hint for drug-induced 
impairment of the mitochondria where cellular energy production takes place.  
Metformin induced genes associated with stress  
Mitochondrial disturbance could be caused by the generation of ROS. During the 
present study Met induced genes encoding antioxidant enzymes like ferritin (FTL) 
[Cairo 1995, Vogt 1995, Orino 2001], thioredoxin (TXN) [Watanabe 2010] and heme 
oxygenase 1 (HMOX1) [Keyse 1990], which have been shown to be upregulated in 
response to oxidative stress. Nevertheless, the genes encoding the antioxidant 
enzymes superoxide dismutase (SOD2) and catalase (CAT) were downregulated 
which could be a consequence of the suppression of genes involved in lipid 
metabolism, since CAT detoxifies ROS produced via peroxisomal lipid oxidation 
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[Marquradt 2004]. While Met downregulated the genes of several phase-I, -II, and -III 
molecules the gene encoding the transporter MDR1, which excretes substrates into 
the bile, was induced. Additionally, the gene for UDP-glucuronosyltransferase 
(UGT1A6), which conjugates metabolites with glucuronides and the genes encoding 
the GSH-synthesizing enzymes glutamate-cystein ligase (GCLC) and 
hydroxyacylglutathione hydrolase (HAGH) were induced on day three. Since GSH 
plays a major role in the detoxification of reactive metabolites and ROS the 
upregulation of genes involved in the metabolism of GSH indicate the formation of 
oxidative stress in the cells [Yuan 2009].  
 
Metformin deregulated genes involved in apoptosis and proliferation 
Met upregulated genes induced by DNA damage, including APEX nuclease 
(APEX1), O-6-methylguanine-DNA methyltransferase (MGMT) and DNA-damage-
inducible transcript (DDIT3) on day one and to greater extent on day three [Edwards 
1998, Matés 2008]. p53 target genes, such as growth arrest DNA-damage-inducible 
(GADD45A), cyclin G1 (CCNG1) and p21 (CDKN1A) were upregulated. GADD45A 
induction is associated with the arrest of the cell cycle related to DNA damage while 
CCNG1 and p21 inhibit the cell cycle progression during the G1 phase [Smith 2000, 
Zhao 2003]. The induction of GADD45A was stronger on day one than on day three 
while p21 was upregulated only on day three. Since Met does not act as a 
genotoxicant, DNA damage could be caused by the suggested increase in ROS, 
indicated by the upregulation of genes encoding antioxidant enzmyes. In contrast, 
genes associated with proliferation and tumor formation, like lipocalin (LCN2) [Kim 
2009, Jin 2011] and annexin (ANXA5) [Glückmann 2007, Xue 2009] as well as with 
DNA replication such as proliferating cell nuclear antigen (PCNA) and polymerase 
(POLD) were induced time-dependently on day one and three [Moldovan 2007]. 
However, genes encoding the pro-apoptotic key factors [Hail 2006] BCL2-
antagonist/killer 1(BAK1), BCL2-associated X protein (BAX) and BH3 interacting 
domain death agonist (BID) were markedly upregulated while the induction of 
apoptosis was indicated by the enhanced gene expression of the effector caspases 
caspase-6 (CASP6) and -7 (CASP7) [Matés 2008]. The gene encoding caspase-2 
(CASP2), which is involved in heat shock induced apoptosis [Tu 2006], was also 
upregulated as well as caspase-4 (CASP4) which is associated with ER stress 
[Hitomi 2004]. The induction of genes associated with proliferation, the upregulation 
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of pro-apoptotic genes and of genes encoding caspases were all stronger on day 
three than on day one. Therefore, the balance between apoptosis and proliferation 
seem to be slightly shifted towards cell death by treatment with Met. 
Met downregulated genes related to different cellular functions 
In correlation to the downregulation of genes encoding several peroxisomal proteins 
Met suppressed the gene expression of PEX11A and PEX19, which are markers for 
peroxisomal biogenesis [Koch 2010]. Met also downregulated genes involved in cell 
adhesion and morphology, like laminin (LAMC2), vimentin (VIM) and E-cadherin 
(CDH1) indicating that the cells are starting to detach due to cytotoxicity [Chen 2006, 
Malcos 2011, Vuoriluoto 2011]. Furthermore, genes encoding proteins which are 
synthesized and secreted by hepatocytes like the coagulation factors F10, 11, and 
F12, the complement components C5, C6, CFH, and CFB, the chemokines CXCL9, 
CXCL11, and CXCL16, as well as the acute phase proteins fibrinogen (FGB), afamin 
(AFM), and kallikrain (KLKB1) were downregulated. Except for the coagulation 
factors, these proteins are involved in the hepatic inflammatory response and are 
regulated by the intercellular signaling between hepatocytes and immune cells 
[Trautwein 1994, Dhainaut 2001]. In these experiments the gene changes are more 
likely to be associated with cytotoxic effects which impair cellular protein production 
since immune cells were missing in this cell system and the gene expression of other 
hepatic proteins like coagulation factors was also suppressed. In addition, Met 
downregulated the gene expression of several basal and apical transporters like 
NTCP, OATP8, OCT, MDR3, and MDR6, while MDR1, which mediates biliary 
excretion, was upregulated. 
 
Taken together, high dose treatment with Met deregulated a large number of genes 
on day one and three but not on day 14. At a first glance this seemed to be 
unexpected for a compound which was used as negative control. However, the gene 
expression profile of the Met treated cells markedly differed from that of cells treated 
with known hepatotoxic substances. In contrast to FF, Tro and EMD, Met suppressed 
the expression of a large number of genes encoding enzymes which are involved in 
lipid metabolism. The downregulation of genes encoding regulatory enzymes of FA 
oxidation was also detected by Fulgencio et al. in Met treated rat primary 
hepatocytes [Fulgencio 2001]. However, this is not consistent with Met’s known 
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pharmacological action since it was shown to reduce serum level of triglycerides and 
free FA in humans and rats [Zhou 2001, Strack 2008]. The increase of FA oxidation 
seems to be triggered by the activation of Met’s molecular target AMPK [Zhou 2001] 
the hepatic enzyme activity of which, but not its protein level, was found to be 
increased in Met treated mice [Huang 2008]. AMPK gene expression was not 
deregulated by Met during the present study. Met furthermore time-dependently 
upregulated genes involved in cellular proliferation while in parallel pro-apoptotic 
genes and cell cycle arrest related genes were induced. In total the balance between 
apoptosis and proliferation seemed to be shifted towards cell death since the gene 
expression of several caspases was also enhanced. Correspondingly, the gene 
expression of pathways generating energy from glucose and lipids was decreased. In 
addition, a small number of genes related to oxidative stress and cell cycle arrest, 
caused by DNA damage, were induced. This is consistent with results of a previous 
gene expression study [Lauer 2009] as well as with the study of Dykens et al. who 
detected the formation of ROS in primary rat hepatocytes treated with equimolar 
concentrations of Met for 24 hours [Dykens 2008]. They also showed that Met 
depleted cellular GSH after treatment with 2000µM, indicating a dose-dependent 
increase in the production of ROS until the cellular defense mechanisms are 
exhausted. The deregulation of genes involved in energy production from lipids and 
glucose, as well as the induction of genes related to oxidative stress, DNA damage 
and apoptosis may indicate mitochondrial impairment due to oxidative stress. It was 
shown that Met can accumulate in the mitochondria and cause adverse effects by 
inhibition of cellular respiration. This can lead to lactic acidosis, which is a known side 
effect of Met, but also to the formation of oxidative stress and cell death [Dykens 
2008, Strack 2008]. In line with this, the media of the Met high dose treated cells 
started to change its colour from red to yellow during the first days in culture, 
suggesting a marked decrease of the pH-value. Lactic acidosis can be caused by 
increased hepatic production of lactic acid due to disturbed energy production in 
affected mitochrondria. In vivo lactic acid is released into the blood and excreted 
renally [Strack 2008]. In vitro, lactic acid is released into the media and subsequently 
decreasing the pH-value. Thus, the observed change in the medium’s colour may 
indicate the development of lactic acidoses in the Met treated cells due to 
mitochondrial impairment and oxidative stress. Met very rarely causes lactic acidosis 
in humans [Strack 2008] and also preclinical studies with rats which received a daily 
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dose of 200mg/kg and possessed a cmax of 66.5 ± 2.5µM showed no increased 
incidence of lactic acidosis after 28 days treatment [Bando 2010]. The maximum 
recommended daily dose of Met for humans is 2550mg, while the resulting human 
cmax after taking 2000mg of Met amounts to 10.8µM [Strack 2008]. Hence, the 
concentration used as the high dose (1000µM) during the present study was many 
times higher than safe plasma concentrations of humans and rodents, which may 
explain the indications of adverse effects observed. The low dose (100µM), which 
was slightly higher than the safe rodent plasma concentration, did neither 
significantly change the gene expression of the treated cells (Figure 4.17) nor change 
the colour of the cell culture medium. This confirms the predictivity of rat primary 
hepatocytes for Met’s toxic effects at in vivo relevant concentrations. Based on the 
gene expression data Met would not have been classified as hepatotoxic since the 
downregulation of several cell functions and the induction of apoptosis seemed to be 
related to general cytotoxicity. However, the gene expression changes triggered by 
treatment with high doses of per se non-hepatotoxic compounds have to be validated 
in order to investigate the robustness of the present system towards false positive 
results.    
 
4.4.1.7 Common deregulated genes  
The aim of the EU Predict-IV project is the development of a cell based in vitro 
system which enables the prediction of organ specific toxicities. Global gene 
expression analyses were performed in order to define a set of genes meeting these 
requirements. Although the data for the seven compounds described in this thesis 
are not sufficient to determine a predictive genomic model, the genes which were 
commonly deregulated by all the test compounds should be discussed. Therefore, 
the gene expression profiles of EMD, FF, Met, Rosi and Tro were compared while 
APAP and VA were not included due to the minor changes in gene expression 
observed. For this comparison the appropriate dose and time point was selected 
where the highest number of genes was deregulated (Table 4.6). Thus, the 
statistically significant (p  0.05, BH-Q  0.2) commonly deregulated genes for EMD 
high dose day 14 (EMD H14), Rosi high dose day 14 (Rosi H14), FF low dose day 
three (FF L3), Tro high dose day three (Tro H3) and Met high dose day three (Met 
H3) are disscussed (Table 4.7).  
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EMD, FF, Rosi and Tro induced genes mainly involved in lipid metabolism and 
energy production, while genes related to proliferation, inflammation and cellular 
transport were downregulated. The gene expression profile of Met clearly differed 
from that of the other compounds since Met downregulated the complete gene set 
except of the transporter SLC20A1. However, the induction of genes encoding lipid 
metabolizing genes by FF, EMD, Rosi and Tro seemed to be associated with the 
expected pharmacological mode of action of these reference compounds. The 
PPARγ agonists Tro and Rosi in vivo reduce the serum level of triglycerides and free 
FA [Kumar 1996, Lebovitz 2001] and have been shown to activate hepatic genes 
involved in lipid metabolism [Memon 2000, Watkins 2002]. 
 
Table 4.7: Overview of common deregulated genes by EMD, Rosi, FF, Met and Tro. 
The statistically significant (p  0.05, BH-Q  0.2) commonly deregulated genes by EMD high dose 
day 14 (EMD), Rosi high dose day 14 (Rosi), FF low dose day 3 (FF), Tro high dose day 3 (Tro) and 
Met high dose day 3 (Met) are listed. (+ = upregulation, - = downregulation, * = BH-Q > 0.2)   
 
Symbol Gene Name  Access. No. Function EMD FF Rosi Tro Met 
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain NM_016986.1 lipid metabolism + + + + - 
Acot1 acyl-CoA thioesterase 1 NM_031315.1 lipid metabolism + + + + - 
CRAT carnitine O-acetyltransferase NM_001004085.2 lipid metabolism + + + + - 
Cyp4a14 cytochrome P450, family 4, subfamily a, polypeptide 14 XM_575886.1 lipid metabolism + + + + - 
DECR2 2,4-dienoyl CoA reductase 2, peroxisomal NM_171996.2 lipid metabolism + + + + - 
LONP2 lon peptidase 2, peroxisomal XM_214655.3 lipid metabolism + + + + - 
NUDT7 nudix (nucleoside diphosphate linked moiety X)-type motif 7 XM_341693.2 lipid metabolism + + + + - 
SLC22A5 
solute carrier family 22 (organic 
cation/carnitine transporter), member 
5 
NM_019269.1 energy production + + + + - 
APOA5 apolipoprotein A-V NM_080576.1 lipid metabolism - - -* - - 
CXCL16 chemokine (C-X-C motif) ligand 16 XM_573130.1 inflammation - - - - - 
PRICKLE1 prickle homolog 1 (Drosophila) XM_235609.3 anti-proliferative - - - - - 
SLC20A1 solute carrier family 20 (phosphate transporter), member 1 NM_031148.1 cellular transport - - - - +* 
 
As a PPARα agonist FF acts directly on the liver and enhances expression of several 
genes involved in lipid catabolism, which has been shown in vitro and in vivo 
[Cornwell 2004, Guo 2006, Tamura 2006]. EMD was associated with several PPARα 
effects during preclinical studies [internal data] and its gene expression profile was 
very similar to that of FF in this study. The gene expression changes caused by EMD 
are comparable to a set of commonly deregulated genes by Tro, Rosi and FF. PPAR 
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agonists induce mitochondrial and peroxisomal lipid metabolism which was shown by 
the set of commonly deregulated genes, which encode mitochondrial enzymes such 
as acyl-CoA dehydrogenase (ACADM) and carnitine O-acetyltransferase (CRAT), 
peroxisomal enzymes like lon peptidase (LONP2) [Omi 2008] and 2,4-dienoyl CoA 
reductase (DECR2). The transport of FA into the mitochondria requires carnitin. In 
line with the increased expression of mitochondrial, genes encoding FA oxidizing 
enzymes, the induction of the gene encoding the solute carrier family 22 (organic 
cation/carnitine transporter) member 5 (SLC22A5) indicates an increased cellular 
uptake of carnitin [Michael 1999]. In addition, the PPAR agonists induced the gene 
encoding the peroxisomal enzyme NUDIX hydrolase 7 (NUDT7) which is involved in 
the homeostasis of coenzyme A and therefore also in lipid metabolism and energy 
production [Reilly 2008]. During the present study EMD, FF, Met, Rosi and Tro 
deregulated genes related to proliferation and cell death whereas none of them 
seemed to activate proliferation of the treated cells. PPARγ agonists were shown to 
trigger anti-proliferative effects in several human tumor cell lines [Morosetti 2004, 
Freudlsperger 2006, Lin 2007] and a mouse model for hepatocarcinogenicity [Galli 
2010]. In contrast, PPARα agonists act as non-genotoxic hepatocarcinogens in 
rodents but not in humans. However, this adverse effect of PPARα agonists can not 
be shown in hepatocyte monocultures since the proliferation of hepatocytes is 
thought to be activated by cellular signaling of Kupffer cells [Parzefall 2001]. Met is 
not associated with carcinogenicity or with anti-proliferative effects [Strack 2008, DB-
Met 2011]. EMD, FF, Met, Rosi and Tro commonly repressed the expression of the 
gene encoding Prickle homolog (PRICKLE1) which is hypothesized to act as a 
putative tumor suppressor in human hepatocellular carcinoma by inhibiting cellular 
proliferation [Chan 2006]. EMD, FF, Rosi, and Tro, but not Met, downregulated the 
gene encoding the solute carrier family 20 member 1 (SLC20A1), a basolateral 
transporter which manages the uptake of phosphate from the blood. Phosphate is 
essential for the synthesis of ATP and nucleic acids as well as for cellular signaling. 
In addition, the depletion of SLC20A1 resulted in reduced proliferation in HepG2 cells 
[Beck 2009]. A further commonly downregulated gene was chemokine (C-X-C motif) 
ligand 16 (CXCL16). The protein encoded by this gene is associated with cancer 
progression [Deng 2010] but also with liver inflammation [Heydtmann 2005]. Whether 
genes involved in proliferation and inflammation play a role in a prediction model 
based on a hepatocyte monoculture has to be further investigated since these 
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complex pathways usually incorporate additional hepatic cell types. As already 
mentioned the activation of proliferation by PPARα agonists require intercellular 
signaling of Kupffer with parenchymal cells [Parzefall 2001]. Kupffer cells and liver-
infiltrating macrophages also play a major role in the triggering of inflammation by the 
release of mediators like cytokines which activate different pathways in hepatocytes 
[Tacke 2009]. Furthermore, hepatocytes, as terminally differentiated cells, remain in 
the G0 phase and proliferate very rarely [Marquardt 2004]. Cell cultures possessing 
an inactive cell cycle are not suited for the prediction of cell cycle arresting drug 
effects, for example triggered by PPARγ agonists. The gene encoding apolipoprotein 
A-V (APOA5) was also repressed by all of the five compounds. APOA5 is produced 
in the liver and secreted into the blood where it is involved in lipid transport and the 
regulation of plasma triglyceride levels. It was shown to be a direct PPARα target 
gene and to be induced by fibrates [Vu-Dac 2003]. The downregulation of the APOA5 
gene by all of the five compounds, including PPARα agonists, indicates cytotoxicity is 
affecting hepatic protein production.  
In conclusion, the commonly deregulated genes caused by EMD, FF, Rosi and Tro 
were mainly associated with the pharmacological mode of action of these substances 
and not with any toxicicity effects. In contrast, Met downregulated the majority of 
these genes clearly indicating the induction of apoptosis. However, the 
downregulation of the APOA5 gene by all of the compounds did not correlate with 
their pharmacological mode of actions and therefore is probably related to a toxic 
effect and indicating the impairment of cellular protein production. Nevertheless, the 
present set of commonly deregulated genes is neither suited for the prediction of 
toxic effects in vivo nor for the classification of the tested drugs as hepatotoxic or 
non-hepatotoxic. On the one hand the number of commonly deregulated genes was 
too small in order to classify the tested compounds while on the other hand the 
genes correlated with the pharmaceutical but not with the toxic effects of the 
reference compounds. However, the definition of a predictive gene set was not the 
major aim of this study. It was rather the question whether the data of the present 
study, representing interim findings of the project Predic-IV, were suited to give first 
hints for the final results. The gene expression profiles of only five out of the seven 
tested compounds could be compared, since treatment with VA and APAP changed 
only a few genes. Furthermore, the remaining drugs possessed very similar 
pharmaceutical mode of actions since Tro and Rosi belong to the class of TZDs 
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which are PPARγ agonists while FF and also likely EMD are PPARα agonists. 
PPARγ and PPARα act as transcription factors for several genes involved in lipid and 
energy metabolism. The final analysis at the end of the project Predict-IV will include 
further compounds with different pharmaceutical mode of actions and diverse toxicity 
profiles. The comparison of compounds with various modes of actions and different 
hepatotoxic mechanisms should better enable the identification of genes associated 
with toxic effects, independent of the pharmaceutical actions of the tested 
compounds, as basis for the identification of predictive transcriptomic markers.
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5 Concluding remarks and future perspectives 
 
During the present study sandwich cultured primary rat hepatocytes were treated for 
14 days with a non-toxic and a toxic dose of seven hepatotoxicity reference 
compounds. After one, three and 14 days whole-genome gene expression analyses 
were performed in order to investigate whether drug-induced in vivo toxicities could 
be predicted based on the gene expression profiles of cells treated in vitro.     
 
5.1 Dose selection 
The selection of the right dose for in vitro models is one of the most important 
challenges at the beginning of a gene expression study. Treatment with very low 
concentrations of a compound may hardly change the gene expression profile of the 
treated cells or affect genes associated with pharmacological but not toxic effects. In 
contrast, the treatment of cells with very high concentrations causing marked 
cytotoxicity may affect genes mainly related to cell death. Both regimes can lead to 
false positive classifications of drug candidates. Currently, there are no guidelines 
available for the choice of the correct dosing-scheme for toxicogenomic studies. The 
“ICH Guidance on genotoxicity testing and data interpretation for pharmaceuticals 
intended for human use for genotoxicity testing” recommends doses causing not 
more than 30% reduction in growth of the used cell line in order to avoid false 
positive results of genotoxicity tests due to high cytotoxic effects [ICH-S2 2008]. 
However, several different approaches are described in the literature. Roth et al. 
used the highest rodent cmax measured during in vivo studies with the test compound 
as the high dose for comparative in vitro tests [Roth 2011]. Further toxicogenomics 
studies were performed with the TC10 or the TC20 of the appropriate compound as 
high dose while the low dose was defined as the highest dose causing no cytotoxicity 
or as one fifth of the TC20, respectively [Barros 2008, Hrach 2011]. 
The Predict-IV consortium decided to use the TC10 as the highest dose and 1/10 of it 
as the low dose. The cell viability was calculated based on the ATP content of living 
cells but there was a discrepancy between the assays’ results and the cell 
morphology as well as with historical in house data for Met, FF and, Rosi. The ATP 
test seemed to be too sensitive, maybe due to mitochondrial effects disturbing the 
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production of ATP. Thus, the ATP test should have been supported by a further 
assay measuring second, different functional endpoint. However, the integration of 
assays with different endpoints like cell membrane integrity or metabolic and 
functional activity often creates the problem that these assays possess varying 
sensitivities and the calculated TC10s differ from each other and have to be 
interpreted carefully [Limonciel 2011].  
During the study described here primary hepatocytes were treated with APAP 
(100µM, 1000µM), EMD (75µM, 750µM) Met (100µM, 1000µM), FF (100µM, 
1000µM), Rosi (8µM, 80µM), Tro (7µM, 70µM) or VA (10µM, 100µM). APAP, Tro and 
VA deregulated either no or only very few genes, which may be a consequence of 
the concentration used being too low. In addition, other gene expression studies 
described in the literature were performed with higher concentrations of these 
substances [Rogiers 1995, Suzuki 2008, Jemnitz 2008, Lauer 2009, Rogue 2011]. 
However, the high dose of APAP was set to 1000µM based on the “ICH Guidance on 
genotoxicity testing and data interpretation for pharmaceuticals intended for human 
use for genotoxicity testing” [ICH-S2 2008] which recommends 1000µM as the 
highest dose if the dosage is not limited by cytotoxicity or solubility. Consequently, 
few gene deregulations were expected for APAP which causes hepatotoxic effects in 
vivo (and in vitro) only at very high concentrations. Responsive concentrations of VA 
reported in the literature exceed the TC10 used in the present study and could 
therefore not be applied using the present study design. The doses used for APAP 
and VA were also lower than the toxic in vivo cmax concentrations reported for 
rodents, strengthening the usefulness of the used in vitro system. However, the dose 
finding study for Tro should be repeated integrating the measurement of further toxic 
endpoints since toxicogenomic investigations for Tro were described in the literature 
at doses feasible to use in the present in vitro system. In contrast, the dose selection 
for EMD and Rosi was appropriate since the high dose triggered marked gene 
expression changes which enabled the reconstruction of known pharmaceutical and 
toxic mechanisms. Nevertheless, both doses selected for treatment with FF caused 
similar effects indicating that the low dose already exhausted the responsiveness of 
the cells. Here the dose finding could also be improved by the integrated 
measurement of different cytotoxicity endpoints.  
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In general, treatment with very high doses could lead to effects related to cell death 
caused by unspecific cytotoxicity rather than by compound-specific toxicity 
mechanisms [ICH-S2 2008]. This seemed to be especially true for the Met treated 
cells, since the high dose induced genes involved in the activation of apoptosis, while 
genes related to metabolic pathways and several cellular functions were repressed.   
Except for FF, the low doses of the reference compounds had very little effect on 
gene expression in the treated cells and were therefore not included into the 
biological data interpretation. Since the low dose was defined as a non-toxic dose, 
which was not expected to markedly change the gene expression profiles of the 
treated cells, these results underline the predictive power of the present in vitro 
system and study design. 
 
5.2 The predictive power of gene expression analyses in drug 
treated primary rat hepatocytes 
During the present study treatment with multiple reference compounds affected 
several different molecular pathways. Cells treated with the PPARα-agonist FF and 
the PPARγ-agonists Rosi and Tro gave very similar gene expression profiles. These 
results are in agreement with a study comparing the cellular response of primary rat 
hepatocytes to PPARγ and PPARα/γ agonists [Rogue 2011]. Consistent with the 
fibrates’ pharmacological mode of action which was shown in rodent and human in 
vivo studies [Corton 2000, Wilson 2000] as well as by hepatic gene expression 
changes of in vivo treated rats [Cornwell 2004], FF heavily upregulated several 
genes involved in the cellular uptake and catabolism of lipids as well as mitochondrial 
and peroxisomal fatty acid oxidation. This also correlated with gene expression 
changes triggered by EMD, strengthening the hypothesis of EMD being a potential 
PPARα-agonist [internal data]. While fibrates directly act on hepatic lipid metabolism, 
related to their lipid lowering action, the antidiabetic drugs Tro and Rosi enhance 
insulin sensitivity by the activation of PPARγ which mainly triggers the increased 
uptake of glucose into muscle tissue [Grossman 1997]. However, Tro and Rosi have 
been also shown to activate the hepatic isoform PPARγ2 and to enhance several 
hepatic genes which were originally found to be PPARα-target genes in adipose 
tissue [Memon 2000, Mandard 2004, Schadinger 2005]. Therefore, the induction of 
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genes related to hepatic lipid uptake and catabolism detected during our study can 
be considered to be a pharmacological effect of Rosi and Tro. While lipid metabolism 
related genes were upregulated by FF and EMD, genes involved in glycolysis as well 
as the synthesis of cholesterol and lipids were downregulated, which may be a 
consequence of the increased lipid catabolism providing enough energy for the cells. 
Consistent with this, the pyruvate dehydrogenase kinase gene (PDK4) was 
upregulated. PDK4 blocks the entrance of glucose-derived pyruvate into the Krebs 
cycle [Sugden 2001]. In addition, EMD activated the gene encoding aldo-keto 
reductase (AKR7A3) which was assumed to be EMD’s pharmacological target. 
These findings are in line with genomic and proteomic profiling in livers of EMD-
treated rats reported recently [Sposny 2011].   
EMD, FF, Rosi and Tro induced genes encoding phase-I and -II drug metabolizing 
enzymes. This indicates an active induction of xenobiotic metabolism as a 
consequence of drug treatment and could not per se considered to be a toxic effect. 
Nevertheless, the induction of phase-I enzymes, e.g., CYPs, could trigger adverse 
effects based on drug-drug-interactions and are therefore required to be tested 
during drug development [FDA 2004, Guengerich 2008, Walsky 2008]. The four 
compounds heavily induced CYP3A4 which is responsible for the metabolism of a 
large number of drugs and effects on CYP3A4 expression often have consequences 
for drug-drug-interactions. A toxic pathway affected by all of the four reference 
compounds was the NRF2 mediated stress response. The upregulation of different 
NRF2 regulated genes indicates the formation of reactive metabolites or oxidative 
stress and this effect was strongest in the EMD treated cells. Furthermore, EMD 
heavily induced genes involved in GSH conjugation, reduction and synthesis and 
therefore seemed to deplete cellular GSH [Yuan 2009], which is consistent with 
preclinical findings [internal data]. While EMD was stopped due to hepatic adverse 
effects during animal studies, FF seldom causes hepatotoxic effects in humans but 
acts as non-genotoxic hepatocarcinogen in rodents [Corton 2000, Moutzouri 2010]. 
During the present study FF upregulated genes encoding antioxidant and GSH-
conjugating enzymes to a lesser extent than EMD and did not induce genes related 
to GSH synthesis. However, the gene expression profile of the FF treated cells 
indicated oxidative DNA damage since genes involved in DNA repair and DNA 
damage related cell cycle arrest were upregulated. This supports the hypothesis that 
FF’s hepatocarcinogenic mechanism may be based on oxidative DNA damage. 
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Cellular proliferation could not be shown since genes related to proliferation and 
cancer, as well as to the inhibition of apoptosis, were downregulated, which is in 
agreement with other published in vitro studies [Tamura 2006]. Based on the present 
data EMD would have been rightly classified as hepatotoxic while FF appears to 
have a low toxic potential. The cmax of in vivo treated rats developing hepatotoxicity 
was twice as high as the high dose used for cellular treatment with EMD and would 
have caused marked hepatotoxicity [internal data]. The high dose used for cellular 
treatment with FF was two times the rodent toxic cmax [Hanafy 2007]. Thus, FF could 
be tested at in vivo relevant doses since the low dose caused gene expression 
changes similar to the high dose.  
Both Rosi and Tro were withdrawn from the market, although only Tro was 
associated with drug-induced hepatotoxicity [Kaplowitz 2005, Beiderbeck 2009, Osei 
2009]. Tro is heavily metabolized in the liver and its reactive intermediates can trigger 
the formation of oxidative stress, GSH depletion and mitochondrial impairment 
[Rachek 2009]. In contrast, Rosi was shown to be less cytotoxic which seems to be a 
consequence of its slightly different molecular structure preventing the formation of 
reactive metabolites [Kirchheiner 2005]. Consistent with the literature, Tro showed a 
greater cytotoxicity at equimolar doses during the dose finding studies of the present 
work [Lloyd 2002, Guo 2006, Rachek 2009, Rogue 2011]. However, the difference in 
the hepatotoxic potential of both drugs could not be explained based on the gene 
expression data. Genes associated with oxidative stress and conjugation reactions of 
GSH with ROS or reactive metabolites were induced by both compounds, and Rosi 
affected a higher number of genes. Therefore, Rosi would have been classified as 
having a low toxic potential based on the present data while Tro probably would have 
been classified as a non- or low toxic compound. The concentrations used for 
treatment were in vivo relevant for Tro but not for Rosi, since the cmax in rats 
developing adverse effects was four times as high as the high dose Rosi used here 
[FDA-Rosi 1999]. Nevertheless, treatment with doses in this concentration range 
would cause marked cytotoxicity. Tro and Rosi furthermore downregulated genes 
related to cellular growth, proliferation and cell cycle progression while pro-apoptotic 
factors were induced. Rosi upregulated genes involved in glycolysis and Krebs cycle 
while genes encoding enzymes of gluconeogenesis were suppressed indicating an 
active energy production without toxic effects on the mitochondria. In contrast, Tro 
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deregulated genes involved in glycolysis, gluconeogenesis and the Krebs cycle 
lacking any clear link to drug-induced mitochondrial impairment.   
The gene expression profile of the Met treated cells clearly differed from those 
derived from EMD, FF, Rosi and Tro, which seemed to be mainly based on the 
compound’s different mode of action since the gene expression profiles of the 
PPARα and PPARγ agonists were highly characterized by their pharmacological 
effects. Met, like Rosi and Tro, is used as a glucose lowering drug for the therapy of 
type II diabetes and does not cause hepatotoxic side effects [Strack 2008]. However, 
its pharmacological mode of action is not based on the activation of PPARγ but on 
the direct enhancement of hepatic glycolysis [Natali 2006]. In contrast to the other 
four compounds, Met downregulated several genes involved in lipid and glucose 
metabolism as well as apical and basolateral transporters. Furthermore, it affected 
genes related to cell death and proliferation while the upregulation of different 
effector caspases indicated the induction of apoptosis. In addition, Met induced the 
gene expression of few antioxidant enzymes. These deregulations seemed to be 
related to Met induced lactic acidosis. Met is able to accumulate in the mitochondria 
and to inhibit cellular respiration. Subsequently, the cells increase aerobic and 
anaerobic glycolysis in order to produce ATP which leads to increased amounts of 
lactate and can cause oxidative stress and cell death. Lactate is released into the 
blood and decreases the pH [Dykens 2008, Strack 2008] while in vitro lactate is 
excreted into the cell culture medium. During our study the color of the cell culture 
medium of the Met treated cells changed from red to yellow during the first days of 
treatment, indicating a decreased pH which may have been due to the release of 
lactate. The high dose of Met used was many times higher than the cmax of rats which 
developed lactic acidosis. Thus, it seems very likely that this adverse effect also 
accurred in the treated hepatocytes. Based on the present gene expression data, 
Met would not have been classified as hepatotoxic since the downregulation of 
several cellular functions as well as the induction of apoptosis seemed to be related 
to general cytotoxicity due to cellular treatment with high doses of a compound. 
However, the robustness of the present system towards false positive results has to 
be further investigated since Rosi would have been incorrectly classified as 
hepatotoxic.  
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The genes and pathways deregulated during the present study correlated well with 
gene expression changes used for the classification of substances during similar 
studies. Roth et al. predicted the hepatotoxicity of test compounds based on 
expression changes of genes related to cellular stress, growth and proliferation after 
the treatment of primary hepatocytes for 24 hours [Roth 2011]. Hrach et al. defined a 
gene set which enabled the hepatotoxicity related classification of different 
pharmaceutical compounds and the top ranked genes were associated with energy 
and drug metabolism, as well as cellular growth, proliferation and cell adhesion. This 
set of top ranked genes included lactate dehydrogenase B (LDHB) and 
triosephosphate isomerase (TPI1) which are involved in glucose metabolism as well 
as junctional adhesion molecule (JAM3) which plays a role in the functionality of the 
canaliculi [Hrach 2011]. During the present study LDHB and JAM3 were repressed 
by EMD, FF, Rosi and Tro, but induced by Met. TPI1 was not deregulated by Met but 
induced by the other four compounds indicating once more the specificity of the 
appropriate gene expression profiles.  
The majority of hepatotoxicity prediction systems published during the last decade 
were based on gene expression studies in livers of in vivo treated animals. Since 
these data were obtained using the genomic material of the complete liver, they also 
identified changes in pathways requiring the signaling between different hepatic cell 
types, e.g., inflammation [Thomas 2001, Kier 2004, Zidek 2007]. During the present 
study EMD, FF, Met, Rosi and Tro downregulated several genes encoding proteins 
which are synthesized and released by hepatocytes which are related to 
inflammation, such as chemokines, acute phase proteins, members of the 
complement system and proteins used for the antigen presentation onto the cell 
surface. These proteins are regulated by immune cells releasing pro-inflammatory 
factors which bind to receptors of the hepatocyte membrane [Trautwein 1994, 
Dhainaut 2001, Tacke 2009, Oo 2010]. Since immune cells were not present in the 
hepatocyte monoculture, the downregulation of these genes indicated cytotoxic 
effects due to a diminishing of cellular protein production. This hypothesis was 
strengthened by the repression of genes encoding coagulation factors which are also 
produced by hepatocytes but are not associated with inflammation [Dhainaut 2001].  
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5.3 Limitations of sandwich cultured rat hepatocytes 
The whole genome gene expression analysis of drug treated primary rat hepatocytes 
enabled the reconstruction of pharmacological as well as toxic mechanisms of the 
different reference compounds. However, the predictive power of hepatocyte 
monocultures is limited to those mechanisms solely related to hepatocytes. 
Hepatocytes make up 78% of the liver’s mass and maintain the hepatic key functions 
like xenobiotic metabolism, production of diverse proteins and bile, as well as 
glucose homeostasis [Schmidt 2005]. However, the various functions of hepatocytes 
are regulated by intercellular signaling with other hepatic cell types. Kupffer cells, the 
resident hepatic macrophages, secrete inflammatory factors like cytokines which can 
induce extrinsic apoptosis or proliferation of the hepatocytes [Tacke 2009]. In 
addition, Parzefall et al. showed that PPARα-agonists fail to induce cellular 
proliferation in hepatocyte monocultures since Kupffer cells stimulate this mechanism 
by the release of TNFα [Parzefall 2001]. Hepatocyte proliferation can also be caused 
by an impaired activity of pit cells which are resident hepatic lymphocytes killing 
tumor cells [Kmieć 2001]. Monocultures of hepatocytes lack other hepatic cell types 
and are therefore not predictive for mechanisms requiring intercellular 
communication like inflammation or Kupffer cell-mediated proliferation. Inflammatory 
processes can be triggered by hepatocytes presenting adducts of, e.g., proteins and 
drug metabolites on their surface. These adducts activate lymphocytes which trigger 
an immune response as well as the lysis of the antigen presenting cells [Kmieć 
2001]. Effects like these are associated with idiosyncratic hepatotoxicity which can be 
only investigated using co-cultures of hepatocytes with immune cells [Kaplowitz 
2005]. The immune response includes the activation of hepatocytes to release acute 
phase proteins, chemokines or complement factors [Dhainaut 2001]. Since the 
present system lacked immune cells, the deregulation of genes encoding these 
protein classes seemed to be related to drug-mediated cytotoxicity.    
Hepatotoxicity is not only restricted to hepatocytes but also affects other hepatic cell 
types like, e.g., endothelial cells of the bile ducts. Hence, cell death or inflammation 
of the biliary system can not be detected with the present cell model system since it 
lacks these cell types. However, the deregulation of genes encoding hepatic 
transporters can give hints for in vivo effects. FF mediated cholestasis was 
associated with an increased excretion of cholesterol into the bile [RX-FF 2011]. The 
upregulation of genes encoding the apical transporters BCRP and ABCG5 by FF and 
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EMD, respectively, indicate a potentially increased biliary excretion which may be 
correlated to in vivo toxicities in the bile ducts. Another hepatic cell type involved in 
adverse effects are the stellate cells, which play a major role in the development of 
liver cirrhosis and fibrosis by the over-production of collagen [Blouin 1977, Friedmann 
1997]. Stellate cells are also involved in hepatocyte proliferation, caused by the 
release of growth factors like transforming growth factor alpha and beta [Kmieć 
2001]. 
 
5.4 Impact on drug development and future perspectives  
The present study describes a gene expression study using primary rat hepatocytes 
treated for 14 days with different hepatotoxic reference compounds. Based on the 
present gene expression data, pharmacological and toxic effects of the test 
compounds could be reconstructed and correlated to in vivo effects. However, in vivo 
relevant concentrations could not be used for all of the reference compounds since 
the concentration used for treatment was limited by cytotoxicity. The present study 
represents an advancement in the field of in vitro prediction systems since the data 
include three different time points based on the long-term, repeat-dose treatment of 
primary hepatocytes. Related studies published so far compared histopathological 
findings with the hepatic gene expression profile of in vivo treated rats or with gene 
expression changes of hepatocytes after short-time treatment in vitro [Thomas 2001, 
Kier 2004, Zidek 2007, Roth 2011]. In contrast to these studies investigating acute 
drug effects, the aim of the work in hand was the study of long-term drug-mediated 
toxic effects based on the repeated treatment of hepatocytes in vitro. Therefore, time-
dependend changes in gene expression of the treated cells were detected 
specifically for every test compound while the changes on day one often suggested 
the findings of the later time points but with lower statistical significance. This was 
consistent with a recently reported pilot study demonstrating the possibility to classify 
drugs related to their hepatotoxicity based on in vitro derived gene expression data. 
In their study the lowest misclassification rate was achieved by the usage of data 
from later time points [Hrach 2011].     
The present work is part of the EU-funded project Predict-IV whose aim is the 
development of an in vitro model for the prediction of human in vivo toxic effects by 
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the combination of genomic, proteomic and metabolomic markers. Therefore, the 
genomic data derived from the seven reference compounds of the present study will 
be compared with the gene expression data of another four reference substances. 
These compounds expand the range of hepatotoxic mechanisms and 
pharmacological mode of actions since they belong to different chemical classes and 
cause different toxic effects in vivo, for example, steatosis and cholestasis. By 
defining marker genes and pathways of high relevance for the prediction of in vivo 
toxicities, this project provided a sound basis for the analysis of the additional 
compounds. During the next steps of data analysis, the whole genome gene 
expression data of all eleven test compounds has to be condensed to a small set of 
genes enabling the prediction of the test compounds’ hepatotoxic potential. The 
resulting gene set then has to be validated using another method for gene 
expression analysis. Nowadays specific gene sets can be analyzed relatively quickly 
with methods such as multiplexed branched DNA assays or quantitative polymerase 
chain reaction (qPCR). The further phases of data analysis will be based on the 
integration of proteomic and metabolomic results in order to define the most relevant 
biomarkers for the prediction of in vivo toxicities from in vitro data. In addition, the 
data obtained from rat primary hepatocytes will be compared with gene expression 
data obtained from the human hepatoma cell line HepaRG as well as primary human 
primary hepatocytes treated with the same eleven reference compounds. The focus 
during this comparison will be the investigation of species-specific differences of 
pharmaceutical and toxic effects since, for example, PPARα-agonists like FF act as 
non-genotoxic hepatocarcinogens in rodents but not in humans [Willson 2000].  
Predict-IV’s aim is the establishment of a non-animal based prediction model. 
However, rat hepatocytes have to be freshly isolated for every experiment so animals 
are still needed. Nevertheless, the results of the Predict-IV project will give new 
insights into the predictive power of rat hepatocytes related to human toxicities. 
Potentially new genomic, proteomic and/or metabolomic biomarkers will be defined 
which may support the preclinical and clinical phases of drug development in two 
different ways: Firstly, the detection of a new drug’s hepatotoxic potential can refine 
the selection of drug candidates prior to preclinical testing and may reduce the 
attrition rates. Secondly, a multiple endpoint in vitro prediction model provides 
additional mechanistic information of a new drugs’ toxicity mechanisms which can 
support the interpretation of findings during animal studies as well as clinical trials. 
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Thus, the use of primary rat hepatocytes, as a well known and unconditionally 
available in vitro model of high in vivo relevance, is an essential tool for the validation 
of rat and human cell lines and the investigation of species-differences.    
During the work reported here the concentrations of the test compounds in the cell 
culture medium at time of treatment were compared to plasma concentrations 
derived from animal studies in order to estimate the in vivo relevance of the doses 
used for in vitro treatment. However, during in vitro studies the medium 
concentrations of the test compounds may not correlate with the real exposure of the 
cells since an unknown amount of the compound may bind to the cell culture plastic 
or the extracellular matrix. Furthermore, the compound may evaporate or remain in 
the cell culture medium without affecting the cells. Therefore, the Predict-IV kinetics 
team will determine the intracellular concentration of the reference compounds in 
order to optimize the correlation to in vivo plasma concentrations. Finally, these data 
will be used for the calculation of the margins of safety by physiologically based 
pharmacokinetic modeling as a basis for the extrapolation of in vitro derived data to 
the in vivo situation. 
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7 Appendix  
Table 7.1: Results of the long term dose finding study in 24 well plate sandwich culture.  
The cell viability is shown as percentage of control and mean of the three biological replicates ± standard deviation in percent. 
compound dose1 dose2 dose3 dose4 dose5 dose6 dose7 dose8 
day 1                                 
Acetaminophen 88.4 ± 28.4 78.0 ± 17.0 68.5 ± 12.3 72.3 ± 12.5 68.3 ± 16.7 62.2 ± 15.4        
EMD 335823 80.4 ± 17.6 69.8 ± 19.1 73.7 ± 21.0 66.3 ± 13.2 53.1 ± 11.4 46.8 ± 2.8        
Fenofibrate 93.3 ± 43.6 62.6 ± 21.9 55.8 ± 22.4 58.3 ± 27.5 58.9 ± 24.9             
Metformin 104.3 ± 29.8 89.4 ± 22.5 66.2 ± 20.6 45.3 ± 17.9 13.6 ± 13.1             
Rosigliatazone 80.8 ± 27.4 70.0 ± 30.8 52.0 ± 23.8 44.1 ± 21.9 43.9 ± 24.9 33.9 ± 17.0        
Troglitazone 45.8 ± 13.0 44.8 ± 3.0 47.8 ± 8.4 44.5 ± 8.3 37.5 ± 7.5 37.6 ± 10.4 27.4 ± 9.7 7.4 ± 7.9 
Valproic acid 66.5 ± 12.6 54.1 ± 10.3 45.6 ± 12.1 43.5 ± 9.1 39.3 ± 7.7 45.5 ± 11.3             
day 3                               
Acetaminophen 114.4 ± 27.1 120.1 ± 39.2 105.5 ± 10.1 102.1 ± 16.5 77.2 ± 11.2 62.0 ± 21.5        
EMD 335823 86.4 ± 17.9 74.3 ± 26.1 65.9 ± 26.4 67.4 ± 26.5 42.3 ± 16.4 27.3 ± 8.7        
Fenofibrate 75.1 ± 30.3 46.8 ± 16.3 62.0 ± 29.3 59.0 ± 20.4 57.1 ± 18.6             
Metformin 105.3 ± 19.2 92.0 ± 15.6 76.5 ± 15.4 87.2 ± 24.8 14.2 ± 14.5             
Rosigliatazone 79.4 ± 26.7 66.1 ± 20.2 51.9 ± 25.3 42.7 ± 22.2 43.5 ± 15.1 17.4 ± 3.7        
Troglitazone 80.4 ± 13.8 75.9 ± 17.1 74.2 ± 21.3 68.1 ± 21.7 71.3 ± 28.4 67.0 ± 26.2 56.6 ± 49.0 0.1 ± 0.2 
Valproic acid 88.7 ± 28.4 69.4 ± 20.8 55.6 ± 27.0 37.5 ± 33.5 31.4 ± 24.7 31.5 ± 24.4             
day 14                                
Acetaminophen 84.9 ± 12.8 82.3 ± 20.0 92.5 ± 27.8 77.5 ± 18.1 67.7 ± 12.4 52.3 ± 3.3        
EMD 335823 122.7 ± 27.5 135.0 ± 23.7 109.1 ± 7.2 90.5 ± 17.1 0.6 ± 0.3 0.0 ± 0.0        
Fenofibrate 81.6 ± 15.3 75.3 ± 12.3 64.6 ± 20.1 61.7 ± 11.6 59.1 ± 9.7             
Metformin 92.8 ± 18.6 80.0 ± 12.8 60.9 ± 5.9 60.8 ± 12.2 9.5 ± 10.8             
Rosigliatazone 88.4 ± 21.2 72.9 ± 16.4 73.7 ± 18.1 88.9 ± 25.5 40.2 ± 12.2 0.0 ± 0.0        
Troglitazone 72.1 ± 14.3 70.3 ± 5.3 75.0 ± 5.0 83.4 ± 4.4 91.7 ± 6.2 101.4 ± 15.8 83.1 ± 20.9 0.0 ± 0.0 
Valproic acid 74.1 ± 9.4 65.8 ± 3.2 63.9 ± 4.4 65.2 ± 8.6 70.2 ± 6.4 86.0 ± 10.3             
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Table 7.2: Genes deregulated by Acetaminophen. 
FC: fold change, Q: BH Q-value, LD: low dose, HD: high dose, 1/3/14: day 1/3/14, grayed out numbers: significantly deregulated genes.  
 
  LD1 HD1 LD3 HD3 LD14 HD14 
Access. No. gene name and symbol FC Q FC Q FC Q FC Q FC Q FC Q 
lipid metabolism            
XM_576485.1  acetyl-CoA acyltransferase 1 ( ACAA1)      1.61 0.39     
NM_013112.1  apolipoprotein A-II (APOA2)      -1.55 0.37     
NM_053995.3 3-hydroxybutyrate dehydrogenase 1 (BDH1)        -1.55 0.52 
NM_031841.1 stearoyl-CoA desaturase 2 (Scd2)      -1.77 0.36  -2.63 0.52 
NM_024143.1  solute carrier family 27 member 5 ( SLC27A5)      -1.71 0.35  -1.61 0.51 
            
drug metabolism            
NM_019363.2  aldehyde oxidase 1 (AOX1)      1.70 0.26     
NM_031543.1 
 cytochrome P450, family 2, subfamily E, polypeptide 1 
(CYP2E1)      -1.53 0.31     
XM_579318.1 glutathione S-transferase alpha 3 ( GSTA3)       -1.72 0.81    
NM_001007718.2  sulfotransferase family 1E, member 1 ( SULT1E1)      -1.62 0.37     
            
stress            
NM_001008520.1 alpha/beta hydolase 1 (ABHD1)       1.52 0.03     
NM_022500.2  ferritin, light polypeptide (FTL)      1.66 0.26     
            
energy production            
NM_013215.1  aldo-keto reductase family 7, member A3 (AKR7A3)      1.51 0.26     
NM_172030.1 
ectonucleoside triphosphate diphosphohydrolase 2 
(ENTPD2)        -1.55 0.54 
NM_012565.1  glucokinase (hexokinase 4) (GCK)  1.51 0.67        
NM_031039.1 glutamic-pyruvate transaminase (GPT)        -1.66 0.51 
            
inflammation            
NM_012488.1  alpha-2-macroglobulin (A2M)      1.65 0.26     
NM_176074.2  complement component 6 (C6)        -1.76 0.53 
NM_139089.1  chemokine (C-X-C motif) ligand 10 (CXCL10)        1.53 0.52 
NM_173123.1 
 cytochrome P450, family 4, subfamily F, polypeptide 2 
(CYP4F2)        -1.73 0.51 
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  LD1 HD1 LD3 HD3 LD14 HD14 
Access. No. gene name and symbol FC Q FC Q FC Q FC Q FC Q FC Q 
cell function            
NM_001001505.1 hyaluronan binding protein 2 (HABP2)        -1.56 0.52 
NM_053469.1 hepcidin antimicrobial peptide (Hamp)        10.11 0.51 
NM_012584.1 hydroxysteroide (3-beta) dehydrogenase 4 (Hsd3b4)      -1.51 0.33     
NM_031620.1 phosphoglycerate dehydrogenase (PHGDH)      1.55 0.28     
NM_013044.2 tropomodulin 1 (TMOD1)        -1.56 0.52 
XM_237288.3 villin 1 (VIL1)       -1.57 0.81    
NM_019156.1  vitronectin (VTN)        -2.05 0.51 
NM_012942.1 
 cytochrome P450, family 7, subfamily A, polypeptide 1 
(CYP7A1)      -1.90 0.31  -2.16 0.55 
NM_145782.1 
 cytochrome P450, family 3, subfamily A, polypeptide 43 
(CYP3A43)        -2.09 0.54 
            
growth, proliferation, cell death           
NM_012551.1  early growth response 1 (EGR1)      1.62 0.26     
NM_130752.1 fibroblast growth factor 21 (FGF21)      1.83 0.26     
NM_001009632.1 G0/G1switch 2 (G0S2)      1.63 0.30     
NM_053453.1  regulator of G-protein signaling 2, 24kDa (RGS2)        -2.33 0.51 
XM_343479.2 
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3B (SEMA3B)        -1.58 0.51 
XM_342920.2 splicing factor proline/glutamine-rich (SFPQ)            -1.61 0.52 
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Table 7.3: Genes deregulated by Valproic acid. 
FC: fold change, Q: BH Q-value, LD: low dose, HD: high dose, 1/3/14: day 1/3/14, grayed out numbers: significantly deregulated genes.  
 
  LD1 HD1 LD3 HD3 LD14 HD14 
Access. No. gene name and symbol FC Q FC Q FC Q FC Q FC Q FC Q 
XM_576485.1 acetyl-CoA acyltransferase (ACAA1) 1.62 1.00        
NM_053515.1 solute carrier family 25, member 4 (SLC25A4)      -1.65 0.81     
NM_031543.1 
 cytochrome P450, family 2, subfamily E, polypeptide 1 
(CYP2E1)      -1.63 0.81  -1.79 0.42 
NM_001007718.2  sulfotransferase family 1E, member 1 ( SULT1E1)   1.76 0.84   1.64 0.87     
NM_053453.1  regulator of G-protein signaling 2, 24kDa (RGS2)      -1.54 0.84     
NM_198780.2  phosphoenolpyruvate carboxykinase 1 (soluble) (PCK1)      -1.55 0.85     
NM_031783.1 neurofilament, light peptide (NEFL)       -1.62 0.39 
NM_053469.1 hepcidin antimicrobial peptide (Hamp)       -2.44 0.38 
NM_022298.1  tubulin, alpha 1a (TUBA1A)      -1.59 0.81     
NM_130741.1  lipocalin 2 (LCN2)       -1.69 0.37 
NM_017259.1 BTG family meber 2 (BTG2)        -1.52 0.86       
 
 
 
 
Table 7.4: Genes deregulated by Fenofibrate. 
The table contains the gene assession numbers, the gene names and symbols, as well as the fold changes for genes deregulated with p < 0.05.   
Grayed out numbers: BH Q ≤ 0.2, FF: Fenofibrate, L: low dose, H: high dose, 1/3/14: treatment day 1/3/14.   
Access. No. gene name and symbol FF L1 FF L3 FF L14 FF H1 FF H3 FF H14 
lipid metabolism          
NM_080576.1  apolipoprotein A-V ( APOA5) -5.00 -12.97 -8.17 -10.36 -24.24 -8.84 
XM_214872.2  apolipoprotein C-II ( APOC2) - -2.83 - - -4.19 -4.16 
NM_019373.1  apolipoprotein M ( APOM) - -1.52 -2.07 - -1.75 -2.35 
NM_175762.2  low density lipoprotein receptor ( LDLR) - -1.50 -1.74 - - -1.93 
XM_243524.3  low density lipoprotein receptor-related protein 1 (LRP1) - - - - - 1.66 
NM_032616.1  lipolysis stimulated lipoprotein receptor ( LSR) - - -2.24 - - -1.93 
NM_013155.1  very low density lipoprotein receptor ( VLDLR) 2.24 7.87 7.57 2.44 9.96 10.39 
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Access. No. gene name and symbol FF L1 FF L3 FF L14 FF H1 FF H3 FF H14 
 
NM_019157.2  aquaporin 7 ( AQP7) 5.04 20.27 11.21 3.55 17.07 10.41 
NM_022960.1  aquaporin 9 (AQP9) -1.93 -1.72 -1.69 -1.76 -1.80 -1.69 
XM_575339.1  CD36 molecule ( CD36) 3.83 5.45 1.59 3.78 5.16 1.93 
NM_012556.1  fatty acid binding protein 1 ( FABP1) 2.91 2.35 3.42 2.81 2.34 3.59 
NM_024162.1  fatty acid binding protein 3 ( FABP3) 3.55 45.26 59.58 3.25 47.67 91.05 
NM_138502.1  monoglyceride lipase ( MGLL) 3.75 4.98 3.34 2.90 4.29 3.86 
NM_012859.1  lipase, hormone-sensitive ( LIPE) - 1.57 1.95 - - 1.99 
NM_012598.1  lipoprotein lipase ( LPL) - - 40.56 - - 60.03 
XM_341960.2 
 patatin-like phospholipase domain containing 2 
(PNPLA2) 2.36 2.19 2.78 2.17 1.93 2.54 
NM_012820.1 
 acyl-CoA synthetase long-chain family member 1 
(ACSL1) 2.81 2.30 2.70 2.63 2.30 2.66 
NM_057107.1 
 acyl-CoA synthetase long-chain family member 3 
(ACSL3) 3.65 4.58 3.77 4.33 5.42 4.22 
NM_175837.1 
 cytochrome P450, family 4, subfamily A, polypeptide 11 
( CYP4A11) 29.96 38.86 21.20 28.05 34.96 17.69 
XM_575886.1 
 cytochrome P450, family 4, subfamily a, polypeptide 14 ( 
Cyp4A14) 7.54 11.15 12.21 8.35 10.76 10.63 
NM_053477.1  malonyl-CoA decarboxylase ( MLYCD) 2.91 3.18 3.10 2.80 3.02 3.13 
NM_031315.1  acyl-CoA thioesterase 1 ( ACOT1) 266.20 163.83 51.25 271.11 161.81 55.08 
NM_001007144.1  perilipin 2 ( PLIN2) 1.90 1.84 1.88 1.89 1.84 2.04 
NM_031118.1  sterol O-acyltransferase 1 ( SOAT1) - - 1.81 - - 1.79 
NM_016987.1  ATP citrate lyase ( ACLY) -1.64 -3.06 - -2.30 -5.04 -2.50 
XM_216452.3  24-dehydrocholesterol reductase ( DHCR24) - -2.03 -2.52 - -2.63 -3.32 
NM_017024.1  lecithin-cholesterol acyltransferase ( LCAT) - -2.30 - -1.61 -4.59 -2.33 
NM_080886.1  sterol-C4-methyl oxidase-like ( SC4MOL) - -2.20 -2.16 - -3.71 -3.08 
NM_024143.1 
 solute carrier family 27 (fatty acid transporter), member 
5 ( SLC27A5) -1.74 -7.46 -29.30 -2.01 -10.90 -46.59 
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Access. No. gene name and symbol FF L1 FF L3 FF L14 FF H1 FF H3 FF H14 
peroxisomal lipid 
metabolism    
NM_033352.1 
 ATP-binding cassette, sub-family D (ALD), member 2 
(ABCD2) - - - - - 2.03 
NM_012804.1 
 ATP-binding cassette, sub-family D (ALD), member 3 
(ABCD3) - 1.87 1.69 - 1.63 1.81 
NM_130756.2  acyl-CoA thioesterase 8 ( ACOT8) 2.75 4.10 3.78 2.34 3.65 3.22 
NM_053493.1  2-hydroxyacyl-CoA lyase 1 ( HACL1) 3.95 3.89 7.01 3.19 2.88 5.06 
XM_576485.1  acetyl-CoA acyltransferase 1 ( ACAA1) 38.64 33.42 36.39 33.80 31.55 34.88 
NM_017340.1  acyl-CoA oxidase 1 ( ACOX1) 8.12 6.05 5.74 8.04 5.94 6.81 
NM_171996.2  2,4-dienoyl CoA reductase 2 ( DECR2) 3.29 3.69 3.35 3.01 3.39 3.15 
NM_022594.1  enoyl CoA hydratase 1 ( ECH1) 3.55 3.00 3.54 3.40 2.99 3.81 
NM_001006966.1  peroxisomal D3,D2-enoyl-CoA isomerase ( PECI) 3.37 3.55 2.39 3.32 3.57 2.57 
          
mitochondrial lipid 
metabolism    
NM_130433.1  acetyl-CoA acyltransferase 2 ( ACAA2) 3.01 2.74 2.98 3.25 2.58 2.91 
NM_016986.1 
 acyl-CoA dehydrogenase, C-4 to C-12 straight chain 
(ACADM) 2.92 3.03 2.57 3.08 2.97 2.69 
NM_012891.1  acyl-CoA dehydrogenase, very long chain ( ACADVL) 2.01 2.47 2.32 2.06 2.59 2.51 
NM_017075.1  acetyl-CoA acetyltransferase 1 ( ACAT1) 4.54 7.71 8.14 3.88 6.28 7.12 
NM_017306.3  dodecenoyl-CoA isomerase ( DCI) 1.99 - - 2.03 1.57 1.67 
NM_057197.1  2,4-dienoyl CoA reductase 1 ( DECR1) 2.17 2.13 2.09 1.98 1.94 2.05 
NM_133618.1 
 hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), beta 
subunit ( HADHB) 1.90 2.32 2.01 1.93 2.34 2.30 
NM_013200.1  carnitine palmitoyltransferase 1B ( CPT1B) 5.26 13.11 15.53 4.57 14.60 15.09 
NM_001004085.2  carnitine O-acetyltransferase ( CRAT) 6.20 6.43 6.34 6.02 5.86 6.03 
NM_031987.1  carnitine O-octanoyltransferase ( CROT) 4.39 6.24 3.57 4.52 6.28 3.56 
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Access. No. gene name and symbol FF L1 FF L3 FF L14 FF H1 FF H3 FF H14 
drug metabolism    
NM_012541.2 
 cytochrome P450, family 1, subfamily A, polypeptide 2 
(CYP1A2) - - -1.63 2.59 - - 
NM_019184.1 
 cytochrome P450, family 2, subfamily C, polypeptide 9 
(CYP2C9) - -22.99 -25.73 - -10.22 -18.81 
XM_217906.3 
 cytochrome P450, family 2, subfamily C, polypeptide 18 
(CYP2C18) - - 1.52 - - 1.67 
NM_031543.1 
 cytochrome P450, family 2, subfamily E, polypeptide 1 
(CYP2E1) 1.89 4.45 5.45 3.83 5.57 3.43 
NM_153312.2 
 cytochrome P450, family 3, subfamily A, polypeptide 4 
(CYP3A4) - 2.08 27.87 - 6.24 97.28 
NM_019286.2 
 alcohol dehydrogenase 1C (class I), gamma polypeptide 
( ADH1C) - - 3.72 - - 3.46 
NM_012844.1  epoxide hydrolase 1 ( EPHX1) - 3.56 - 2.38 5.03 - 
NM_022936.1  epoxide hydrolase 2 ( EPHX2) 3.55 4.27 5.32 3.37 4.01 4.89 
XM_579318.1 glutathione S-transferase alpha 3 ( GSTA3) - 2.29 - 1.81 3.60 - 
NM_001010921.1 glutathione S-transferase alpha 5 ( GSTA5) - 1.96 4.00 - 5.19 8.58 
NM_022407.3 
aldehyde dehydrogenase 1 family, member A1 
(ALDH1A1) 2.28 2.04 - 2.63 - - 
XM_214478.3 
aldehyde dehydrogenase 5 family, member A1 
(ALDH5A1) - 2.44 2.33 - - 1.75 
NM_012683.1 
 UDP glucuronosyltransferase 1 family, polypeptide A1 
(UGT1A1) 2.04 2.18 1.56 2.04 - 1.65 
NM_001007718.2  sulfotransferase family 1E, member 1 ( SULT1E1) - 15.53 34.74 - 16.90 27.14 
NM_012623.2 
 ATP-binding cassette, sub-family B, member 1B 
(Abcb1b, MDR1) - -2.32 -14.58 - - -7.66 
NM_080581.1 
 ATP-binding cassette, sub-family C, member 3 (ABCC3, 
MRP3) -1.93 - -2.87 - - -1.73 
NM_181381.2 
 ATP-binding cassette, sub-family G (WHITE), member 1 
(ABCG2, BCRP) 1.76 1.79 - 1.78 - - 
NM_017047.1  solute carrier family 10, member 1 (SLC10A1, NTCP) - - - -1.97 - -3.10 
NM_053537.1  solute carrier family 22, member 7 (SLC22A7, OAT2) - - 2.74 - - 2.51 
NM_031650.1 
solute carrier organic anion transporter family, member 
1B3 (SLCO1B3, OATP8) - - 2.27 - - - 
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Access. No. gene name and symbol FF L1 FF L3 FF L14 FF H1 FF H3 FF H14 
stress    
NM_012520.1 catalase ( CAT) 2.45 3.13 2.29 2.18 - - 
NM_030826.2 glutathione peroxidase 1 ( GPX1) 1.53 2.43 3.42 1.55 2.12 3.04 
NM_012580.1  heme oxygenase (decycling) 1 ( HMOX1) - 1.90 - - 2.77 - 
NM_017051.2 superoxide dismutase 2 ( SOD2) - 1.69 - - 2.00 - 
NM_001008767.1  thioredoxin interacting protein ( TXNIP) 7.98 - - 7.10 - -2.22 
XM_577041.1  ferritin, light polypeptide ( FTL) - 2.05 - 1.53 2.25 1.71 
NM_012815.2  glutamate-cysteine ligase, catalytic subunit ( GCLC) -1.57 -1.70 - - -1.52 -2.00 
NM_012962.1  glutathione synthetase (GSS) - -1.77 -1.61 - - -1.63 
          
energy 
metabolism    
NM_012879.1  solute carrier family 2, member 2 (GLUT2) ( SLC2A2) - -3.09 -4.96 - -4.11 -8.31 
NM_012624.2  pyruvate kinase, liver and RBC ( PKLR) -3.23 -5.46 -2.85 -4.09 -9.83 -5.60 
NM_012595.1  lactate dehydrogenase B (LDHB) - -2.32 -6.85 - -2.59 -5.38 
NM_207592.1  glucose-6-phosphate isomerase ( GPI) - - - - - -2.08 
XM_576370.1  triosephosphate isomerase 1 (TPI1) 1.51 2.02 - - 2.13 - 
XM_233688.3 
 hexose-6-phosphate dehydrogenase (glucose 1-
dehydrogenase) ( H6PD) - - - - -1.54 -1.78 
NM_031589.2 
 solute carrier family 37 (glucose-6-phosphate 
transporter), member 4 ( SLC37A4) -2.46 -2.86 -3.13 -3.21 -4.88 -6.23 
NM_013098.1 glucose-6-phosphatase, catalytic subunit ( G6PC) - -2.20 - - -4.83 - 
NM_012744.2  pyruvate carboxylase (PC) 2.12 - - - - - 
NM_198780.2  phosphoenolpyruvate carboxykinase 1 (soluble) (PCK1) 4.16 - - 2.71 - - 
NM_053551.1  pyruvate dehydrogenase kinase, isozyme 4 ( PDK4) 22.76 21.68 19.05 24.35 24.40 20.82 
NM_024398.2  aconitase 2, mitochondrial ( ACO2) 1.92 1.91 - 1.78 1.67 - 
NM_053752.1  succinate-CoA ligase, alpha subunit ( SUCLG1) - 1.82 - - 1.78 - 
NM_031510.1  isocitrate dehydrogenase 1 (NADP+), soluble ( IDH1) - 1.73 - - 1.62 - 
NM_012600.1  malic enzyme 1, NADP(+)-dependent, cytosolic ( ME1) 3.42 5.73 4.96 3.19 5.85
 
5.43 
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Access. No. gene name and symbol FF L1 FF L3 FF L14 FF H1 FF H3 FF H14 
NM_022215.2 
 glycerol-3-phosphate dehydrogenase 1 (soluble) ( 
GPD1) - 1.80 3.12 - 1.55 2.61 
NM_012736.1 
 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 
(GPD2) 3.87 3.33 3.58 2.88 2.37 2.47 
NM_019269.1 
 solute carrier family 22 (organic cation/carnitine 
transporter), member 5 ( SLC22A5) 3.89 4.25 3.18 3.80 4.42 2.92 
NM_019354.1 
 uncoupling protein 2 (mitochondrial, proton carrier) 
(UCP2) 7.46 17.29 - 6.52 19.10 5.68 
NM_017025.1  lactate dehydrogenase A (LDHA) 3.10 2.90 2.55 2.59 2.51 - 
NM_013089.1  glycogen synthase 2 (liver) ( GYS2) - - - - - -1.74 
XM_341693.2 
 nudix (nucleoside diphosphate linked moiety X)-type 
motif 7 ( NUDT7) 3.68 4.84 6.31 3.32 - 5.70 
          
cell function    
XM_344194.2  interferon regulatory factor 6 ( IRF6) -1.65 -1.69 -3.31 -1.51 - -2.87 
NM_053373.1  peptidoglycan recognition protein 1 ( PGLYRP1) - -2.91 -7.52 - -2.82 -6.52 
XM_341957.2 
 interferon induced transmembrane protein 3 (1-8U) 
(IFITM3) - -2.52 -15.01 - -2.64 -11.77 
NM_207604.1  toll-like receptor 6 ( TLR6) -2.29 -2.33 -2.19 - -2.54 -2.06 
NM_017020.1  interleukin 6 receptor ( IL6R) -1.97 -2.00 -1.72 -2.35 -2.42 -1.94 
NM_012747.2 
 signal transducer and activator of transcription 3 (acute-
phase response factor) ( STAT3) -1.58 -1.96 -3.01 - -1.84 -2.54 
NM_145672.3  chemokine (C-X-C motif) ligand 9 ( CXCL9) - - - - 4.34 - 
NM_182952.2  chemokine (C-X-C motif) ligand 11 (CXCL11) - - -3.07 - - -3.75 
XM_573130.1  chemokine (C-X-C motif) ligand 16 ( CXCL16) -3.07 -4.13 -15.49 -2.31 -2.83 - 
NM_176074.2  complement component 6 ( C6) - -2.10 -4.49 - -2.81 -4.50 
NM_172222.2  complement component 2 (C2) - - -2.28 - - -2.21 
NM_130409.1  complement factor H ( CFH) -1.66 -1.91 -2.27 - -1.93 -1.93 
NM_012898.2  alpha-2-HS-glycoprotein (AHSG) - - - - -4.64 -2.63 
NM_020071.1  fibrinogen beta chain (FGB) -1.79 -2.36 -2.89 - -2.71 -2.93 
NM_012488.1  alpha-2-macroglobulin ( A2M) - - -2.55 - - -2.10 
NM_017096.1  C-reactive protein, pentraxin-related ( CRP) - - - - 1.74 1.63 
NM_012681.1  transthyretin (TTR) - -1.68 -1.82 - -2.05 -2.18 
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Access. No. gene name and symbol FF L1 FF L3 FF L14 FF H1 FF H3 FF H14 
NM_172320.1  afamin (AFM) 1.52 2.09 2.79 - 1.69 1.62 
NM_012725.1  kallikrein B, plasma (Fletcher factor) 1 (KLKB1) - -2.35 -1.78 - -2.21 -1.53 
NM_022519.2 
 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 (SERPINA1) - -1.81 -1.54 - -1.87 -1.55 
XM_215303.3  major histocompatibility complex, class I, E (HLA-E) -2.49 -4.34 -5.02 -2.94 -5.57 -5.82 
NM_053487.1  peroxisomal biogenesis factor 11 alpha ( PEX11A) 6.95 6.05 6.90 7.21 6.22 6.48 
XM_213930.3  peroxisomal biogenesis factor 19 ( PEX19) 2.90 3.20 2.39 2.33 2.99 2.65 
XM_222831.3  coagulation factor V (proaccelerin, labile factor) ( F5) - -2.88 -3.13 - -4.26 -3.81 
XM_346365.2  coagulation factor IX ( F9) - - -1.96 - - -2.29 
XM_224872.3  coagulation factor XI ( F11) -2.27 -3.30 -1.62 -2.49 -3.48 -1.65 
NM_031334.1  cadherin 1, type 1, E-cadherin (epithelial) ( CDH1) -2.36 -2.94 -5.78 - -3.26 -4.80 
NM_019143.1  fibronectin 1 ( FN1) - -2.93 -10.43 - -2.95 -8.91 
NM_001004269.1  junctional adhesion molecule 3 ( JAM3) - -1.81 -5.83 - - -4.22 
NM_019156.1  vitronectin ( VTN) - -2.89 -20.59 - -4.63 -29.07 
XM_213902.3  laminin, gamma 2 ( LAMC2) - - -3.77 - - -3.33 
XM_243637.3  fibulin 1 ( FBLN1) -3.19 -2.83 -2.71 -2.89 -2.56 -2.42 
NM_022298.1  tubulin, alpha 1a ( TUBA1A) - - -31.65 - - -17.85 
XM_238167.3  filamin A, alpha ( FLNA) - - -9.96 - - -5.89 
NM_031140.1  vimentin ( VIM) -2.82 -7.53 -48.09 -2.09 -5.70 -31.31 
NM_012504.1 
 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
(ATP1A1) - -1.69 -2.32 - -1.60 -2.54 
NM_012942.1 
 cytochrome P450, family 7, subfamily A, polypeptide 1 
(CYP7A1) -5.71 -3.98 -8.99 -4.47 - - 
XM_341151.2  retinoid X receptor, gamma ( RXRG) 2.25 2.79 2.77 2.09 2.33 2.26 
NM_022941.2 nuclear receptor subfamily 1, group I, member 3 (NR1I3) - - 2.01 - 1.73 - 
          
growth, 
proliferation, cell 
death    
NM_013132.1  annexin A5 (ANXA5) - -1.53 -6.76 - - -2.99 
XM_576514.1 
 serum response factor (c-fos serum response element-
binding transcription factor) ( SRF) - - -1.78 - - -1.67 
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NM_022266.1  connective tissue growth factor ( CTGF) - -45.41 -146.28 -9.16 -53.21 -95.46 
NM_012551.1  early growth response 1 ( EGR1) - - -3.17 - - -2.76 
XM_341981.2  polymerase (DNA-directed), delta 4 ( POLD4) - -1.66 -1.94 - -1.69 - 
XM_341386.2  topoisomerase (DNA) II beta 180kDa (TOP2B) - - -1.61 - - -1.56 
NM_012671.1  transforming growth factor, alpha ( TGFA) - - -2.20 - - -1.92 
NM_031131.1  transforming growth factor, beta 2 ( TGFB2) - - -6.00 - - -4.62 
XM_216492.3  cAMP responsive element binding protein 3 ( CREB3) - - - - - -1.76 
NM_012842.1  epidermal growth factor ( EGF) - -1.76 -1.81 - -1.93 -1.95 
NM_024148.1 
 APEX nuclease (multifunctional DNA repair enzyme) 1 
(APEX1) - 1.75 - - 2.12 - 
NM_024127.1 
 growth arrest and DNA-damage-inducible, alpha 
(GADD45A) - 1.96 - - 2.46 - 
NM_012861.1  O-6-methylguanine-DNA methyltransferase ( MGMT) - - -2.31 - - - 
XM_214477.2  geminin, DNA replication inhibitor ( GMNN) 1.65 - - 1.72 1.68 - 
NM_171992.2  cyclin D1 ( CCND1) - - -2.67 - - -2.39 
XM_342632.2  cyclin-dependent kinase 14 ( CDK14) - - -4.01 - - - 
NM_012923.1  cyclin G1 ( CCNG1) - - -2.95 - - - 
NM_012524.1 
 CCAAT/enhancer binding protein (C/EBP), alpha 
(CEBPA) - - 1.71 - - 1.65 
NM_139087.1  cell growth regulator with EF-hand domain 1 ( CGREF1) - -1.77 -2.37 - -1.65 -2.30 
XM_574454.1  growth arrest-specific 2 ( GAS2) - - -1.88 - -1.62 -2.04 
NM_053812.1  BCL2-antagonist/killer 1 ( BAK1) - - -3.18 - - -2.60 
NM_017059.1  BCL2-associated X protein ( BAX) - - -1.50 - - - 
NM_017312.2  BCL2-related ovarian killer ( BOK) - - -3.34 - - -3.13 
XM_214551.3  cell death-inducing DFFA-like effector a ( CIDEA) - - 3.75 2.34 4.12 3.82 
NM_012935.2  crystallin, alpha B ( CRYAB) - -2.94 -20.72 - -2.66 -14.78 
NM_022526.1  death-associated protein ( DAP) - -1.86 -4.30 - - - 
NM_139194.1  Fas (TNF receptor superfamily, member 6) ( FAS) - - -1.87 - - -1.83 
NM_181086.2 
 tumor necrosis factor receptor superfamily, member 12A 
( TNFRSF12A) - - -4.31 - - -2.57 
XM_575700.1  BCL2-like 14 (apoptosis facilitator) ( BCL2L14) - - 2.12 - 2.70 2.86 
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NM_021835.2  jun proto-oncogene ( JUN) - - -2.66 - - -2.60 
NM_133571.1  cell division cycle 25 homolog A (S. pombe) ( CDC25A) 2.31 2.15 1.54 2.26 2.12 1.54 
NM_012603.2 
 v-myc myelocytomatosis viral oncogene homolog 
(avian) ( MYC) - - -2.43 - - - 
XM_342470.2  apoptosis inhibitor 5 ( API5) - - -1.76 - - -1.61 
NM_033230.1  v-akt murine thymoma viral oncogene homolog 1 (AKT1) - - -1.85 - - -1.52 
NM_001007732.1 
 serpin peptidase inhibitor, clade B (ovalbumin), member 
9 ( SERPINB9) - - -12.52 - - -7.22 
NM_131914.2  caveolin 2 ( CAV2) - - -4.32 - - -4.30 
NM_001009632.1  G0/G1switch 2 (G0S2) 1.86 4.38 10.96 1.79 3.96 8.02 
NM_134432.2 
 angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8) (AGT) - 1.90 1.62 - - - 
NM_012649.1  syndecan 4 (SDC4) -1.54 -1.83 -1.61 - -1.82 -1.84 
XM_343604.2 
 serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 2 (SERPINE2) 2.12 7.89 13.28 2.09 7.56 12.76 
 
 
 
Table 7.5: Genes deregulated by Rosiglitazone. 
The table contains the the gene assession numbers, the gene names and symbols as well as the fold changes of genes deregulated with p < 0.05.  
Grayed out numbers: BH Q ≤ 0.2, Rosi: Rosiglitazone, H: high dose, 1/3/14: treatment day 1/3/14.   
Access. No. gene name and symbol Rosi H1 Rosi H3 Rosi H14 
lipid metabolism      
NM_080576.1  apolipoprotein A-V (APOA5) -2.94 -3.82 -2.11 
XM_243524.3  low density lipoprotein receptor-related protein 1 (LRP1)  - 1.69 1.56 
NM_013155.1  very low density lipoprotein receptor (VLDLR)  - 5.03 3.75 
NM_012598.1  lipoprotein lipase (LPL)  -  - 3.61 
NM_138502.1  monoglyceride lipase (MGLL) 1.51 2.07 1.85 
NM_019157.2  aquaporin 7 (AQP7)  - 4.88 6.40 
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XM_575339.1  CD36 molecule (thrombospondin receptor) (CD36)  - 2.26 1.52 
NM_012556.1  fatty acid binding protein 1, liver (FABP1) 1.68 2.14 2.81 
NM_053477.1  malonyl-CoA decarboxylase (MLYCD) 1.82 2.00 2.14 
NM_031315.1  acyl-CoA thioesterase 1 (Acot1) 20.98 91.35 38.81 
NM_012820.1  acyl-CoA synthetase long-chain family member 1 (ACSL1) 2.21 2.31 2.35 
NM_175837.1  cytochrome P450, family 4, subfamily A, polypeptide 11 (CYP4A11) 3.03 12.22 7.38 
XM_575886.1  cytochrome P450, family 4, subfamily a, polypeptide 14 (Cyp4a14) 2.77 5.24 5.08 
XM_230827.3  fat storage-inducing transmembrane protein 2 (FITM2) 2.09 2.13 2.00 
NM_001007144.1  perilipin 2 (PLIN2) 1.82 1.84  - 
NM_080886.1  sterol-C4-methyl oxidase-like (SC4MOL)  - -1.72 -1.91 
NM_017274.1  glycerol-3-phosphate acyltransferase, mitochondrial (GPAM) 1.73 2.28  - 
NM_031841.1  stearoyl-Coenzyme A desaturase 2 (Scd2) 3.07 7.74 2.57 
NM_024143.1  solute carrier family 27 (fatty acid transporter), member 5 (SLC27A5) -1.73 -4.63 -7.24 
       
peroxisomal lipid 
metabolism    
NM_012804.1  ATP-binding cassette, sub-family D (ALD), member 3 (ABCD3)  - 1.61 1.84 
XM_576485.1  acetyl-CoA acyltransferase 1 (ACAA1) 10.67 21.14 19.75 
NM_130756.2  acyl-CoA thioesterase 8 (ACOT8)  - 2.35 1.71 
NM_017340.1  acyl-CoA oxidase 1, palmitoyl (ACOX1) 2.46 3.94 3.91 
NM_171996.2  2,4-dienoyl CoA reductase 2, peroxisomal (DECR2)  - 2.86 2.30 
NM_022594.1  enoyl CoA hydratase 1, peroxisomal (ECH1)  - 2.30 2.51 
NM_053493.1  2-hydroxyacyl-CoA lyase 1 (HACL1) 1.81 2.29 2.86 
NM_001006966.1  peroxisomal D3,D2-enoyl-CoA isomerase (PECI) 2.11 2.12  - 
       
mitochondrial lipid 
metabolism    
NM_013200.1  carnitine palmitoyltransferase 1B (muscle) (CPT1B)  - 4.00 4.79 
NM_001004085.2  carnitine O-acetyltransferase (CRAT) 2.85 3.29 3.25 
NM_031987.1  carnitine O-octanoyltransferase (CROT)  - 1.87 1.54 
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NM_130433.1  acetyl-CoA acyltransferase 2 (ACAA2) 1.80 1.88 1.84 
NM_016986.1  acyl-CoA dehydrogenase, C-4 to C-12 straight chain (ACADM) 1.65 2.18 1.96 
NM_017075.1  acetyl-CoA acetyltransferase 1 (ACAT1) 1.73 2.94 2.57 
NM_017306.3  dodecenoyl-CoA isomerase (DCI) 1.66 1.63 1.50 
NM_057197.1  2,4-dienoyl CoA reductase 1, mitochondrial (DECR1)  - 1.73 1.57 
NM_057186.1  hydroxyacyl-CoA dehydrogenase (HADH) 1.96 2.38 1.78 
       
drug metabolism    
NM_012540.2  cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) 3.01 3.50  - 
NM_173294.1  cytochrome P450, family 2, subfamily b, polypeptide 9 (Cyp2b9) - - 3.08 
NM_019184.1  cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) - -3.19 -5.64 
XM_217906.3  cytochrome P450, family 2, subfamily C, polypeptide 18 (CYP2C18) 1.88 - 1.82 
XM_215255.3  cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) - - 2.24 
NM_031543.1  cytochrome P450, family 2, subfamily E, polypeptide 1 (CYP2E1) - -1.69 -2.32 
NM_153312.2  cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) 6.13 4.78 30.76 
NM_022407.3  aldehyde dehydrogenase 1 family, member A1 (ALDH1A1) 1.58 1.68  - 
NM_012844.1  epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1) 2.65 2.81 1.52 
NM_022936.1  epoxide hydrolase 2, cytoplasmic (EPHX2) 1.73 3.10 2.75 
XM_579318.1  glutathione S-transferase alpha 3 (GSTA3) 1.60 3.12 2.00 
NM_001010921.1  glutathione S-transferase alpha 5 (GSTA5) 4.10 5.65 6.85 
NM_001007718.2  sulfotransferase family 1E, estrogen-preferring, member 1 (SULT1E1)  - 2.27 5.53 
NM_012683.1  UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) 1.79 1.78  - 
NM_130407.1  UDP glucuronosyltransferase 1 family, polypeptide A7C (Ugt1a7c) 1.79 1.72  - 
NM_012623.2  ATP-binding cassette, sub-family B (MDR/TAP), member 1B (Abcb1b, MDR1)  - -2.70 -2.92 
NM_031650.1  solute carrier organic anion transporter family, member 1B3 (SLCO1B3, OATP8)  -  - 2.21 
NM_053537.1  solute carrier family 22 (organic anion transporter), member 7 (SLC22A7, OAT2)  -  - 2.25 
       
stress    
NM_012520.1  catalase (CAT)  - 2.44  - 
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NM_030826.2  glutathione peroxidase 1 (GPX1)  - 1.56 2.20 
NM_053906.1  glutathione reductase (GSR) 2.15 1.57  - 
NM_012580.1  heme oxygenase (decycling) 1 (HMOX1) 3.50 2.88  - 
NM_017051.2  superoxide dismutase 2, mitochondrial (SOD2)  - 1.51  - 
NM_001008767.1  thioredoxin interacting protein (TXNIP) 2.27 1.90  - 
XM_215293.3  vanin 1 (VNN1)  - 2.17 1.80 
 XM_576192.1  ferritin, light polypeptide (FTL) 1.72 1.99 - 
       
energymetabolism    
NM_012879.1  solute carrier family 2 (facilitated glucose transporter), member 2 (SLC2A2)  - -1.71  - 
NM_012565.1  glucokinase (hexokinase 4) (GCK)  - 1.55  - 
NM_013190.2  phosphofructokinase, liver (PFKL)  - 2.08  - 
NM_053291.2  phosphoglycerate kinase 1 (PGK1)  - 1.87  - 
 NM_012595.1  lactate dehydrogenase B (LDHB) - -2.09 -2.07 
XM_576370.1  triosephosphate isomerase 1 (TPI1)  - 2.32  - 
NM_012495.1  aldolase A, fructose-bisphosphate (ALDOA) 1.66 1.74  - 
NM_012554.1  enolase 1, (alpha) (ENO1)  - 1.70  - 
NM_013098.1  glucose-6-phosphatase, catalytic subunit (G6PC)  - -1.70  - 
NM_012744.2  pyruvate carboxylase (PC)  - 2.53  - 
NM_198780.2  phosphoenolpyruvate carboxykinase 1 (soluble) (PCK1) 2.65 -1.79  - 
NM_031589.2  solute carrier family 37 (glucose-6-phosphate transporter), member 4 (SLC37A4) -1.96  - -2.52 
NM_053551.1  pyruvate dehydrogenase kinase, isozyme 4 (PDK4) 3.58 3.48 6.29 
NM_012600.1  malic enzyme 1, NADP(+)-dependent, cytosolic (ME1) 1.79 5.02 2.89 
NM_012736.1  glycerol-3-phosphate dehydrogenase 2 (mitochondrial) (GPD2) 2.08 2.88 1.97 
NM_019269.1  solute carrier family 22 (organic cation/carnitine transporter), member 5 (SLC22A5) 1.69 2.21 1.69 
NM_019354.1  uncoupling protein 2 (mitochondrial, proton carrier) (UCP2) 2.52 3.67  - 
XM_576370.1  triosephosphate isomerase 1 (TPI1) - 2.32 - 
 NM_017025.1  lactate dehydrogenase A (LDHA) 1.98 2.88 2.05 
XM_341693.2  nudix (nucleoside diphosphate linked moiety X)-type motif 7 (NUDT7)  - 2.41 2.99 
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cell function    
NM_017020.1  interleukin 6 receptor (IL6R) -1.93  - -1.62 
NM_012747.2  signal transducer and activator of transcription 3 (acute-phase response factor) (STAT3)  - -1.53 -1.52 
NM_207604.1  toll-like receptor 6 (TLR6) -1.81 -1.84 -1.83 
XM_341957.2  interferon induced transmembrane protein 3 (1-8U) (IFITM3)  - -1.83 -4.47 
NM_145672.3  chemokine (C-X-C motif) ligand 9 (CXCL9) 1.54 2.71 1.97 
NM_182952.2  chemokine (C-X-C motif) ligand 11 (CXCL11) -1.53 - -1.59 
XM_573130.1  chemokine (C-X-C motif) ligand 16 (CXCL16) -1.57 -3.00 -2.41 
NM_176074.2  complement component 6 (C6)  - -1.70 -1.91 
NM_130409.1  complement factor H (CFH) - - -1.50 
NM_024157.1  complement factor I (CFI) - - -1.82 
XM_215303.3  major histocompatibility complex, class I, E (HLA-E) -2.06 -1.93 -2.08 
NM_012488.1  alpha-2-macroglobulin (A2M)  -  - -2.04 
NM_022519.2  serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 (SERPINA1) - - -1.61 
NM_020071.1  fibrinogen beta chain (FGB) - - -1.74 
NM_053373.1  peptidoglycan recognition protein 1 (PGLYRP1) -1.94 -2.61 -5.65 
NM_172320.1  afamin (AFM) - 1.71 2.06 
NM_053487.1  peroxisomal biogenesis factor 11 alpha (PEX11A) 2.67 3.33 2.62 
XM_213930.3  peroxisomal biogenesis factor 19 (PEX19)  - 1.96 1.87 
XM_222831.3  coagulation factor V (proaccelerin, labile factor) (F5) -1.64 -1.95 -1.95 
XM_346365.2  coagulation factor IX (F9) -1.53 - -1.95 
NM_031753.1  activated leukocyte cell adhesion molecule (ALCAM) -1.66 -2.31 -3.14 
NM_031334.1  cadherin 1, type 1, E-cadherin (epithelial) (CDH1) -1.75 -1.92 -2.13 
NM_019143.1  fibronectin 1 (FN1) -1.51 -2.20 -3.10 
NM_001001505.1  hyaluronan binding protein 2 (HABP2)  - -2.68 -3.17 
NM_012967.1  intercellular adhesion molecule 1 (ICAM1)  -  - -1.58 
NM_001004269.1  junctional adhesion molecule 3 (JAM3)  - -1.86 -2.81 
XM_213902.3  laminin, gamma 2 (LAMC2)  -  - -2.56 
NM_019156.1  vitronectin (VTN)  -  - -3.15 
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XM_238167.3  filamin A, alpha (FLNA)  - -1.58 -3.32 
NM_013044.2  tropomodulin 1 (TMOD1) -1.71 -2.45 -3.49 
NM_022298.1  tubulin, alpha 1a (TUBA1A)  - -2.16 -7.23 
NM_031140.1  vimentin (VIM)  -  - -4.47 
NM_012504.1  ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1)  - -1.64 -1.76 
NM_012942.1  cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1) - -2.16 - 
XM_341151.2  retinoid X receptor, gamma (RXRG)  - 2.73 2.27 
       
growth, 
proliferation, cell 
death    
NM_013132.1  annexin A5 (ANXA5) - - -1.61 
NM_013144.1  insulin-like growth factor binding protein 1 (IGFBP1) -1.79 -1.94 -1.85 
XM_576514.1  serum response factor (c-fos serum response element-binding transcription factor) (SRF)  -  - -1.57 
NM_022266.1  connective tissue growth factor (CTGF) -5.37 -14.78 -7.46 
NM_012671.1  transforming growth factor, alpha (TGFA)  -  - -1.89 
XM_341981.2  polymerase (DNA-directed), delta 4 (POLD4)  -  - -1.54 
NM_012861.1  O-6-methylguanine-DNA methyltransferase (MGMT)  -  - -1.63 
NM_012923.1  cyclin G1 (CCNG1)  -  - -2.27 
NM_080782.2  cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A)  -  - -1.53 
NM_031762.2  cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)  -  - -1.65 
NM_171992.2  cyclin D1 (CCND1) 2.26  -  - 
NM_053453.1  regulator of G-protein signaling 2, 24kDa (RGS2)  - -2.48 -12.03 
NM_012801.1  platelet-derived growth factor alpha polypeptide (PDGFA)  - -1.53 -1.72 
NM_053812.1  BCL2-antagonist/killer 1 (BAK1)  -  - -1.59 
NM_053420.2  BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3)  - 2.39  - 
NM_017312.2  BCL2-related ovarian killer (BOK)  -  - -1.84 
XM_214551.3  cell death-inducing DFFA-like effector a (CIDEA)  - 2.28 2.21 
NM_012935.2  crystallin, alpha B (CRYAB)  - -2.31 -2.25 
XM_225138.3  death-associated protein kinase 1 (DAPK1) 3.39 3.00 1.74 
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NM_139194.1  Fas (TNF receptor superfamily, member 6) (FAS)  -  - -1.54 
NM_181086.2  tumor necrosis factor receptor superfamily, member 12A (TNFRSF12A)  -  - -1.64 
XM_575700.1  BCL2-like 14 (apoptosis facilitator) (BCL2L14)  - 1.59 1.79 
NM_133571.1  cell division cycle 25 homolog A (S. pombe) (CDC25A) 1.51 1.72  - 
NM_021835.2  jun proto-oncogene (JUN) -1.51  - -1.65 
NM_012603.2  v-myc myelocytomatosis viral oncogene homolog (avian) (MYC)  -  - -1.82 
NM_212505.1  immediate early response 3 (IER3)  -  - -2.79 
NM_001007732.1  serpin peptidase inhibitor, clade B (ovalbumin), member 9 (SERPINB9)  -  - -1.89 
NM_134432.2  angiotensinogen (AGT) - 1.88 - 
NM_012649.1  syndecan 4 (SDC4) - - -1.50 
XM_343604.2  serpin peptidase inhibitor, clade E member 2 (SERPINE2) - 1.94 4.24 
NM_001009632.1  G0/G1switch 2 (G0S2) - 4.23 4.57 
 
 
Table 7.6: Genes deregulated by Troglitazone. 
The table contains the gene assession numbers, the gene names and symbols, as well as the fold changes of genes deregulated with p < 0.05.  
Grayed out numbers: BH Q ≤ 0.2, Tro: Troglitazone, H: high dose, 3/14: treatment day 3/14.   
Access. No. gene name and symbol Tro H3 Tro H14 
lipid metabolism       
 NM_080576.1  apolipoprotein A-V (APOA5) -2.11 - 
 NM_013155.1  very low density lipoprotein receptor (VLDLR) 3.27 - 
 XM_243524.3  low density lipoprotein receptor-related protein 1 (LRP1) 1.63 1.56 
 NM_019157.2  aquaporin 7 (AQP7) 3.81 3.93 
 NM_012556.1  fatty acid binding protein 1, liver (FABP1) 1.99 2.12 
 XM_575339.1  CD36 molecule (thrombospondin receptor) (CD36) 2.06 - 
 NM_138502.1  monoglyceride lipase (MGLL) 1.94 1.54 
 NM_053477.1  malonyl-CoA decarboxylase (MLYCD) 1.84 1.63 
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 NM_031315.1  acyl-CoA thioesterase 1 (ACOT1) 53.19 18.33 
 NM_012820.1  acyl-CoA synthetase long-chain family member 1 (ACSL1) 2.17 1.88 
 NM_175837.1  cytochrome P450, family 4, subfamily A, polypeptide 11 (CYP4A11) 7.37 2.73 
 XM_575886.1  cytochrome P450, family 4, subfamily a, polypeptide 14 (CYP4A14) 3.66 2.76 
 XM_230827.3 fat storage-inducing transmembrane protein 2 (FITM2) 2.19 - 
 NM_001007144.1  perilipin 2 (PLIN2) 1.65 - 
 NM_080886.1  sterol-C4-methyl oxidase-like (SC4MOL) -1.59 - 
      
peroxisomal lipid 
metabilism    
 NM_012804.1  ATP-binding cassette, sub-family D (ALD), member 3 (ABCD3) 1.62 - 
 XM_576485.1  acetyl-CoA acyltransferase 1 (ACAA1) 15.72 14.86 
 NM_171996.2  2,4-dienoyl CoA reductase 2, peroxisomal (DECR2) 2.15 1.68 
 NM_053493.1  2-hydroxyacyl-CoA lyase 1 (HACL1) 2.62 - 
 NM_022594.1  enoyl CoA hydratase 1, peroxisomal (ECH1) 1.93 - 
 NM_001006966.1  peroxisomal D3,D2-enoyl-CoA isomerase (PECI) 1.98 - 
 NM_017340.1  acyl-CoA oxidase 1, palmitoyl (ACOX1) 3.30 2.96 
      
mitochondrial lipid 
metabolism    
 NM_013200.1  carnitine palmitoyltransferase 1B (muscle) (CPT1B) 2.83 - 
 NM_001004085.2  carnitine O-acetyltransferase (CRAT) 2.82 - 
 NM_031987.1  carnitine O-octanoyltransferase (CROT) 1.82 - 
 NM_130433.1  acetyl-CoA acyltransferase 2 (ACAA2) 1.87 - 
 NM_057186.1 hydroxyacyl-CoA dehydrogenase (HADH) 2.09 - 
 NM_133618.1 
 hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit 
(HADHB) 1.77 - 
 NM_016986.1  acyl-CoA dehydrogenase, C-4 to C-12 straight chain (ACADM) 1.92 1.61 
 NM_017075.1  acetyl-CoA acetyltransferase 1 (ACAT1) 2.01 1.54 
 NM_012891.1  acyl-CoA dehydrogenase, very long chain (ACADVL) 1.54 - 
 NM_017306.3  dodecenoyl-CoA isomerase (DCI) 1.59 - 
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Access. No. gene name and symbol Tro H3 Tro H14 
drug metabolism    
 NM_019363.2 aldehyd oxidase (AOX1) 1.95 - 
 NM_022407.3 aldehyddehydrogenase 1 family member A1 (ALDH1A1) 1.62 - 
NM_019184.1  cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) -2.71   
 NM_153312.2  cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) 8.24 39.08 
 NM_012844.1  epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1) 2.09 1.67 
 NM_022936.1 epoxide hydrolase 2 (EPHX2) 2.65 - 
 NM_001010921.1  glutathione S-transferase alpha 5 (GSTA5) 4.81 12.38 
 NM_181371.2  glutathione S-transferase kappa 1 (GSTK1) 1.84 1.69 
 NM_177426.1  glutathione S-transferase mu 1 (GSTM1) -1.66 - 
 XM_341791.2 sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 6 (Sult2a6) 1.55 3.77 
 NM_001007718.2  sulfotransferase family 1E, estrogen-preferring, member 1 (SULT1E1) 3.18 - 
 NM_012683.1  UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) 1.56 - 
 NM_130407.1  UDP glucuronosyltransferase 1 family, polypeptide A7C (Ugt1a7c) 1.58 - 
 NM_173295.1  UDP glucuronosyltransferase 2 family, polypeptide B4 (UGT2B4) - 1.64 
 XM_223299.3  UDP glucuronosyltransferase 2 family, polypeptide B10 (UGT2B10) - 1.53 
NM_031650.1  solute carrier organic anion transporter family, member 1B3 (SLCO1B3, OATP8) - 1.54 
NM_022287.1 solute carrier falily 26 (sulfate transporter), member 1 (SLC26A1) -1.56 - 
      
stress    
 NM_030826.2  glutathione peroxidase 1 (GPX1) 1.63 1.71 
 XM_574282.1 vanin 2 (VNN2) 1.64 1.73 
 NM_001008767.1  thioredoxin interacting protein (TXNIP) 1.84 - 
 NM_012520.1  catalase (CAT) 1.89 - 
 XM_577041.1 ferritin, light polypeptide (FTL) 1.68 - 
      
energy production    
 NM_013190.2 phosphofructokinase  (PFKL) 1.89 - 
 NM_012624.2  pyruvate kinase, liver and RBC (PKLR) -1.78 - 
201 Appendix 
 
Access. No. gene name and symbol Tro H3 Tro H14 
NM_012595.1  lactate dehydrogenase B (LDHB) -1.52 1.59 
 NM_053291.2 phosphoglycerate kinase 1 (PGK1) 1.74 - 
 XM_576370.1 triosephosphate isomerase  (TPI1) 1.93 - 
 NM_012554.1  enolase 1, (alpha) (ENO1) 1.50 - 
 NM_012744.2  pyruvate carboxylase (PC) 2.20 - 
 XM_341319.2 phosphoenolpyruvate carboxykinase 2 (PEPCK) (PCK2) 1.60 - 
 NM_001008282.1 galactokinase 1 (GALK1) 1.66 - 
 XM_216372.3  galactose-1-phosphate uridylyltransferase (GALT) 1.51 - 
 NM_053551.1  pyruvate dehydrogenase kinase, isozyme 4 (PDK4) 3.21 3.78 
 NM_012736.1  glycerol-3-phosphate dehydrogenase 2 (mitochondrial) (GPD2) 1.89 - 
 NM_019269.1  solute carrier family 22 (organic cation/carnitine transporter), member 5 (SLC22A5) 1.88 - 
 NM_012600.1 malic enzyme, NADP(+) dependent, cytosolic (ME1) 2.78 1.83 
 NM_019354.1  uncoupling protein 2 (mitochondrial, proton carrier) (UCP2) 3.27 - 
NM_017025.1  lactate dehydrogenase A (LDHA) 2.31 -1.52 
 XM_341693.2  nudix (nucleoside diphosphate linked moiety X)-type motif 7 (NUDT7) 2.14 2.06 
 
      
cell function     
 NM_031531.1  serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 (SERPINA3) -1.87 - 
 XM_341957.2 interferon induced transmembrane protein 3 (IFITM3) -1.74 - 
 NM_207604.1  toll-like receptor 6 (TLR6) -1.58 - 
 NM_030845.1  chemokine (C-X-C motif) ligand 2 (CXCL2) -2.00 - 
 NM_022177.2  chemokine (C-X-C motif) ligand 12 (CXCL12) 1.92 - 
 NM_145672.3  chemokine (C-X-C motif) ligand 9 (CXCL9) - 2.09 
 NM_017096.1  C-reactive protein, pentraxin-related (CRP) - 1.52 
 NM_012516.1  complement component 4 binding protein, beta (C4BPB) -1.79 - 
 NM_172320.1  afamin (AFM) 1.85 - 
 XM_215303.3  major histocompatibility complex, class I, E (HLA-E) -1.87 - 
 NM_176074.2  complement component 6 (C6) -1.71 - 
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 NM_053487.1 peroxisomal biogenesis factor 11 alpha (PEX11A) 1.82 2.56 
 XM_213930.3 peroxisomal biogenesis factor 19 (PEX19) 1.82 - 
 NM_013044.2 tropomodulin 1 (TMOD1) -1.81 -2.24 
 NM_022298.1  tubulin, alpha 1a (TUBA1A) -2.07 - 
 NM_019143.1  fibronectin 1 (FN1) -1.59 - 
 NM_031334.1  cadherin 1, type 1, E-cadherin (epithelial) (CDH1) -1.57 - 
 NM_031699.1 claudin 1 (CLDN1) - -1.65 
 XM_224872.3 coagulation factor XI (F11) -1.68 - 
 XM_341151.2 retinoid X receptor, gamma (RXRG) 2.21 - 
      
growth, 
proliferation, cell 
death    
 NM_022266.1  connective tissue growth factor (CTGF) -4.49 - 
 NM_012861.1  O-6-methylguanine-DNA methyltransferase (MGMT) - -1.54 
 XM_214551.3  cell death-inducing DFFA-like effector a (CIDEA) 2.13 - 
 XM_575700.1 BCL2-like 14 (BCL2L14) - 1.79 
 NM_139194.1  Fas (TNF receptor superfamily, member 6) (FAS) - -1.59 
 NM_181086.2  tumor necrosis factor receptor superfamily, member 12A (TNFRSF12A) -1.55 - 
 NM_133571.1  cell division cycle 25 homolog A (S. pombe) (CDC25A) 1.61 - 
 NM_053458.1 RAB9A, member RAS oncogen family (RAB9A) 1.64 - 
 NM_001007732.1  serpin peptidase inhibitor, clade B (ovalbumin), member 9 (SERPINB9) -1.59 - 
 NM_012551.1  early growth response 1 (EGR1) -2.06 - 
 XM_341386.2  topoisomerase (TOP2B) - -1.53 
 XM_343604.2  serpin peptidase inhibitor, clade E (SERPINE2) 1.68 - 
 NM_134432.2  angiotensinogen (AGT) 1.69 - 
 NM_001009632.1  G0/G1switch 2 (G0S2) 2.87 - 
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Table 7.7: Genes deregulated by EMD335823. 
The table contains the gene assession numbers, the gene names and symbols, as well as the fold changes of genes deregulated with p < 0.05.  
Grayed out numbers: BH Q ≤ 0.2, EMD: EMD335823, H: high dose, 1/3/14: treatment day 1/3/14,  
Access. No. gene name and symbol EMD H1 EMD H3 EMD H14 
lipid metabolism        
NM_080576.1  apolipoprotein A-V (APOA5) -3.48 -11.26 -6.37 
XM_214872.2  apolipoprotein C-II (APOC2) - -2.64 -2.59 
NM_013155.1  very low density lipoprotein receptor (VLDLR) - 5.39 5.22 
NM_175762.2  low density lipoprotein receptor (LDLR) - -1.68 -1.73 
NM_053541.1  low density lipoprotein receptor-related protein 3 (LRP3) - -1.61 -1.92 
NM_032616.1  lipolysis stimulated lipoprotein receptor (LSR) - -1.58 -1.66 
NM_012597.2  lipase, hepatic (LIPC) - -1.52 -3.14 
NM_012598.1  lipoprotein lipase (LPL) - - 6.87 
NM_019157.2  aquaporin 7 (AQP7) - 3.72 2.87 
XM_575339.1  CD36 molecule (thrombospondin receptor) (CD36) 1.84 1.81 - 
NM_012556.1  fatty acid binding protein 1, liver (FABP1) 1.57 1.75 2.45 
NM_031315.1  acyl-CoA thioesterase 1 (Acot1) 19.31 90.77 29.98 
NM_012820.1  acyl-CoA synthetase long-chain family member 1 (ACSL1) 2.26 2.14 2.20 
NM_175837.1  cytochrome P450, family 4, subfamily A, polypeptide 11 (CYP4A11) 8.80 14.85 4.95 
XM_575886.1  cytochrome P450, family 4, subfamily a, polypeptide 14 (Cyp4a14) 4.13 4.79 3.46 
XM_230827.3  fat storage-inducing transmembrane protein 2 (FITM2) 1.74 2.39 1.82 
NM_001007144.
1  perilipin 2 (PLIN2) - 1.69 - 
NM_022193.1  acetyl-CoA carboxylase alpha (ACACA) -1.55 -2.65 -1.98 
NM_016987.1  ATP citrate lyase (ACLY) -2.01 -5.72 - 
NM_017024.1  lecithin-cholesterol acyltransferase (LCAT) - -1.99 -1.93 
NM_080886.1  sterol-C4-methyl oxidase-like (SC4MOL) - -2.01 -2.34 
NM_024143.1  solute carrier family 27 (fatty acid transporter), member 5 (SLC27A5) -1.94 -7.33 -15.08 
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Access. No. gene name and symbol EMD H1 EMD H3 EMD H14 
peroxisomal lipid 
metabolism     
NM_012804.1  acyl-CoA binding domain containing 3 (ACBD3) - - -1.54 
NM_171996.2  2,4-dienoyl CoA reductase 2, peroxisomal (DECR2) 1.60 2.60 1.69 
NM_022594.1  enoyl CoA hydratase 1, peroxisomal (ECH1) 2.11 2.28 2.35 
NM_130756.2  acyl-CoA thioesterase 8 (ACOT8) 1.51 2.41 1.75 
NM_053493.1  2-hydroxyacyl-CoA lyase 1 (HACL1) - 2.44 2.12 
NM_001006966.
1  peroxisomal D3,D2-enoyl-CoA isomerase (PECI) - 2.01 - 
XM_576485.1  acetyl-CoA acyltransferase 1 (ACAA1) 15.10 26.03 24.11 
NM_017340.1  acyl-CoA oxidase 1, palmitoyl (ACOX1) 3.32 4.65 5.17 
        
mitochondrial 
lipid metabolism     
NM_001004085.
2  carnitine O-acetyltransferase (CRAT) 2.53 2.64 2.28 
NM_031987.1  carnitine O-octanoyltransferase (CROT) - 1.72 - 
NM_013200.1  carnitine palmitoyltransferase 1B (muscle) (CPT1B) 1.94 4.65 3.93 
NM_130433.1  acetyl-CoA acyltransferase 2 (ACAA2) 1.83 1.90 1.54 
NM_016986.1  acyl-CoA dehydrogenase, C-4 to C-12 straight chain (ACADM) 1.60 1.91 1.63 
NM_017075.1  acetyl-CoA acetyltransferase 1 (ACAT1) 2.20 4.13 2.67 
NM_133618.1 
 hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional     protein), beta subunit 
(HADHB) - 1.77 - 
        
drug metabolism     
NM_012541.2  cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) - - -1.66 
NM_019184.1  cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) -1.78 -13.31 -10.58 
NM_138515.1  cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) - -1.63 - 
NM_031543.1  cytochrome P450, family 2, subfamily E, polypeptide 1 (CYP2E1) - 3.02 - 
NM_153312.2  cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) 1.79 6.40 26.34 
NM_019286.2  alcohol dehydrogenase 1C (class I), gamma polypeptide (ADH1C) - 1.52 2.52 
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NM_022407.3  aldehyde dehydrogenase 1 family, member A1 (ALDH1A1) 1.97 2.48 - 
NM_019363.2  aldehyde oxidase 1 (AOX1) 1.70 4.97 2.10 
NM_012844.1  epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1) 3.59 4.95 1.93 
NM_022936.1  epoxide hydrolase 2, cytoplasmic (EPHX2) - 2.71 2.35 
XM_579318.1  glutathione S-transferase alpha 3 (GSTA3) 3.33 8.96 4.09 
NM_001010921.
1  glutathione S-transferase alpha 5 (GSTA5) 4.18 17.05 20.93 
NM_181371.2  glutathione S-transferase kappa 1 (GSTK1) - 2.48 2.11 
NM_138974.1  glutathione S-transferase pi 1 (GSTP1) 3.46 17.81 8.22 
NM_053293.2  glutathione S-transferase theta 1 (GSTT1) - 1.70 1.80 
NM_012683.1  UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) 1.67 2.09 - 
NM_057105.2  UDP glucuronosyltransferase 1 family, polypeptide A6 (UGT1A6) 2.35 4.47 2.52 
NM_130407.1  UDP glucuronosyltransferase 1 family, polypeptide A7C (Ugt1a7c) 1.64 1.93 - 
NM_173295.1  UDP glucuronosyltransferase 2 family, polypeptide B4 (UGT2B4) 1.65 1.50 1.62 
NM_012623.2  ATP-binding cassette, sub-family B (MDR/TAP), member 1B (Abcb1b, MDR1) - -1.74 -3.32 
NM_181381.2  ATP-binding cassette, sub-family G (WHITE), member 2 (ABCG2, BCRP) - 1.67 - 
NM_053754.2  ATP-binding cassette, sub-family G (WHITE), member 5 (ABCG5) 1.96 6.20 5.00 
NM_080581.1  ATP-binding cassette, sub-family C (CFTR/MRP), member 3 (ABCC3, MRP3) 2.46 3.07 - 
NM_031013.1  ATP-binding cassette, sub-family C (CFTR/MRP), member 6 (ABCC6, MRP6) - - -2.10 
NM_080786.1  solute carrier organic anion transporter family, member 2B1 (SLCO2B1, OATP-B) -1.57 -1.74 -2.22 
        
stress     
NM_030835.2  stress-associated endoplasmic reticulum protein 1 (SERP1) 1.57 1.90 - 
NM_138504.2  oxidative stress induced growth inhibitor 1 (OSGIN1) 1.60 2.56 - 
XM_214316.3 FK506 binding protein 8, 38kDa (FKBP8) - 2.18 1.80 
NM_017051.2  superoxide dismutase 2, mitochondrial (SOD2) - 1.69 - 
NM_017000.2  NAD(P)H dehydrogenase, quinone 1 (NQO1) 3.08 5.27 2.53 
NM_012580.1  heme oxygenase (decycling) 1 (HMOX1) 3.03 11.60 - 
NM_001008767.
1  thioredoxin interacting protein (TXNIP) 2.16 - - 
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NM_031614.1  thioredoxin reductase 1 (TXNRD1) 2.61 3.74 2.19 
NM_012520.1  catalase (CAT) 1.64 2.70 1.89 
XM_577041.1  ferritin, light polypeptide (FTL) 2.17 3.13 2.00 
NM_053906.1  glutathione reductase (GSR) 1.98 3.55 1.87 
NM_012815.2  glutamate-cysteine ligase, catalytic subunit (GCLC) 1.82 2.63 - 
NM_019354.1  uncoupling protein 2 (mitochondrial, proton carrier) (UCP2) 1.84 3.14 - 
        
energy  
production     
NM_012879.1  solute carrier family 2 (facilitated glucose transporter), member 2 (SLC2A2) - -3.63 -2.30 
NM_012565.1  glucokinase (hexokinase 4) (GCK) -1.64 -1.62 - 
NM_012624.2  pyruvate kinase, liver and RBC (PKLR) -3.58 -10.88 -4.10 
NM_012595.1  lactate dehydrogenase B (LDHB) - -2.36 -2.99 
NM_207592.1  glucose-6-phosphate isomerase (GPI) - -1.63 -1.77 
NM_012495.1  aldolase A, fructose-bisphosphate (ALDOA) 1.63 1.86 - 
XM_576370.1  triosephosphate isomerase 1 (TPI1) - 2.00 - 
NM_013098.1  glucose-6-phosphatase, catalytic subunit (G6PC) - -3.86 - 
NM_031589.2  solute carrier family 37 (glucose-6-phosphate transporter), member 4 (SLC37A4) -2.17 -3.20 -3.28 
NM_013089.1  glycogen synthase 2 (liver) (GYS2) - -1.66 -1.54 
NM_172091.1  glucagon receptor (GCGR) -1.76 -1.67 -1.69 
NM_001007620.
1  pyruvate dehydrogenase (lipoamide) beta (PDHB) - -1.71 - 
NM_031510.1  isocitrate dehydrogenase 1 (NADP+), soluble (IDH1) 1.54 1.91 - 
NM_031151.2  malate dehydrogenase 2, NAD (mitochondrial) (MDH2) - - -1.51 
NM_053551.1  pyruvate dehydrogenase kinase, isozyme 4 (PDK4) 4.88 7.64 6.48 
XM_341693.2  nudix (nucleoside diphosphate linked moiety X)-type motif 7 (NUDT7) 1.97 3.12 2.89 
NM_012600.1  malic enzyme 1, NADP(+)-dependent, cytosolic (ME1) 1.78 2.74 2.21 
NM_022215.2  glycerol-3-phosphate dehydrogenase 1 (soluble) (GPD1) - - 1.69 
NM_019269.1  solute carrier family 22 (organic cation/carnitine transporter), member 5 (SLC22A5) 2.00 2.60 1.57 
NM_013215.1  aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) (AKR7A3) 6.83 13.46 6.13 
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NM_017025.1  lactate dehydrogenase A (LDHA) 1.54 2.00 - 
        
cell function     
XM_344194.2  interferon regulatory factor 6 (IRF6) - -1.58 -1.55 
NM_053373.1  peptidoglycan recognition protein 1 (PGLYRP1) -1.75 -2.02 -4.60 
NM_207604.1  toll-like receptor 6 (TLR6) - -1.71 -1.80 
NM_145672.3  chemokine (C-X-C motif) ligand 9 (CXCL9) - 2.30 3.84 
NM_139089.1  chemokine (C-X-C motif) ligand 10 (CXCL10) - - 1.61 
XM_573130.1  chemokine (C-X-C motif) ligand 16 (CXCL16) -1.80 -5.22 -3.42 
NM_012747.2  signal transducer and activator of transcription 3 (acute-phase response factor) (STAT3) - -1.61 -1.93 
NM_017020.1  interleukin 6 receptor (IL6R) -2.05 -2.04 -1.91 
NM_172222.2  complement component 2 (C2) - - -1.76 
XM_345342.2  complement component 5 (C5) - - -1.69 
NM_176074.2  complement component 6 (C6) -1.61 -2.92 -2.84 
NM_212466.2  complement factor B (CFB) - -1.69 -3.96 
NM_130409.1  complement factor H (CFH) - -1.55 -1.78 
NM_024157.1  complement factor I (CFI) - - -1.74 
XM_215303.3  major histocompatibility complex, class I, E (HLA-E) -1.76 -1.54 - 
NM_012488.1  alpha-2-macroglobulin (A2M) - - -2.30 
NM_017096.1  C-reactive protein, pentraxin-related (CRP) 1.66 1.90 1.91 
NM_012898.2  alpha-2-HS-glycoprotein (AHSG) - -2.32 -2.17 
NM_012725.1  kallikrein B, plasma (Fletcher factor) 1 (KLKB1) - - 1.57 
NM_012681.1  transthyretin (TTR) - - -1.74 
NM_012504.1  ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1) - -1.88 -1.77 
NM_053487.1  peroxisomal biogenesis factor 11 alpha (PEX11A) 2.79 4.66 2.79 
XM_213930.3  peroxisomal biogenesis factor 19 (PEX19) - 1.76 - 
XM_222831.3  coagulation factor V (proaccelerin, labile factor) (F5) - -2.22 -2.32 
XM_224872.3  coagulation factor XI (F11) -1.86 -2.09 - 
XM_225172.3  coagulation factor XII (Hageman factor) (F12) - -1.50 -2.02 
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NM_012548.1  endothelin 1 (EDN1) - -1.77 -1.99 
XM_243637.3  fibulin 1 (FBLN1) -2.33 -2.68 -2.35 
XM_216386.3  catenin (cadherin-associated protein), alpha-like 1 (CTNNAL1) - -1.51 -1.72 
NM_019156.1  vitronectin (VTN) - -2.23 -13.92 
NM_031334.1  cadherin 1, type 1, E-cadherin (epithelial) (CDH1) - -2.29 -2.78 
NM_019143.1  fibronectin 1 (FN1) - -3.21 -4.65 
NM_001004269.
1  junctional adhesion molecule 3 (JAM3) - -1.75 -2.67 
XM_213902.3  laminin, gamma 2 (LAMC2) - - -3.99 
NM_031140.1  vimentin (VIM) -2.97 -5.34 -11.55 
NM_022298.1  tubulin, alpha 1a (TUBA1A) -1.63 -3.71 -16.30 
XM_238167.3  filamin A, alpha (FLNA) - -2.74 -8.61 
NM_012942.1  cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1) -2.36 -5.40 - 
NM_021745.1  nuclear receptor subfamily 1, group H, member 4 (NR1H4) - -1.56 -1.56 
NM_022941.2  nuclear receptor subfamily 1, group I, member 3 (NR1I3) - 2.74 - 
        
growth, 
proliferation, cell 
death     
XM_576514.1  serum response factor (c-fos serum response element-binding transcription factor) (SRF) - - -1.53 
NM_022266.1  connective tissue growth factor (CTGF) -6.82 -43.57 -17.94 
NM_012671.1  transforming growth factor, alpha (TGFA) - - -1.60 
NM_031131.1  transforming growth factor, beta 2 (TGFB2) - - -4.63 
NM_012551.1  early growth response 1 (EGR1) - - -3.53 
NM_212505.1  immediate early response 3 (IER3) 1.77 3.60 - 
NM_001007732.
1  serpin peptidase inhibitor, clade B (ovalbumin), member 9 (SERPINB9) -1.68 -3.72 -5.68 
NM_130741.1  lipocalin 2 (LCN2) - - -14.33 
NM_024148.1  APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1) 1.56 - - 
NM_024127.1  growth arrest and DNA-damage-inducible, alpha (GADD45A) - 1.91 - 
NM_012861.1  O-6-methylguanine-DNA methyltransferase (MGMT) - - -1.65 
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XM_214477.2  geminin, DNA replication inhibitor (GMNN) 1.62 1.69 - 
NM_031762.2  cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) - - -1.53 
NM_171992.2  cyclin D1 (CCND1) - - -3.26 
XM_575700.1  BCL2-like 14 (apoptosis facilitator) (BCL2L14) - 1.51 - 
NM_053812.1  BCL2-antagonist/killer 1 (BAK1) - -1.52 -2.50 
NM_053420.2  BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) 1.55 2.48 - 
NM_017312.2  BCL2-related ovarian killer (BOK) - - -3.31 
XM_214551.3  cell death-inducing DFFA-like effector a (CIDEA) - 2.29 - 
NM_012935.2  crystallin, alpha B (CRYAB) - -4.20 -6.94 
NM_022526.1  death-associated protein (DAP) - 1.87 1.89 
NM_139194.1  Fas (TNF receptor superfamily, member 6) (FAS) - - -2.02 
NM_181086.2  tumor necrosis factor receptor superfamily, member 12A (TNFRSF12A) - -1.67 -1.75 
NM_021835.2  jun proto-oncogene (JUN) - -1.63 -1.81 
NM_133571.1  cell division cycle 25 homolog A (S. pombe) (CDC25A) 1.53 1.75 - 
 
 
 
Table 7.8: Genes deregulated by Metformin. 
The table contains the gene assession numbers, the gene names and symbols, as well as the fold changes of genes deregulated with p < 0.05.  
Grayed out numbers: BH Q ≤ 0.2, Met: Metformin, H1/3: high dose at treatment day 1/3.   
Access. No. gene name and symbol Met H1 Met H3 
lipid metabolism      
NM_080576.1  apolipoprotein A-V (APOA5) -3.66 -12.60 
XM_214872.2  apolipoprotein C-II (APOC2) -3.35 -3.40 
NM_013155.1  very low density lipoprotein receptor (VLDLR) 2.12 8.44 
XM_243524.3  low density lipoprotein receptor-related protein 1 (LRP1) -1.94 -2.13 
NM_175762.2  low density lipoprotein receptor (LDLR) - -1.82 
NM_012597.2  lipase, hepatic (LIPC) -1.80 -2.87 
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NM_138502.1  monoglyceride lipase (MGLL) -2.74 -2.56 
NM_012556.1  fatty acid binding protein 1, liver (FABP1) -5.28 -26.22 
XM_575339.1  CD36 molecule (thrombospondin receptor) (CD36) - -2.30 
NM_053477.1  malonyl-CoA decarboxylase (MLYCD) -1.94 -2.98 
NM_175837.1  cytochrome P450, family 4, subfamily A, polypeptide 11 (CYP4A11) -3.64 -5.97 
XM_575886.1  cytochrome P450, family 4, subfamily a, polypeptide 14 (Cyp4a14) -4.15 -9.21 
NM_031315.1  acyl-CoA thioesterase 1 (Acot1) -1.82 -2.07 
NM_012820.1  acyl-CoA synthetase long-chain family member 1 (ACSL1) -4.26 -3.00 
NM_057107.1  acyl-CoA synthetase long-chain family member 3 (ACSL3) - -1.67 
XM_230773.3  acyl-CoA synthetase short-chain family member 2 (ACSS2) -2.87 -6.28 
XM_230827.3  fat storage-inducing transmembrane protein 2 (FITM2) -2.53 -2.13 
NM_016987.1  ATP citrate lyase (ACLY) -2.21 -2.87 
NM_013134.2  3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) - 1.78 
NM_017024.1  lecithin-cholesterol acyltransferase (LCAT) -3.89 -12.16 
NM_022193.1  acetyl-CoA carboxylase alpha (ACACA) -2.17 - 
NM_080886.1  sterol-C4-methyl oxidase-like (SC4MOL) - -3.08 
NM_024143.1  solute carrier family 27 (fatty acid transporter), member 5 (SLC27A5) -6.70 -48.94 
      
peroxisomal lipid 
metabolism    
NM_012804.1  ATP-binding cassette, sub-family D (ALD), member 3 (ABCD3) -2.57 -2.21 
XM_576485.1  acetyl-CoA acyltransferase 1 (ACAA1) -4.14 -7.45 
NM_017340.1  acyl-CoA oxidase 1, palmitoyl (ACOX1) -2.18 -1.62 
NM_001006966.1  enoyl-CoA delta isomerase 2 (PECI) -3.65 -4.15 
NM_057197.1  2,4-dienoyl CoA reductase 1, mitochondrial (DECR1) -4.19 -6.41 
NM_171996.2  2,4-dienoyl CoA reductase 2, peroxisomal (DECR2) -3.47 -3.18 
NM_022389.2  7-dehydrocholesterol reductase (DHCR7) -3.40 -8.46 
XM_216452.3  24-dehydrocholesterol reductase (DHCR24) -9.10 -10.12 
NM_022594.1  enoyl CoA hydratase 1, peroxisomal (ECH1) -5.50 -5.30 
211 Appendix 
 
Access. No. gene name and symbol Met H1 Met H3 
NM_053493.1  2-hydroxyacyl-CoA lyase 1 (HACL1) -7.11 -5.07 
      
mitochondrial lipid 
metabolism    
NM_031559.1  carnitine palmitoyltransferase 1A (liver) (CPT1A) -7.14 -12.61 
NM_001004085.2  carnitine O-acetyltransferase (CRAT) -1.52 -2.06 
NM_031987.1  carnitine O-octanoyltransferase (CROT) -2.32 -1.81 
NM_057186.1  hydroxyacyl-CoA dehydrogenase (HADH) -5.37 -5.02 
NM_130433.1  acetyl-CoA acyltransferase 2 (ACAA2) -3.59 -5.17 
NM_012819.1  acyl-CoA dehydrogenase, long chain (ACADL) - -1.91 
NM_016986.1  acyl-CoA dehydrogenase, C-4 to C-12 straight chain (ACADM) -3.00 -4.33 
NM_022512.1  acyl-CoA dehydrogenase, C-2 to C-3 short chain (ACADS) -2.53 -2.69 
NM_012891.1  acyl-CoA dehydrogenase, very long chain (ACADVL) -2.09 -2.38 
NM_017075.1  acetyl-CoA acetyltransferase 1 (ACAT1) -2.54 -3.47 
      
drug metabolism    
NM_022407.3  aldehyde dehydrogenase 1 family, member A1 (ALDH1A1) -3.70 -2.72 
NM_012540.2  cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) -3.87 -2.46 
NM_138515.1  cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) -2.35 -3.33 
NM_031543.1  cytochrome P450, family 2, subfamily E, polypeptide 1 (CYP2E1) - -2.64 
NM_153312.2  cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) - -2.53 
NM_022936.1  epoxide hydrolase 2, cytoplasmic (EPHX2) -3.37 -1.99 
NM_177426.1  glutathione S-transferase mu 1 (GSTM1) -2.41 -14.57 
NM_053293.2  glutathione S-transferase theta 1 (GSTT1) -1.63 -1.51 
NM_031834.1  sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 (SULT1A1) -5.22 -24.47 
XM_214935.3  sulfotransferase family, cytosolic, 2B, member 1 (SULT2B1) -1.61 -1.68 
NM_012683.1  UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) -1.62 -1.69 
NM_130407.1  UDP glucuronosyltransferase 1 family, polypeptide A7C (Ugt1a7c) 1.51 -1.61 
NM_173295.1  UDP glucuronosyltransferase 2 family, polypeptide B4 (UGT2B4) -2.60 -7.11 
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NM_057105.2  UDP glucuronosyltransferase 1 family, polypeptide A6 (UGT1A6) - 3.38 
NM_012623.2  ATP-binding cassette, sub-family B (MDR/TAP), member 1B (Abcb1b, MDR1) 2.06 3.04 
NM_012690.1  ATP-binding cassette, sub-family B (MDR/TAP), member 4 (ABCB4, MDR3) -2.13 -4.03 
NM_031013.1  ATP-binding cassette, sub-family C (CFTR/MRP), member 6 (ABCC6, MDR6) -2.13 -4.00 
NM_053537.1  solute carrier family 22 (organic anion transporter), member 7 (SLC22A7, OAT2) -3.10 -2.78 
NM_017047.1  solute carrier family 10 (sodium/bile acid cotransporter family), member 1 (SLC10A1, NTCP) -14.09 -31.43 
NM_031650.1  solute carrier organic anion transporter family, member 1B3 (SLCO1B3, OATP8) -3.96 -4.64 
NM_080786.1  solute carrier organic anion transporter family, member 2B1 (SLCO2B1, OATP-B) -5.82 -8.65 
NM_012697.1  solute carrier family 22 (organic cation transporter), member 1 (SLC22A1, OCT1) -2.17 -3.08 
      
stress    
NM_012912.1  activating transcription factor 3 (ATF3) 10.04 4.43 
NM_138504.2  oxidative stress induced growth inhibitor 1 (OSGIN1) - -1.63 
NM_031970.1  heat shock 27kDa protein 1 (HSPB1) 2.81 4.24 
NM_175761.2  heat shock protein 90kDa alpha (cytosolic), class A member 1 (HSP90AA1) 1.58 1.59 
NM_012580.1  heme oxygenase (decycling) 1 (HMOX1) 2.97 3.18 
NM_017000.2  NAD(P)H dehydrogenase, quinone 1 (NQO1) - 3.36 
NM_053800.2  thioredoxin (TXN) - 1.57 
XM_577041.1  ferritin, light polypeptide (FTL) 1.66 3.35 
NM_017051.2  superoxide dismutase 2, mitochondrial (SOD2) -1.88 -1.61 
NM_012520.1  catalase (CAT) -2.09 -2.27 
NM_012815.2  glutamate-cysteine ligase, catalytic subunit (GCLC) - 1.65 
NM_033349.1  hydroxyacylglutathione hydrolase (HAGH) - 1.64 
      
energy production    
NM_031741.1  solute carrier family 2 (facilitated glucose/fructose transporter), member 5 (SLC2A5) -6.99 -6.49 
NM_013190.2  phosphofructokinase, liver (PFKL) - -1.71 
NM_053291.2  phosphoglycerate kinase 1 (PGK1) - 1.63 
NM_012624.2  pyruvate kinase, liver and RBC (PKLR) -5.05 -6.64 
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NM_012565.1  glucokinase (GCK) -1.68 - 
NM_207592.1  glucose-6-phosphate isomerase (GPI) -2.31 -1.81 
XM_233688.3  hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) (H6PD) -3.15 -3.41 
NM_031589.2  solute carrier family 37 (glucose-6-phosphate transporter), member 4 (SLC37A4) -6.78 -8.26 
NM_013098.1  glucose-6-phosphatase, catalytic subunit (G6PC) -34.93 -31.68 
NM_012744.2  pyruvate carboxylase (PC) -6.95 -8.44 
NM_198780.2  phosphoenolpyruvate carboxykinase 1 (soluble) (PCK1) -1.67 -4.10 
XM_341319.2  phosphoenolpyruvate carboxykinase 2 (mitochondrial) (PCK2) - 2.44 
NM_012621.3  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 (PFKFB1) -5.68 -2.89 
XM_214047.3  phosphoglucomutase 2 (PGM2) 1.69 2.23 
NM_199118.1  glucosidase, alpha; acid (GAA) - 2.48 
NM_013089.1  glycogen synthase 2 (liver) (GYS2) -3.01 -1.89 
NM_053551.1  pyruvate dehydrogenase kinase, isozyme 4 (PDK4) -1.69 -2.31 
XM_225729.3  malic enzyme 2, NAD(+)-dependent, mitochondrial (ME2) 1.66 2.48 
NM_022215.2  glycerol-3-phosphate dehydrogenase 1 (soluble) (GPD1) -3.02 -5.70 
NM_019269.1  solute carrier family 22 (organic cation/carnitine transporter), member 5 (SLC22A5) -1.62 -1.57 
NM_033235.1  malate dehydrogenase 1, NAD (soluble) (MDH1) -1.94 -1.51 
XM_237203.3  malate dehydrogenase 1B, NAD (soluble) (MDH1B) 1.71 1.53 
NM_017025.1  lactate dehydrogenase A (LDHA) -1.75 - 
NM_012595.1  lactate dehydrogenase B (LDHB) 1.57 2.93 
XM_341693.2  nudix (nucleoside diphosphate linked moiety X)-type motif 7 (NUDT7) -3.06 -2.21 
      
cell function    
NM_207604.1  toll-like receptor 6 (TLR6) 1.66 2.08 
NM_017020.1  interleukin 6 receptor (IL6R) - -2.40 
NM_145672.3  chemokine (C-X-C motif) ligand 9 (CXCL9) -2.03 -2.72 
NM_182952.2  chemokine (C-X-C motif) ligand 11 (CXCL11) -5.61 -2.76 
XM_573130.1  chemokine (C-X-C motif) ligand 16 (CXCL16) - -2.33 
XM_230854.3  CD40 molecule, TNF receptor superfamily member 5 (CD40) - 1.78 
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XM_345342.2  complement component 5 (C5) -1.59 -2.05 
NM_176074.2  complement component 6 (C6) -1.81 -3.89 
NM_130409.1  complement factor H (CFH) -2.42 -2.74 
NM_024157.1  complement factor I (CFI) -1.95 - 
NM_212466.2  complement factor B (CFB) -2.07 -4.38 
NM_017096.1  C-reactive protein, pentraxin-related (CRP) -3.57 -6.57 
XM_215303.3  major histocompatibility complex, class I, E (HLA-E) -3.46 -10.25 
NM_020071.1  fibrinogen beta chain (FGB) -5.00 -4.18 
NM_012582.1  haptoglobin (HP) - -1.52 
NM_012725.1  kallikrein B, plasma (Fletcher factor) 1 (KLKB1) -2.33 -1.82 
NM_012681.1  transthyretin (TTR) -2.45 -2.56 
NM_172320.1  afamin (AFM) -2.05 -2.87 
NM_053487.1  peroxisomal biogenesis factor 11 alpha (PEX11A) -1.92 -2.30 
XM_213930.3  peroxisomal biogenesis factor 19 (PEX19) -2.36 -2.00 
NM_012942.1  cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1) -7.24 -14.26 
NM_017300.1  bile acid CoA: amino acid N-acyltransferase (glycine N-choloyltransferase) (BAAT) -14.16 -10.37 
NM_012548.1  endothelin 1 (EDN1) 1.68 -1.95 
NM_019156.1  vitronectin (VTN) -1.90 -4.17 
XM_213902.3  laminin, gamma 2 (LAMC2) - -1.68 
NM_031334.1  cadherin 1, type 1, E-cadherin (epithelial) (CDH1) - -4.59 
NM_024351.1  heat shock 70kDa protein 8 (HSPA8) - 1.91 
NM_022298.1  tubulin, alpha 1a (TUBA1A) 4.36 2.22 
NM_001004269.1  junctional adhesion molecule 3 (JAM3) 2.57 2.85 
NM_031140.1  vimentin (VIM) - -8.79 
NM_017143.2  coagulation factor X (F10) -2.33 -2.13 
XM_224872.3  coagulation factor XI (F11) -1.55 -2.20 
XM_225172.3  coagulation factor XII (Hageman factor) (F12) -1.95 -4.93 
NM_021745.1  nuclear receptor subfamily 1, group H, member 4 (NR1H4) -2.56 -1.57 
NM_052980.1  nuclear receptor subfamily 1, group I, member 2 (NR1I2) -2.35 -2.21 
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NM_022941.2  nuclear receptor subfamily 1, group I, member 3 (NR1I3) -2.85 -3.80 
NM_013124.1  peroxisome proliferator-activated receptor gamma (PPARG) 2.30 2.23 
XM_341151.2  retinoid X receptor, gamma (RXRG) -4.44 -2.31 
      
growth, 
proliferation, cell 
death    
XM_576514.1  serum response factor (c-fos serum response element-binding transcription factor) (SRF) 2.81 1.52 
NM_013132.1  annexin A5 (ANXA5) 5.12 4.52 
NM_022381.2  proliferating cell nuclear antigen (PCNA) 3.02 2.42 
XM_214079.3  polymerase (DNA directed), delta 2, regulatory subunit 50kDa (POLD2) 2.37 2.68 
XM_341981.2  polymerase (DNA-directed), delta 4 (POLD4) -1.51 - 
XM_236934.3  polymerase (DNA directed), eta (POLH) - 1.82 
NM_022266.1  connective tissue growth factor (CTGF) 2.18 -16.82 
NM_130741.1  lipocalin 2 (LCN2) - 8.26 
NM_031131.1  transforming growth factor, beta 2 (TGFB2) 2.24 2.36 
NM_024148.1  APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1) 2.47 2.83 
NM_012861.1  O-6-methylguanine-DNA methyltransferase (MGMT) 1.93 4.31 
NM_024134.1  DNA-damage-inducible transcript 3 (DDIT3) 10.30 12.22 
NM_024127.1  growth arrest and DNA-damage-inducible, alpha (GADD45A) 4.80 4.12 
XM_214477.2  geminin, DNA replication inhibitor (GMNN) 1.98 1.84 
NM_012524.1  CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA) -2.58 -3.55 
NM_080782.2  cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) - 1.52 
XM_342812.2  cyclin C (CCNC) 2.82 2.99 
NM_171992.2  cyclin D1 (CCND1) - -1.60 
NM_012923.1  cyclin G1 (CCNG1) 4.72 4.78 
XM_342632.2  cyclin-dependent kinase 14 (CDK14) 8.49 5.86 
NM_053812.1  BCL2-antagonist/killer 1 (BAK1) 2.02 2.08 
NM_181086.2  tumor necrosis factor receptor superfamily, member 12A (TNFRSF12A) 3.07 -1.71 
NM_012935.2  crystallin, alpha B (CRYAB) - -2.40 
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XM_214551.3  cell death-inducing DFFA-like effector a (CIDEA) -2.01 -1.88 
XM_575641.1  cell death-inducing DFFA-like effector c (CIDEC) -4.21 -3.45 
NM_017059.1  BCL2-associated X protein (BAX) 2.62 2.91 
NM_021850.2  BCL2-like 2 (BCL2L2) 2.54 1.68 
NM_022684.1  BH3 interacting domain death agonist (BID) - 1.51 
NM_053420.2  BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) 1.83 2.73 
NM_022522.2  caspase 2, apoptosis-related cysteine peptidase (CASP2) 2.91 1.84 
NM_053736.1  caspase 4, apoptosis-related cysteine peptidase (CASP4) 2.80 7.38 
NM_031775.2  caspase 6, apoptosis-related cysteine peptidase (CASP6) 1.82 1.65 
NM_022260.2  caspase 7, apoptosis-related cysteine peptidase (CASP7) 4.25 4.39 
NM_022277.1  caspase 8, apoptosis-related cysteine peptidase (CASP8) - 1.71 
XM_235169.3  Mdm2 p53 binding protein homolog (mouse) (MDM2) 4.36 3.33 
XM_231692.3  v-raf murine sarcoma viral oncogene homolog B1 (BRAF) 2.25 1.90 
NM_021835.2  jun proto-oncogene (JUN) - -2.65 
NM_053720.1  apoptosis antagonizing transcription factor (AATF) 3.26 2.44 
NM_001007732.1  serpin peptidase inhibitor, clade B (ovalbumin), member 9 (SERPINB9) - -3.07 
NM_131914.2  caveolin 2 (CAV2) - -1.60 
NM_012551.1  early growth response 1 (EGR1) - -2.43 
XM_235169.3  Mdm2 p53 binding protein homolog (mouse) (MDM2) 4.36 3.33 
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